Fungicidal compositions

MYPI2025003052A0Undetermined Publication Date: 2024-05-30SYNGENTA CROP PROTECITON AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025003052
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-11-30
Filing Date
2023-11-29
Publication Date
2024-05-30

AI Technical Summary

Technical Problem

Current fungicidal compositions often fall short in providing adequate biological activity, spectrum of activity, safety profile, and environmental sustainability for effectively controlling phytopathogenic fungi in agricultural practices, necessitating the development of new compounds with enhanced properties.

Method used

A fungicidal composition comprising a mixture of a compound of formula (I) and a second fungicidal compound, where the compound of formula (I) is combined with other active ingredients such as pydiflumetofen, benzovindiflupyr, or Aureobasidin A, to create a formulation with improved biological activity and reduced environmental impact.

Benefits of technology

The composition demonstrates enhanced biological activity, improved safety, and reduced environmental impact, offering superior control of phytopathogenic fungi while minimizing application frequency and environmental harm.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A fungicidal composition comprising a mixture of components (A) and (B), wherein components (A) and (B) are as defined in claim 1, and use of the compositions in agriculture or horticulture for controlling or preventing infestation of plants by phytopathogenic microorganisms, preferably fungi.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] FUNGICIDAL COMPOSITIONS

[0002] The present invention relates to novel fungicidal compositions, to their use in agriculture or horticulture for controlling diseases caused by phytopathogens, especially phytopathogenic fungi, and to methods of controlling diseases on useful plants.

[0003] Whilst many fungicidal compounds and compositions, belonging to various different chemical classes, have and are being developed for use as fungicides in crops of useful plants, crop tolerance and activity against particular phytopathogenic fungi do not always satisfy the needs of agricultural practice in many respects. Therefore, there is a continuing need to find new compounds and compositions having superior biological properties for use in controlling or preventing infestation of plants by phytopathogenic fungi. For example, compounds possessing a greater biological activity, an advantageous spectrum of activity, an increased safety profile, improved physico-chemical properties, increased biodegradability. Or else, compositions possessing a broader spectrum of activity, improved crop tolerance, synergistic interactions or potentiating properties, or compositions which display a more rapid onset of action or which have longer lasting residual activity or which enable a reduction in the number of applications and / or a reduction in the application rate of the compounds and compositions required for effective control of a phytopathogen, thereby enabling beneficial resistancemanagement practices, reduced environmental impact and reduced operator exposure.

[0004] The use of compositions comprising mixtures of different fungicidal compounds possessing different modes of action can address some of these needs (e.g., by combining fungicides with differing spectrums of activity).

[0005] According to the present invention, there is provided a fungicidal composition comprising a mixture of components (A) and (B) as active ingredients, wherein component (A) is a compound of formula (I): wherein

[0006] R1is selected from hydrogen, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, or C3-C6 cycloalkyl;

[0007] R2is selected from hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C1-C4 alkylcarbonyl, N-C1-C4 alkoxy-C-Ci-C4 alkyl-carbonimidoyl, N-hydroxy-C-Ci-C4 alkylcarbonimidoyl, or C1-C4 alkoxycarbonyl;

[0008] R3and R4are independently selected from hydrogen, halogen, or C1-C4 alkyl;

[0009] R5and R6are independently selected from hydrogen, or C1-C4 alkyl; R7is selected from hydrogen, C1-C4 alkyl, C1-C4 alkylcarbonyl, N-Ci-C4 alkoxy-C-Ci-C4 alkyl-carbonimidoyl, N- hydroxy-C-Ci-C4-alkyl-carbonimidoyl, C1-C4 alkoxycarbonyl, N-methoxy-N-methyl-carbonyl, C1-C4 alkylaminocarbonyl, di(Ci-C4 alkyl)aminocarbonyl, phenyl, 5- or 6-membered heteroaryl, or C3-C6 cycloalkyl; wherein any of said 5- or 6-membered heteroaryl contains 1 , 2, 3 or 4 heteroatoms individually selected from N, O, and S, with the proviso that no more than one is O or S; and wherein any of said phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl are unsubstituted or substituted by 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;

[0010] B1is CR10or N;

[0011] B2is CR11or N;

[0012] R8, R9, R10and R11are independently selected from hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, C1-C4 alkylsulfanyl, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, Ci-C4 alkoxy-Ci-C4 alkyl, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, N-Ci-C4alkoxy-C-Ci-C4 alkylcarbonimidoyl, N-hydroxy-C-Ci-C4 alkyl-carbonimidoyl, hydroxy, trifluoromethylsulfonyloxy, cyano, carboxy, phenyl, 5- or 6-membered heteroaryl, or C3-C6 cycloalkyl; wherein any of said 5- or 6-membered heteroaryl contains 1 , 2, 3 or 4 heteroatoms individually selected from N, O and S, with the proviso that no more than one is O or S; and wherein any of said phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl are unsubstituted or substituted by 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 alkoxy;

[0013] A1, A2and A3are independently selected from CR12, N, NR13, O, or S, with the proviso that at least one of A1, A2and A3is selected from N, O and S, and that no more than one of A1, A2and A3is O or S;

[0014] R12is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl;

[0015] R13is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, or C2-C4 alkynyl; and

[0016] Z1is selected from C3-C4 alkyl, phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl; wherein said 5- or 6-membered heteroaryl contains 1 , 2, 3 or 4 heteroatoms individually selected from N, O and S, with the proviso that no more than one is O or S; and wherein any of said phenyl, 5- or 6-membered heteroaryl and C3-C6- cycloalkyl are unsubstituted or substituted by 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylsulfanyl, C1-C4 alkylsulfinyl, Ci- 04 alkylsulfonyl, or C2-C4 alkynyl; and component (B) is a compound selected from: pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penflufen, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, isofetamid, fluindapyr, cyclobutrifluram, fluoxastrobin, fenamidone, mandestrobin, picoxystrobin, pyraclostrobin, famoxadone, kresoxim-methyl, trifloxystrobin, azoxystrobin, metyltetraprole, amisulbrom, cyazofamid, fenpicoxamid, florylpicoxamid, metharylpicoxamid, ametoctradin, fluazinam, fentin hydroxide, silthiofam, fenpropimorph, fenpropidine, spiroxamine, fenhexamid, imazalil, pyrisoxazole, bromuconazole, cyproconazole, difenoconazole, epoxiconazole, flutriafol, hexaconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole, triticonazole, prothioconazole, fluoxytioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, kasugamycin, mancozeb, copper fungicides, sulphur, zinc thiazole, captan, folpet, chlorothalonil, dithianon, quinoxyfen, proquinazid, fludioxonil, iprodione, procymidone, thiabendazole, zoxamide, metrafenone, fluopicolide, propamocarb, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, isotianil, phosphorous acid, cyflufenamid, tebufloquin, picarbutrazox, tricyclazole, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N- [(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3-chloro-1- methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1 -[(3-fluorophenyl)methyl]-1 ,3- dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl- butyl]quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N- [(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-((1 R)-1 -benzyl-3-chloro-1 -methyl-but- 3-enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline- 3-carboxamide, methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3- isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3- propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1 - yl]phenoxy]prop-2-enoate, methyl (Z)-2-(5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5- methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5- methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)- (oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A.

[0017] According to the first aspect of the invention, there is provided a fungicidal composition comprising a mixture of components (A) and (B) as active ingredients, wherein component (A) is a compound of formula (I), with the proviso that the compound of formula (I) is not

[0018] or an agrochemically acceptable salt, stereoisomer, enantiomer, tautomer or N-oxide thereof.

[0019] The PubChem Compound ID given for the above disclaimed compounds refers to the identification number of each compound in the PubChem website htt s: / / pubchem.ncbi.nlm.nih.gov / . The term “compounds of formula (I)” refers to component A.

[0020] In general, the weight ratio of component (A) to component (B) may preferably be from 100:1 to 1 :100, from 50:1 to 1 :50, from 20:1 to 1 :40, from 15:1 to 1 :30, from 12:1 to 1 :25, from 10:1 to 1 :20, from 5:1 to 1 :15, from 3:1 to 1 :10 or from 2:1 to 1 :5.

[0021] Further according to the invention, there is provided a method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a fungicidal composition according to the invention.

[0022] The benefits provided by certain fungicidal mixture compositions according to the invention may also include, inter alia, advantageous levels of biological activity for protecting plants against diseases that are caused by fungi or superior properties for use as agrochemical active ingredients (for example, greater biological activity, an advantageous spectrum of activity, an increased safety profile, improved physico-chemical properties, or increased biodegradability). The presence of one or more possible asymmetric carbon atoms in a compound of formula (I) means that the compounds may occur in optically isomeric forms, i.e., enantiomeric or diastereomeric forms. Also atropisomers may occur as a result of restricted rotation about a single bond. The present invention includes all those possible isomeric forms (e.g., geometric isomers) and mixtures thereof for a compound of formula (I). The present invention includes all possible tautomeric forms for a compound of formula (I), and also a racemic compound, i.e., a mixture of at least two enantiomers in a ratio of substantially 50:50.

[0023] In each case, the compounds of formula (I) according to the invention are in free form, in oxidized form as a N- oxide or in salt form, e.g., an agronomically usable salt form.

[0024] N-oxides are oxidized forms of tertiary amines or oxidized forms of nitrogen containing heteroaromatic compounds. They are described for instance in the book “Heterocyclic N-oxides” by A. Albini and S. Pietra, CRC Press, Boca Raton 1991.

[0025] The compounds of formula (I) according to the invention also include hydrates which may be formed during the salt formation.

[0026] Where substituents are indicated as being “optionally substituted”, this means that they may or may not carry one or more identical or different substituents, e.g., one, two or three Rxsubstituents. For example, Ci-Cealkyl substituted by 1 , 2 or 3 halogens, may include, but not be limited to, -CH2CI, -CHCI2, -CCh, -CH2F, -CHF2, - CF3, -CH2CF3 or -CF2CH3 groups. As another example, Ci-Cealkoxy substituted by 1 , 2 or 3 halogens, may include, but not be limited to, CH2CIO-, CHCI2O-, CCI3O-, CH2FO-, CHF2O-, CF3O-, CF3CH2O- or CH3CF2O- groups. Further the term “optionally substituted”, as used herein, can be used interchangeably with the term “unsubstituted or substituted”.

[0027] As used herein, the term "halogen" or “halo” refers to fluorine (fluoro), chlorine (chloro), bromine (bromo) or iodine (iodo), preferably fluorine, chlorine or bromine. This also applies, correspondingly, to halogen in combination with other meanings, such as haloalkyl, haloalkenyl, haloalkynyl, haloalkoxy, and halocycloalkyl.

[0028] As used herein, amino means a -NH2 group.

[0029] As used herein, cyano means a -CN group.

[0030] As used herein, the term “hydroxyl” or “hydroxy” means an -OH group.

[0031] As used herein, the term “carboxylic acid” means a -COOH group.

[0032] As used herein, the term "Ci-Cn-alkyl” refers to a saturated straight-chain or branched hydrocarbon radical attached via any of the carbon atoms having 1 to n carbon atoms, for example, any one of the radicals methyl, ethyl, n-propyl, 1 -methylbutyl, 2-methylbutyl, 3-methylbutyl, 2, 2-dimethylpropyl, 1 -ethylpropyl, n-hexyl, n- pentyl, 1 ,1 -dimethylpropyl, 1 , 2-dimethylpropyl, 1 -methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 ,1 -dimethylbutyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1 -ethylbutyl, 2-ethylbutyl, 1 ,1 ,2-trimethylpropyl, 1 ,2,2-trimethylpropyl, 1 -ethyl-1 -methylpropyl, or 1-ethyl-2- methylpropyl. As used herein, the term “C2-Cn-alkenyl” refers to a straight or branched alkenyl chain moiety having from two to n carbon atoms and one or two double bonds, for example, ethenyl, prop-1 -enyl, but-2-enyl.

[0033] As used herein, the term “C2-Cn-alkynyl” refers to a straight or branched alkynyl chain moiety having from two to n carbon atoms and one triple bond, for example, ethynyl, prop-2-ynyl, but-3-ynyl,

[0034] As used herein, the term “Cs-Cn-cycloalkyl” refers to three (3) to n membered cycloalkyl radical such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

[0035] As used herein, the term "Ci-Cn-alkoxy" refers to a straight-chain or branched saturated alkyl radical having one (1) to n carbon atoms (as mentioned above) which is attached via an oxygen atom, i.e., for example, any one of the radicals methoxy, ethoxy, n-propoxy, 1 -methylethoxy, n-butoxy, 1 -methylpropoxy, 2-methylpropoxy and 1 ,1 -dimethylethoxy. The term “C2-Cn-alkenyloxy” as used herein refers to a straight-chain or branched alkenyl chain having two (2) to n carbon atoms (as mentioned above) which is attached via an oxygen atom.

[0036] As used herein, the term "C2-Cnalkynyloxy" refers to a radical of the formula -ORawhere Rais a C2-Cn alkynyl radical as generally defined above.

[0037] As used herein, the term “Ci-Cn-alkoxy-Ci-Cn-alkyl” refers to an alkyl radical (as mentioned above) substituted with a Ci-Cn-alkoxy group. Examples are methoxymethyl, methoxyethyl, ethoxymethyl and propoxymethyl.

[0038] As used herein, the term "Ci-Cn-haloalkyl" refers to a straight-chain or branched saturated alkyl radical attached via any of the carbon atoms having 1 to n carbon atoms (as mentioned above), where some or all of the hydrogen atoms in these radicals may be replaced by fluorine, chlorine, bromine and / or iodine, i.e., for example, any one of chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 2-fluoroethyl, 2-chloroethyl, 2- bromoethyl, 2-iodoethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, 2-fluoropropyl, 3-fluoropropyl, 2,2- difluoropropyl, 2,3-difluoropropyl, 2-chloropropyl, 3-chloropropyl, 2,3-dichloropropyl, 2-bromopropyl, 3- bromopropyl, 3,3,3-trifluoropropyl, 3,3,3-trichloropropyl, 2, 2, 3, 3, 3- pentafluoropropyl, heptafluoropropyl, 1- (fluoromethyl)-2-fluoroethyl, 1-(chloromethyl)-2-chloroethyl, 1 -(bromomethyl)-2-bromoethyl, 4-fluorobutyl, 4- chlorobutyl, 4-bromobutyl or nonafluorobutyl. Accordingly, a term "Ci-C2fluoroalkyl" would refer to a Ci-C2alkyl radical which carries 1 , 2, 3, 4, or 5 fluorine atoms, for example, any one of difluoromethyl, trifluoromethyl, 1 - fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 1 ,1 ,2,2-tetrafluoroethyl or pentafluoroethyl. Similarly, the term “C2-Cn-haloalkenyl” or “C2-Cn-haloalkynyl” as used herein refers to a C2-Cn-alkenyl or C2- Cn-alkynyl radical respectively substituted with one or more halogen atoms which may be the same or different. Similarly, the term “Cs-Cn-halocycloalkyl” or “Ci-Cn-haloalkoxy” as used herein refers to a Cs-Cn-cycloalkyl radical or Ci-Cn-alkoxyl radical respectively substituted with one or more halo atoms which may be the same or different.

[0039] As used herein, the term “Ci-Cn-alkylthio“ or “Ci-Cn-alkylsulfanyl“refers to a Ci-Cn-alkyl group linked through a sulfur atom. As used herein, the term “Ci-Cn-haloalkylthio“ or “Ci-Cn-haloalkylsulfanyl“refers to a Ci-Cnhaloalkyl group linked through a sulfur atom.

[0040] As used herein, the term “Ci-Cn-alkylsulfinyl“ refers to a Ci-Cnalkyl group linked through the sulfur atom of a sulfinyl (or S(=O)-) group.

[0041] As used herein, the term “Ci-Cn-alkylsulfonyl“ refers to a Ci-Cnalkyl group linked through the sulfur atom of a sulfonyl (or S(=O)2-) group.

[0042] As used herein, the term “Ci-Cn-alkylcarbonyl” refers to a Ci-Cn-alkyl group linked through the carbon atom of a carbonyl (C=O) group.

[0043] As used herein, the term “Ci-Cn-alkoxycarbonyl” refers to a Ci-Cn-alkoxy moiety linked through a carbon atom of a carbonyl (or C=0) group.

[0044] As used herein, the term “benzoyl” refers to a phenyl group linked through the carbon atom of a carbonyl (C=O) group.

[0045] As used herein, the term “Ci-Cn-alkylaminocarbonyl” refers to a Ci-Cn-alkylamino group (or RaNHC(=O)-, wherein Rais a Ci-Cn-alkyl group) linked through the carbon atom of a carbonyl (C=O) group.

[0046] As used herein, the term “N-Ci-Cn alkylamino” refers to a radical of the formula -NH-Rawhere Rais a Ci-Cn alkyl radical as defined above.

[0047] As used herein, the term "N,N-di(Ci-Cnalkyl)amino" refers to a radical of the formula -N(Ra)Rawhere each Rais a Ci-Cn alkyl radical, which may be the same or different, as defined above.

[0048] As used herein, the term “N-C1-C4 alkoxy-C-Ci-C4 alkyl-carbonimidoyl” refers to a radical of the formula - C(Ra)=NO(Rb) where Rais a C1-C4 alkyl radical as generally defined above, and Rb is a C1-C4 alkyl radical as generally defined above.

[0049] As used herein the term “N-hydroxy-C-Ci-C4alkyl-carbonimidoyl” refers to a radical of the formula -C(Ra)=NOH where Rais a C1-C4 alkyl radical as generally defined above.

[0050] As used herein, the term “heteroaryl" refers to a 5- or 6-membered aromatic monocyclic ring radical which comprises 1 , 2, 3 or 4 heteroatoms individually selected from N, O and S. Examples of heteroaryl include, but are not limited to, furanyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazinyl, pyridazinyl, pyrimidyl or pyridyl. The term “heteroaryl-Ci-Cn-alkyl” or “heteroaryl- Cs-Cn-cycloalkyl” refers to an Ci-Cn-alkyl or Cs-Cn-cycloalkyl radical respectively substituted by a heteroaryl group. The heteroaryl-Ci-Cn-alkyl or heteroaryl-Cs-Cn-cycloalkyl radical may be substituted on heteroaryl, alkyl and / or cycloalkyl group as appropriate.

[0051] As used herein, the term "controlling" refers to reducing the number of pests, eliminating pests and / or preventing further pest damage such that damage to a plant or to a plant derived product is reduced. As used herein, the term "pest" refers to insects, and molluscs that are found in agriculture, horticulture, forestry, the storage of products of vegetable origin (such as fruit, grain and timber); and those pests associated with the damage of man-made structures. The term pest encompasses all stages in the life cycle of the pest.

[0052] As used herein, the term "effective amount" refers to the amount of the compound, or a salt thereof, which, upon single or multiple applications provides the desired effect.

[0053] An effective amount is readily determined by the skilled person in the art, using known techniques and by observing results obtained under analogous circumstances. In determining the effective amount, a number of factors are considered including, but not limited to the type of plant or derived product to be applied; the pest to be controlled and its lifecycle; the particular compound applied; the type of application; and other relevant circumstances.

[0054] As used herein, the term “room temperature” or “RT” or “rt” or “ambient temperature” refer to a temperature of about 15° C to about 35° C. For example, rt can refer to a temperature of about 20° C to about 30° C.

[0055] The following list provides definitions, including preferred definitions, for substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, B1, B2, A1, A2, A3and Z1with reference to the compounds of formula (I) of the present invention. For any one of these substituents, any of the definitions given below may be combined with any definition of any other substituent given below or elsewhere in this document.

[0056] In one embodiment of the invention R1is selected from hydrogen, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, or Cs-Cecycloalkyl. In another embodiment of the invention, R1is C1-C4 alkyl. Preferably, R1is methyl, ethyl or isopropyl. More preferably, R1is methyl.

[0057] In one embodiment of the invention, R2is selected from hydrogen, halogen, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4- alkynyl, Ci-C4-haloalkyl, Cs-Ce-cycloalkyl, Ci-C4-alkylcarbonyl, N-Ci-C4 alkoxy-C-Ci-C4 alkyl-carbonimidoyl, N- hydroxy-C-Ci-C4 alkyl-carbonimidoyl, or Ci-C4-alkoxycarbonyl. In another embodiment of the invention, R2is hydrogen, halogen, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkylcarbonyl, N-Ci-C4 alkoxy-Ci-C4 alkyl-carbonimidoyl or N-hydroxy-Ci-C4 alkyl-carbonimidoyl. Preferably R2is hydrogen, halogen, methyl, ethyl, cyclopropyl, C1-C2 alkylcarbonyl, N-C1-C2 alkoxy-C-Ci-C2 alkyl-carbonimidoyl, or N-hydroxy-C-Ci-C2 alkyl-carbonimidoyl. More preferably R2is hydrogen, fluorine, chlorine, bromine, methyl, ethyl, cyclopropyl, acetyl, -C(CH3)=NOCH3, - C(CH3)=NOCH2CH3, or -C(CH3)=NOH. In a preferred embodiment of the invention R2is selected from hydrogen, halogen or C1-C4 alkyl. Most preferably R2is hydrogen, chlorine or methyl. In one preferred embodiment R2is hydrogen. In another preferred embodiment R2is methyl. In still another preferred embodiment R2is chlorine.

[0058] In one embodiment R3is selected from hydrogen, halogen, C1-C4 haloalkyl or C1-C4 alkyl. Preferably R3is hydrogen or C1-C4 alkyl. More preferably R3is hydrogen or methyl. Most preferably R3is hydrogen.

[0059] In one embodiment of the invention R4is selected from hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl or C3- Ce-cycloalkyl. Preferably R4is hydrogen, chlorine, bromine, fluorine, methyl, ethyl, trifluoromethyl, difluoromethyl or cyclopropyl. More preferably R4is hydrogen, chlorine, bromine or methyl. Still more preferably R4is hydrogen or methyl. Most preferably R4is hydrogen. In one embodiment of the invention R4is hydrogen. In another embodiment of the invention R4is methyl.

[0060] In one embodiment of the invention R5and R6are independently selected from hydrogen or Ci-C4-alkyl. Preferably R5and R6are independently selected from hydrogen, methyl or ethyl. More preferably, R5and R6are independently selected from hydrogen or methyl. Even more preferably, R5and R6are hydrogen.

[0061] In one embodiment R7is selected from hydrogen, Ci-C4alkyl, Ci-C4-alkylcarbonyl, N-C1-C4 alkoxy-C-Ci-C4 alkyl-carbonimidoyl, N-hydroxy-C-Ci-C4-alkyl-carbonimidoyl, Ci-C4-alkoxycarbonyl, N-methoxy-N-methyl- carbonyl, Ci-C4alkylaminocarbonyl, di (Ci-C4alkylamino)carbonyl, phenyl, a 5- to 6- membered heteroaryl or Cs-Ce-cycloalkyl; wherein said 5- or 6-membered heteroaryl contains 1 , 2, 3 or 4 heteroatoms individually selected from N, O and S, with the proviso that no more than one is O or S; and wherein said phenyl and 5- to 6- membered heteroaryl are unsubstituted or substituted with 1 , 2 or 3 substituents independently selected from halogen, Ci-C4haloalkyl, cyano, carboxy, Ci-C4alkyl or Ci-C4-alkoxy; and wherein said Cs-Ce-cycloalkyl is unsubstituted or substituted with 1 , 2 or 3 substituents independently selected from halogen, Ci-C4-haloalkyl, cyano, Ci-C4alkyl or Ci-C4alkoxy.

[0062] In another embodiment of the invention R7is selected from hydrogen, Ci-C4alkyl, Ci-C4alkylcarbonyl, C1-C4 alkoxycarbonyl, N-C1-C4 alkoxy-C-Ci-C4alkyl-carbonimidoyl, N-hydroxy-C-Ci-C4 alkyl-carbonimidoyl, N- methoxy-N-methyl-carbonyl, C1-C4 alkylaminocarbonyl, di(Ci-C4 alkylamino)carbonyl, phenyl, a 5- to 6- membered heteroaryl or Cs-Ce-cycloalkyl; wherein said 5- to 6- membered heteroaryl contains 1 heteroatom selected from N; and wherein said phenyl and 5- to 6- membered heteroaryl are unsubstituted or substituted with 1 to 2 substituent independently selected from halogen, Ci-C4haloalkyl, cyano or Ci-C4alkyl; and wherein said Cs-Cs-cycloalkyl is unsubstituted or substituted with 1 substituent selected from cyano. Preferably R7is selected from hydrogen, methyl, acetyl, C(CHs)=NOCHs, -C(CH3)=NOCH2CHs, -C(CH3)=NOH, methoxycarbonyl, ethoxycarbonyl, N-methoxy-N-methyl-carbonyl, methylaminocarbonyl, dimethylaminocarbonyl, phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, [4-(trifluoromethyl)pyrazol-1- yl], [3-(trifluoromethyl)pyrazol-1-yl], 3-cyanopyrazol-1-yl, 4-cyanopyrazol-1-yl, 5-chloropyrazol-1-yl, 5- fluoropyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, 5-methylpyrazol-1-yl, pyrazol-1-yl, cyclopropyl or 1- cyanocyclopropyl. More preferably R7is selected from hydrogen, methyl, acetyl, C(CH3)=NOCH3, - C(CH3)=NOCH2CH3, -C(CH3)=NOH, phenyl, 4-cyanophenyl, pyrazol-1-yl, cyclopropyl or 1 -cyanocyclopropyl. Even more preferably R7is selected from hydrogen, methyl, cyclopropyl or 1 -cyanocyclopropyl.

[0063] In another embodiment R7is selected from hydrogen, C1-C4 alkyl or Cs-Ce-cycloalkyl. Preferably R7is hydrogen, methyl, cyclopropyl or 1 -cyanocyclopropyl. Even more preferably R7is hydrogen, methyl or cyclopropyl.

[0064] In another preferred embodiment R7is C1-C4 alkyl. Preferably R7is methyl or ethyl. More preferably R7is methyl.

[0065] In one embodiment of the invention R8, R9, R10and R11are independently selected from hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, C1-C4 alkylsulfanyl, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 alkoxy-Ci-C4 alkyl, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, N-C1-C4 alkoxy-C-Ci-C4 alkyl-carbonimidoyl, N-hydroxy-C-Ci-C4 alkyl-carbonimidoyl, hydroxy, trifluoromethylsulfonyloxy, cyano, carboxy, phenyl, 5- or 6-membered heteroaryl and C3-C6 cycloalkyl; wherein said 5- or 6-membered heteroaryl contains 1 , 2, 3 or 4 heteroatoms individually selected from N, O and S, with the proviso that no more than one is O or S; and wherein any of said phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl are unsubstituted or substituted by 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl or Ci-C4 alkoxy;

[0066] In one embodiment of the invention, R8and R9are independently selected from hydrogen, halogen, cyano, Ci- 04 alkyl or C1-C4 alkoxy. Preferably, R8and R9are independently selected from hydrogen, halogen, methyl, methoxy or cyano. More preferably, R8and R9are independently selected from hydrogen, methyl, chlorine, fluorine, bromine or methoxy. Even more preferably, R8and R9are independently selected from hydrogen or methoxy.

[0067] In another embodiment ofthe invention, R8is hydrogen, halogen or cyano. Preferably R8is hydrogen, bromine, chlorine or cyano. More preferably, R8is hydrogen, cyano or bromine. Even more preferably, R8is hydrogen.

[0068] In another embodiment R9is selected from hydrogen, halogen, C1-C3 alkyl, C1-C2 haloalkyl, C1-C3 haloalkoxy, C1-C4 alkoxy, Ci-Csalkenyloxy, Ci-Csalkynyloxy, Ci-C2alkylsulfanyl, C1-C2 alkylsulfinyl, C1-C2 alkylsulfonyl, Ci- 02 alkoxy-Ci-C2 alkyl, Ci-Csalkoxycarbonyl, Ci-C2alkylcarbonyl, N-C1-C2 alkoxy-C-Ci-C2 alkyl-carbonimidoyl, N-hydroxy-C-Ci-C2alkyl-carbonimidoyl hydroxy, Ci-C2alkylaminocarbonyl, di(Ci-C2alkylamino)carbonyl, trifluoromethylsulfonyloxy, cyano, carboxy, phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2- methylphenyl, 3-methylphenyl, 4-methylphenyl, [4-(trifluoromethyl)pyrazol-1-yl], [3-(trifluoromethyl)pyrazol-1- yl], 3-cyanopyrazol-1-yl, 4-cyanopyrazol-1-yl, 5-chloropyrazol-1-yl, 4-chloropyrazol-1-yl, 3-chloropyrazol-1-yl, 5-fluoropyrazol-1-yl, 4-fluoropyrazol-1-yl, 3-fluoropyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, 5-methylpyrazol-1-yl, 4-methylpyrazol-1-yl, 3-methylpyrazol-1-yl, pyrazol-1 -yl, cyclopropyl or 1 -cyanocyclopropyl. Preferably R9is hydrogen, chloro, fluoro, bromo, methyl, ethyl, trifluoromethyl, difluoromethyl, difluoromethoxy, 2,2- difluoroethoxy, 2,2,2-trifluoroethoxy, methoxy, ethoxy, propoxy, allyloxy, prop-2-ynoxy, methylsulfanyl, methylsulfinyl, methylsulfonyl, methoxymethyl, ethoxymethyl, 2-methoxyethoxymethyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, acetyl, propanoyl, -C(CH3)=NOCH3, -C(CH3)=NOCH2CH3, - C(CH3)=NOH, methylaminocarbonyl, di(methylamino)carbonyl, trifluoromethylsulfonyloxy, cyano, carboxy, phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, [4- (trifluoromethyl)pyrazol-l-yl], [3-(trifluoromethyl)pyrazol-1-yl], 3-cyanopyrazol-1-yl, 4-cyanopyrazol-1-yl, 5- chloropyrazol-1-yl, 4-chloropyrazol-1-yl, 3-chloropyrazol-1-yl, 5-fluoropyrazol-1-yl, 4-fluoropyrazol-1-yl, 3- fluoropyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, 5-methylpyrazol-1-yl, 4-methylpyrazol-1-yl, 3-methylpyrazol-1-yl, pyrazol-1-yl, cyclopropyl or 1 -cyanocyclopropyl. More preferably R9is hydrogen, chloro, bromo, fluoro, cyano, methyl, methoxy, propoxy, allyloxy, methoxymethyl, 2-methoxyethoxymethyl, phenyl, 2-cyanophenyl, 3- cyanophenyl, 4-cyanophenyl, [4-(trifluoromethyl)pyrazol-1-yl], [3-(trifluoromethyl)pyrazol-1-yl], 3- cyanopyrazol-1-yl, 4-cyanopyrazol-1-yl, 5-chloropyrazol-1-yl, 4-chloropyrazol-1-yl, 3-chloropyrazol-1-yl, 5- fluoropyrazol-1-yl, 4-fluoropyrazol-1-yl, 3-fluoropyrazol-1 -yl, 3,5-dimethylpyrazol-1-yl, 5-methylpyrazol-1-yl, 4- methylpyrazol-1 -yl, 3-methylpyrazol-1-yl, pyrazol-1 -yl, cyclopropyl or 1 -cyanocyclopropyl. Even more preferably R9is hydrogen, chloro, bromo, cyano, methyl, or methoxy. Most preferably R9is hydrogen or methoxy.

[0069] In an embodiment of the invention, B1is CR10and B2is CR11, or B1is N and B2is CR11, or B1is CR10and B2is N. Preferably, B1is CR10and B2is CR11.

[0070] In one embodiment of the invention R10and R11are independently selected from hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, C1-C4 alkylsulfanyl, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, C1-C4 alkoxy-Ci-C4 alkyl, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, N- C1-C4 alkoxy-C-Ci-C4 alkyl-carbonimidoyl, N-hydroxy-C-Ci-C4 alkyl-carbonimidoyl, hydroxy, trifluoromethylsulfonyloxy, cyano, carboxy, phenyl, 5- or 6-membered heteroaryl and C3-C6 cycloalkyl; wherein said 5- or 6-membered heteroaryl contains 1 , 2, 3 or 4 heteroatoms individually selected from N, O and S, with the proviso that no more than one is O or S; and wherein any of said phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl are unsubstituted or substituted by 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl or C1-C4 alkoxy. Preferably R10and R11are independently selected from hydrogen, chloro, fluoro, bromo, methyl, ethyl, trifluoromethyl, difluoromethyl, difluoromethoxy, 2,2- difluoroethoxy, 2,2,2-trifluoroethoxy, methoxy, ethoxy, propoxy, allyloxy, prop-2-ynoxy, methylsulfanyl, methylsulfinyl, methylsulfonyl, methoxymethyl, ethoxymethyl, 2-methoxyethoxymethyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, acetyl, propanoyl, -C(CH3)=NOCH3, -C(CH3)=NOCH2CH3, - C(CH3)=NOH, methylaminocarbonyl, di(methylamino)carbonyl, trifluoromethylsulfonyloxy, cyano, carboxy, phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, [4- (trifluoromethyl)pyrazol-l-yl], [3-(trifluoromethyl)pyrazol-1-yl], 3-cyanopyrazol-1-yl, 4-cyanopyrazol-1-yl, 5- chloropyrazol-1-yl, 4-chloropyrazol-1-yl, 3-chloropyrazol-1-yl, 5-fluoropyrazol-1-yl, 4-fluoropyrazol-1-yl, 3- fluoropyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, 5-methylpyrazol-1-yl, 4-methylpyrazol-1-yl, 3-methylpyrazol-1-yl, pyrazol-1-yl, cyclopropyl or 1 -cyanocyclopropyl. More preferably R10and R11are independently selected from hydrogen, chloro, bromo, fluoro, cyano, methyl, methoxy, propoxy, allyloxy, methoxymethyl, 2- methoxyethoxymethyl, phenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, [4-(trifluoromethyl)pyrazol-1- yl], [3-(trifluoromethyl)pyrazol-1-yl], 3-cyanopyrazol-1-yl, 4-cyanopyrazol-1-yl, 5-chloropyrazol-1-yl, 4- chloropyrazol-1-yl, 3-chloropyrazol-1-yl, 5-fluoropyrazol-1-yl, 4-fluoropyrazol-1-yl, 3-fluoropyrazol-1-yl, 3,5- dimethylpyrazol-1-yl, 5-methylpyrazol-1-yl, 4-methylpyrazol-1-yl, 3-methylpyrazol-1-yl, pyrazol-1-yl, C(CH3)=NOCH3, -C(CH3)=NOCH2CH3, -C(CH3)=NOH, cyclopropyl or 1 -cyanocyclopropyl. Still more preferably R10and R11are independently selected from hydrogen, chlorine, bromine or cyano.

[0071] In another embodiment R10and R11are independently selected from hydrogen, halogen, C1-C3 alkyl or C1-C4 alkoxy. Preferably R10and R11are independently selected from hydrogen or halogen. More preferably R10and R11are hydrogen, bromine or chlorine. Even more preferably R10and R11are hydrogen.

[0072] In one embodiment of the invention A1, A2and A3are independently selected from CR12, N, NR13, O and S, with the proviso that at least one of A1, A2and A3is selected from N, O and S, and that no more than one of A1, A2and A3is O or S. In another embodiment of the invention, A1and A2are independently selected from CR12, N and O and A3is CR12, N, O or S, preferably A1and A2are independently selected from N and O and A3is CR12, O or S, with the proviso that at least one of A1, A2and A3is N or O and that no more than one of A1, A2and A3is O.

[0073] In an embodiment of the invention, R12is hydrogen or C1-C4 alkyl. Preferably, R12is hydrogen or methyl. More preferably R12is hydrogen.

[0074] In an embodiment of the invention, R13is hydrogen or C1-C4 alkyl. Preferably, R13is hydrogen or methyl. More preferably R13is hydrogen.

[0075] In one embodiment of the invention, Z1is selected from C3-C4 alkyl, phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl; wherein said 5- or 6-membered heteroaryl contains 1 , 2, 3 or 4 heteroatoms individually selected from N, O and S, with the proviso that no more than one is O or S; and wherein any of said phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl are unsubstituted or substituted by 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1- C4 alkylsulfanyl, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl or C2-C4 alkynyl.

[0076] In another embodiment of the invention Z1is selected from phenyl, a 5- to 6- membered heteroaryl or Cs-Ce- cycloalkyl; wherein said 5- or 6-membered heteroaryl contains 1 heteroatom selected from N; and wherein said phenyl and 5- to 6- membered heteroaryl are unsubstituted or substituted with 1 or 2 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy or C1-C4 alkoxy and wherein said Cs-Ce-cycloalkyl is unsubstituted or substituted with 1 substituent selected from halogen or C1-C4 alkyl. Preferably Z1is selected from phenyl or a 5- to 6- membered heteroaryl; wherein said 5- or 6- membered heteroaryl contains 1 heteroatom selected from N, and wherein said phenyl and 5- to 6- membered heteroaryl are unsubstituted or substituted with 1 or 2 substituents independently selected from fluoro, chloro, C1-C4 alkyl, or C1-C4 alkoxy.

[0077] In another embodiment of the invention, Z1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 or 2 heteroatoms selected from N; and wherein said phenyl and 6-membered heteroaryl are unsubstituted or substituted with 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C2-C4 alkynyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylsulfanyl, C1-C4 alkylsulfinyl, or C1-C4 alkylsulfonyl. Preferably, Z1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 or 2 heteroatoms selected from N; and wherein said phenyl and 6-membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 haloalkoxy or C1-C4 alkoxy. More preferably Z1is selected from phenyl or a 6-membered heteroaryl, wherein said heteroaryl contains 1 or 2 heteroatoms selected from N; and wherein said phenyl and 6-membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents independently selected from halogen or C1-C4 haloalkyl. Even more preferably Z1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 or 2 heteroatoms selected from N; and wherein said phenyl and said 6- membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents selected from fluorine. Still even more preferably Z1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 heteroatom selected from N; and wherein said phenyl and said 6-membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents selected from fluorine.

[0078] Preferably Z1is selected from phenyl, 2,3,4-trifluorophenyl, 2,3-difluorophenyl, 3,4-difluorophenyl, 2,4,6- trifluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-4-methoxy-phenyl, 2-fluoro-4-methylsulfonyl- phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 2- chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,6-difluoro-2-pyridyl, 4,6-difluoro-2-pyridyl, 4,5-difluoro-2- pyridyl, 5,6-difluoro-2-pyridyl, 3-fluoro-4-pyridyl, 2-fluoro-4-pyridyl, 2,3-difluoro-4-pyridyl, 2,5-difluoro-4-pyridyl, 2,6-difluoro-4-pyridyl, 3,5-difluoro-4-pyridyl, 2,5-difluoro-4-pyridyl, 2-fluoro-3-pyridyl, 6-fluoro-3-pyridyl, 5- fluoro-3-pyridyl, 4-fluoro-3-pyridyl, 2,6-difluoro-3-pyridyl, 2,5-difluoro-3-pyridyl, 2,4-difluoro-3-pyridyl, 4,6- difluoro-3-pyridyl, 5,6-difluoro-3-pyridyl, 3,5-difluoro-2-pyridyl, 3,4-difluoro-2-pyridyl, 6-fluoro-2-pyridyl, 4- fluoro-2-pyridyl, 5-fluoro-2-pyridyl, 3-fluoro-2-pyridyl or 4,5-difluoro-3-pyridyl. More preferably Z1is selected from phenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2-chlorophenyl, 2-fluorophenyl, 3,4-difluorophenyl, 3- chlorophenyl, 3-fluorophenyl, 3-methylphenyl, 4-fluorophenyl, 3-fluoro-2-pyridyl, 5-fluoro-2-pyridyl, 6-fluoro-2- pyridyl, 3,4-difluoro-2-pyridyl, 3,5-difluoro-2-pyridyl, 2-fluoro-4-pyridyl. Even more preferably Z1is selected from 2,4-difluorophenyl, 3,5-difluoro-2-pyridyl, 2-fluorophenyl, 4-fluorophenyl or phenyl.

[0079] The present invention, accordingly, makes available a compound of formula (I) having R1, R2, R3, R4, R5, R6, R7, R8, R9, B1, B2, A1, A2, A3and Z1as defined above in all combinations I each permutation.

[0080] Embodiments according to the invention are provided as set out below.

[0081] The term “compound of formula (I)” refers to component A.

[0082] In one embodiment of the invention, the compound of formula (I) may be a compound of formula (l-A) wherein

[0083] R1, R2, R3, R4, R5, R6, R7, R8, R9, B1, B2and Z1are as defined for the compounds of formula (I) according to the present invention, and A is selected from A1 to A36: wherein denotes the bond to the C(=O) group and the arrow denotes the bond to the Z1group, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, B1, B2and Z1are as defined for the compounds of formula (I) according to the present invention, and R12a, R13a, R14a, R12b, R13band R14bare independently selected from hydrogen, Ci- C4 alkyl, C2-C4 alkenyl and C2-C4 alkynyl.

[0084] In an embodiment of the invention, in the compound of formula (l-A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, B1, B2and Z1are as defined for the compounds of formula (I) according to the present invention, and A is selected from wherein denotes the bond to the C(=O) group and the arrow denotes the bond to the Z1group, and R12a, R13aand R14aare independently selected from hydrogen or C1-C4 alkyl. Preferably R12a, R13aand R14aare hydrogen.

[0085] In another embodiment of the invention, in the compound of formula (l-A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, B1, B2and Z1are as defined for the compounds of formula (I) according to the present invention, and A is selected from wherein denotes the bond to the C(=O) group and the arrow denotes the bond to the Z1group, and Ri23, R13aand R14aare independently selected from hydrogen or C1-C4 alkyl. Preferably R12a, R13aand R14aare hydrogen.

[0086] In another embodiment of the invention, in the compound of formula (l-A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, B1, B2and Z1are as defined for the compounds of formula (I) according to the present invention, and A is selected from wherein denotes the bond to the C(=O) group and the arrow denotes the bond to the Z1group, and R14ais selected from hydrogen or C1-C4 alkyl. Preferably R14ais hydrogen.

[0087] In another embodiment of the invention, in the compound of formula (l-A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, B1, B2and Z1are as defined for the compounds of formula (I) according to the present invention, and A is selected from wherein denotes the bond to the C(=O) group and the arrow denotes the bond to the Z1group, and R14ais selected from hydrogen or C1-C4 alkyl. Preferably R14ais hydrogen.

[0088] In an embodiment of the invention, R12a, R13a, R14a, R12b, R13band R14bare independently selected from hydrogen and methyl.

[0089] In another embodiment of the invention, R12a, R13a, R14a, R12b, R13band R14bare hydrogen.

[0090] In another embodiment of the invention, R12a, R13a, R14a, R12b, R13band R14bare methyl.

[0091] Preferably in the compound of formula (l-A) A is selected from A4, A7 or A9; and R14ais hydrogen.

[0092] In one embodiment the compound of formula (I) may be a compound of formula (l-A), wherein

[0093] R1is methyl,

[0094] R2is hydrogen, chlorine, or methyl;

[0095] R3is hydrogen;

[0096] R4is hydrogen, or methyl;

[0097] R5and R6are hydrogen;

[0098] R7is hydrogen, C1-C4 alkyl, or Cs-Ce-cycloalkyl;

[0099] R8is hydrogen, bromine, chlorine, or cyano;

[0100] R9is hydrogen, bromine, chlorine, cyano, methyl, or methoxy;

[0101] B1is N or CR10, wherein R10is hydrogen, bromine, chlorine, or cyano;

[0102] B2is N or CR11, wherein R11is hydrogen, bromine, chlorine, or cyano;

[0103] A is A4, A6, A7, A9, or A10; and

[0104] Z1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 or 2 heteroatoms selected from N; and wherein said phenyl and said 6-membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents selected from fluorine.

[0105] In another embodiment the compound of formula (I) may be a compound of formula (l-A), wherein

[0106] R1is methyl, R2is hydrogen, chlorine, or methyl;

[0107] R3is hydrogen;

[0108] R4is hydrogen, or methyl;

[0109] R5and R6are hydrogen;

[0110] R7is hydrogen, C1-C4 alkyl, or Cs-Ce-cycloalkyl;

[0111] R8is hydrogen, bromine, chlorine, or cyano;

[0112] R9is hydrogen, bromine, chlorine, cyano, methyl, or methoxy;

[0113] B1is CR10, wherein R10is hydrogen, bromine, chlorine, or cyano;

[0114] B2is CR11, wherein R11is hydrogen, bromine, chlorine, or cyano;

[0115] A is A4, A6, A7, A9, or A10; and

[0116] Z1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 or 2 heteroatoms selected from N; and wherein said phenyl and said 6-membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents selected from fluorine.

[0117] In a further embodiment the compound of formula (I) may be a compound of formula (l-A), wherein

[0118] R1is methyl,

[0119] R2is hydrogen, chlorine, or methyl;

[0120] R3is hydrogen;

[0121] R4is hydrogen, or methyl;

[0122] R5and R6are hydrogen;

[0123] R7is hydrogen, C1-C4 alkyl, or Cs-Ce-cycloalkyl;

[0124] R8is hydrogen, bromine, chlorine, or cyano;

[0125] R9is hydrogen, bromine, chlorine, cyano, methyl, or methoxy;

[0126] B1is CR10, wherein R10is hydrogen, bromine, chlorine, or cyano;

[0127] B2is CR11, wherein R11is hydrogen, bromine, chlorine, or cyano;

[0128] A is A4, A7, or A9; and

[0129] Z1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 or 2 heteroatoms selected from N; and wherein said phenyl and said 6-membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents selected from fluorine.

[0130] In a further embodiment the compound of formula (I) may be a compound of formula (l-A), wherein

[0131] R1is methyl,

[0132] R2is hydrogen, chlorine, or methyl;

[0133] R3is hydrogen;

[0134] R4is hydrogen, or methyl;

[0135] R5and R6are hydrogen;

[0136] R7is hydrogen, C1-C4 alkyl, or Cs-Ce-cycloalkyl;

[0137] R8is hydrogen;

[0138] R9is hydrogen, bromine, chlorine, cyano, methyl, or methoxy;

[0139] B1is CH; B2is N or CR11, wherein R11is hydrogen;

[0140] A is selected from A1 , A4, A7, A9, or A10; and

[0141] Z1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 heteroatom selected from N; and wherein said phenyl and said 6-membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents selected from fluorine.

[0142] Preferably, component (A) is a compound selected from the group consisting of

[0143] [5-(2,4-difluorophenyl)-1 ,3,4-oxadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.01),

[0144] [3-(2,4-difluorophenyl)-1 ,2,4-oxadiazol-5-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.02),

[0145] [4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-propyl-1 ,3, 4-thiadiazol-2-yl) methanone

[0146] (X.03),

[0147] (5-cyclohexyl-1 ,3,4-thiadiazol-2-yl)-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.04),

[0148] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1 -methyl-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinolin-2-yl]methanone (X.05),

[0149] [5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[(4R)-4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.06),

[0150] [5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.07), 1-[4-[2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-3,4-dihydro-1 H-isoquinolin-4-yl]-2-methyl-pyrazol-3- yl]ethenone (X.08), methyl 2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinoline-1 - carboxylate (X.09),

[0151] [5-(4-fluorophenyl)-1 ,3,4-oxadiazol-2-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.10),

[0152] [4-(5-chloro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2,4-difluorophenyl)isoxazol-3- yl]methanone (X.11), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(5-fluoro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.12),

[0153] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[3,3-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,4-dihydroisoquinolin-2- yl]methanone (X.13),

[0154] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2-yl]methanone (X.14),

[0155] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[5-(1 ,3,5-trimethylpyrazol-4-yl)-6,8-dihydro-5H-1 ,7-naphthyridin-7- yl]methanone (X.15),

[0156] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.16), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 ,2,4-oxadiazol-3-yl)methanone (X.17), (3-cyclohexylisoxazol-5-yl)-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.18), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 ,3,4-oxadiazol-2-yl)methanone (X.19), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.20),

[0157] [5-(3,5-difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1 -methyl-3,4-dihydro-1 H- isoquinolin-2-yl]methanone (X.21 ),

[0158] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-1 ,4-dimethyl-4-(1 -methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.22), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(4-pyridyl)isoxazol-3-yl]methanone (X.23), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(3-pyridyl)isoxazol-3-yl]methanone (X.24), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2-pyridyl)isoxazol-3-yl]methanone (X.25), [5-(6-methoxy-3-pyridyl)isoxazol-3-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone

[0159] (X.26), [5-(2-methoxy-3-pyridyl)isoxazol-3-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.27),

[0160] [5-(3,5-difluoro-2-pyridyl)-1 ,3,4-thiadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.28), or

[0161] [5-(2,6-difluoro-3-pyridyl)-1 ,3,4-thiadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.29), or one of the (S)- or (R)-enantiomers thereof, as defined in Table X below.

[0162] More preferably, component (A) is a compound selected from the group consisting of [5-(2,4-difluorophenyl)-1 ,3,4-oxadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.01),

[0163] [3-(2,4-difluorophenyl)-1 ,2,4-oxadiazol-5-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.02),

[0164] [4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-propyl-1 ,3, 4-thiadiazol-2-yl) methanone (X.03),

[0165] (5-cyclohexyl-1 ,3,4-thiadiazol-2-yl)-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.04),

[0166] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1 -methyl-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinolin-2-yl]methanone (X.05),

[0167] [5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[(4R)-4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.06),

[0168] [5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.07), 1-[4-[2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-3,4-dihydro-1 H-isoquinolin-4-yl]-2-methyl-pyrazol-3- yl]ethenone (X.08), methyl 2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinoline-1 - carboxylate (X.09),

[0169] [5-(4-fluorophenyl)-1 ,3,4-oxadiazol-2-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.10), [4-(5-chloro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2,4-difluorophenyl)isoxazol-3- yl]methanone (X.11), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(5-fluoro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.12), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[3,3-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,4-dihydroisoquinolin-2- yl]methanone (X.13),

[0170] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2-yl]methanone (X.14),

[0171] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[5-(1 ,3,5-trimethylpyrazol-4-yl)-6,8-dihydro-5H-1 ,7-naphthyridin-7- yl]methanone (X.15),

[0172] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.16),

[0173] [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 ,2,4-oxadiazol-3-yl)methanone (X.17), (3-cyclohexylisoxazol-5-yl)-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.18), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 ,3,4-oxadiazol-2-yl)methanone (X.19), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.20),

[0174] [5-(3,5-difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1 -methyl-3,4-dihydro-1 H- isoquinolin-2-yl]methanone (X.21 ),

[0175] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-1 ,4-dimethyl-4-(1 -methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.22),

[0176] [5-(3,5-difluoro-2-pyridyl)-1 ,3,4-thiadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.28), or

[0177] [5-(2,6-difluoro-3-pyridyl)-1 ,3,4-thiadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.29), or one of the (S)- or (R)-enantiomers thereof, as defined in Table X below.

[0178] Even more preferably, component (A) is a compound selected from:

[0179] [3-(2,4-difluorophenyl)-1 ,2,4-oxadiazol-5-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.02),

[0180] (5-cyclohexyl-1 ,3,4-thiadiazol-2-yl)-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.04),

[0181] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1 -methyl-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinolin-2-yl]methanone (X.05),

[0182] [5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[(4R)-4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.06), [5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.07),

[0183] 1-[4-[2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-3,4-dihydro-1 H-isoquinolin-4-yl]-2-methyl-pyrazol-3- yl]ethenone (X.08), methyl 2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinoline-1 - carboxylate (X.09),

[0184] [4-(5-chloro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2,4-difluorophenyl)isoxazol-3- yl]methanone (X.11),

[0185] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(5-fluoro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.12), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[3,3-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,4-dihydroisoquinolin-2- yl]methanone (X.13),

[0186] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2-yl]methanone

[0187] (X.14),

[0188] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone

[0189] (X.16),

[0190] [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 ,3,4-oxadiazol-2-yl)methanone (X.19)

[0191] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone

[0192] (X.20),

[0193] [5-(3,5-difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1 -methyl-3,4-dihydro-1 H- isoquinolin-2-yl]methanone (X.21), or

[0194] [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-1 ,4-dimethyl-4-(1 -methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.22), or one of the (S)- or (R)-enantiomers thereof, as defined in Table X below.

[0195] Table X: Component (A)

[0196] In one embodiment component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penflufen, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, isofetamid, fluindapyr, cyclobutrifluram, fluoxastrobin, fenamidone, mandestrobin, picoxystrobin, pyraclostrobin, famoxadone, kresoxim-methyl, trifloxystrobin, azoxystrobin, metyltetraprole, amisulbrom, cyazofamid, fenpicoxamid, florylpicoxamid, metharylpicoxamid, ametoctradin, fluazinam, fentin hydroxide, silthiofam, fenpropimorph, fenpropidin, spiroxamine, fenhexamid, imazalil, pyrisoxazole, bromuconazole, cyproconazole, difenoconazole, epoxiconazole, flutriafol, hexaconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole, triticonazole, prothioconazole, fluoxytioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, kasugamycin, mancozeb, copper fungicides, sulphur, zinc thiazole, captan, folpet, chlorothalonil, dithianon, quinoxyfen, proquinazid, fludioxonil, iprodione, procymidone, thiabendazole, zoxamide, metrafenone, fluopicolide, propamocarb, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, isotianil, phosphorous acid, cyflufenamid, tebufloquin, picarbutrazox, tricyclazole, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N- [(1 R)-1 -benzyl-3-chloro-1 -methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-3-chloro-1 - methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1 -[(3-fluorophenyl)methyl]-1 ,3- dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl- butyl]quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N- [(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-((1 R)-1 -benzyl-3-chloro-1 -methyl-but- 3-enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline- 3-carboxamide, methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3- isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3- propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1 - yl]phenoxy]prop-2-enoate, methyl (Z)-2-(5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate (these compounds may be prepared from the methods described in W02020 / 193387), 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N- spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5- methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)- (oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A.

[0197] Preferably, component (B) is a compound selected from pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, fluindapyr, cyclobutrifluram, pyraclostrobin, trifloxystrobin, azoxystrobin, metyltetraprole, fenpicoxamid, florylpicoxamid, metharylpicoxamid, fluazinam, fenpropidin, fenhexamid, cyproconazole, difenoconazole, metconazole, penconazole, propiconazole, tebuconazole, tetraconazole, prothioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, mancozeb, copper-compounds (different salts), sulphur, folpet, chlorothalonil, dithianon, proquinazid, fludioxonil, metrafenone, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, phosphorous acid, cyflufenamid, tricyclazole, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N- [(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3-chloro-1- methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1 -[(3-fluorophenyl)methyl]-1 ,3- dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl- butyl]quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N- [(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-((1 R)-1 -benzyl-3-chloro-1 -methyl-but- 3-enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline- 3-carboxamide, methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3- isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3- propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1 - yl]phenoxy]prop-2-enoate, methyl (Z)-2-(5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate (these compounds may be prepared from the methods described in W02020 / 193387), 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N- spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5- methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)- (oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A.

[0198] More preferably, component (B) is a compound selected from pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S- methyl, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3- yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl- thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A.

[0199] Still more preferably, component (B) is a compound selected from pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl.

[0200] In one embodiment component (B) is a compound selected from pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl.

[0201] In another embodiment component (B) is a compound selected from TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A.

[0202] In another prefered embodiment component (B) is a compound selected from pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broadspectrum botanical biofungicide)), or Aureobasidin A.

[0203] The component (B) compounds are referred to herein and above by a so-called "ISO common name" or another "common name" being used in individual cases or a trademark name. The component (B) compounds are known and are commercially available and / or can be prepared using procedures known in the art and / or procedures reported in the literature.

[0204] N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2- dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1 - [[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl]phenyl]methyl]urea, these compounds may be prepared from the methods described in WO 2017 / 055473, WO 2017 / 055469, WO 2017 / 093348 and WO 2017 / 118689.

[0205] Methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3- methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)- 2-methyl-phenoxy]-3-methoxy-prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1- yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop- 2-enoate (these compounds may be prepared from the methods described in W02020 / 079111), methyl (Z)-2- (5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3- methoxy-prop-2-enoate, these compounds may be prepared from the methods described in W02020 / 193387.

[0206] N-[(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3-chloro- 1 -methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1 -[(3-fluorophenyl)methyl]-1 ,3- dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl- butyl]quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N- [(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-((1 R)-1 -benzyl-3-chloro-1 -methyl-but- 3-enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline- 3-carboxamide, these compounds may be prepared from the methods described in WO2017 / 153380.

[0207] 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano- (2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-hexyl-5-methyl-thiazole-4-carboxamide, these compounds may be prepared from the methods described in WO2017207362A1 , WO2019105933A1 , W02020109509A1 ; 2-[(2,6-difluoro-4- pyridyl)-(2-methoxyacetyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl- thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N- (2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, these compounds may be prepared from the methods described in WO2017207362A1 , WO2019105933A1 , W02020109511A1 , WO2021244952A1 .

[0208] “TIMOREX Gold™" or “Timorex Gold®” as used herein refers to melaluca alternifolia oil, which is an extract of the tea tree plant Melaluca alternifolia, commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide.

[0209] TAEGRO™ or TAEGRO® as used herein refers to a microorganism-based fungicide formulated as a wettable powder containing 130 g / kg Bacillus amyloliquefaciens strain FZB24, having Accession No. DSM 10271 (13% w / w minimum of 1x1013 cfu / kg), commercially available as TAEGRO®.

[0210] BOTRISTOP® as used herein refers to a broad spectrum biofungicide, a plant extract based on the extract of Quillaja saponaria Molina

[0211] “REGALIA®” as used herein refers to a biofungicide, a plant extract based on the extract of Reynoutria sachalinensis extract (commercially available as REGALIA®) Aureobasidin A is an antifungal cyclic depsipeptide antibiotic produced by Aureobasidium pullulans. See, for instance, Takesako et al., J. of Antibiot. 1991 , 44, 919-924. WO 2018 / 102345 discloses use of Aureobasidin A as an agricultural fungicide to treat, 10 prevent or control fungal infections in plants and seeds.

[0212] According to another aspect the present invention, there is provided a fungicidal composition comprising a mixture of components (A) and (B) as active ingredients, wherein component (A) is a compound of formula (I- wherein R1is methyl; R2is hydrogen, chlorine, or methyl; R3is hydrogen; R4is hydrogen, or methyl; R5and R6are hydrogen; R7is hydrogen, C1-C4 alkyl, or Cs-Ce-cycloalkyl; R8is hydrogen; R9is hydrogen, bromine, chlorine, cyano, methyl, or methoxy; B1is CH; B2is N or CR11, wherein R11is hydrogen; A is selected from A1 , A4, A7, A9, or A10; , , , wherein denotes the bond to the C(=O) group and the arrow denotes the bond to the Z1group, and Z1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 heteroatom selected from N; and wherein said phenyl and said 6-membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents selected from fluorine. and component (B) is a compound selected from: pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penflufen, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, isofetamid, fluindapyr, cyclobutrifluram, fluoxastrobin, fenamidone, mandestrobin, picoxystrobin, pyraclostrobin, famoxadone, kresoxim-methyl, trifloxystrobin, azoxystrobin, metyltetraprole, amisulbrom, cyazofamid, fenpicoxamid, florylpicoxamid, metharylpicoxamid, ametoctradin, fluazinam, fentin hydroxide, silthiofam, fenpropimorph, fenpropidine, spiroxamine, fenhexamid, imazalil, pyrisoxazole, bromuconazole, cyproconazole, difenoconazole, epoxiconazole, flutriafol, hexaconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole, triticonazole, prothioconazole, fluoxytioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, kasugamycin, mancozeb, copper fungicides, sulphur, zinc thiazole, captan, folpet, chlorothalonil, dithianon, quinoxyfen, proquinazid, fludioxonil, iprodione, procymidone, thiabendazole, zoxamide, metrafenone, fluopicolide, propamocarb, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, isotianil, phosphorous acid, cyflufenamid, tebufloquin, picarbutrazox, tricyclazole, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N- [(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3-chloro-1- methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1 -[(3-fluorophenyl)methyl]-1 ,3- dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl- butyl]quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N- [(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-((1 R)-1 -benzyl-3-chloro-1 -methyl-but- 3-enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline- 3-carboxamide, methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3- isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3- propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1 - yl]phenoxy]prop-2-enoate, methyl (Z)-2-(5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5- methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5- methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)- (oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A, with the proviso that the compound of formula (I) is not or an agrochemically acceptable salt, stereoisomer, enantiomer, tautomer or N-oxide thereof.

[0213] The PubChem Compound ID given for the above disclaimed compounds refers to the identification number of each compound in the PubChem website htt s: / / pubchem.ncbi.nlm.nih.gov / . Preferably, there is provided a fungicidal composition comprising a mixture of components (A) and (B) as active ingredients, wherein component (A) is a compound of formula (l-A) wherein R1is methyl; R2is hydrogen, chlorine, or methyl; R3is hydrogen; R4is hydrogen, or methyl; R5and R6are hydrogen; R7is hydrogen, C1-C4 alkyl, or Cs-Ce-cycloalkyl; R8is hydrogen; R9is hydrogen, bromine, chlorine, cyano, methyl, or methoxy; B1is CH; B2is N or CR11, wherein R11is hydrogen; A is selected from A1 , A4, A7, A9, or A10;

[0214] A1 A4 , A7 , A9, or A10 wherein denotes the bond to the C(=O) group and the arrow denotes the bond to the Z1group, and Z1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 heteroatom selected from N; and wherein said phenyl and said 6-membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents selected from fluorine. and component (B) is a compound selected from pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1- benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro- quinoline-3-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5- methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl- thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broadspectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A, with the proviso that the compound of formula (I) is not or an agrochemically acceptable salt, stereoisomer, enantiomer, tautomer or N-oxide thereof.

[0215] The PubChem Compound ID given for the above disclaimed compounds refers to the identification number of each compound in the PubChem website https: / / pubchem.ncbi.nlm.nih.gov / .

[0216] Enantiomerically pure final compounds may be obtained from racemic starting materials as appropriate via standard physical separation techniques, such as reverse phase chiral chromatography, or through stereoselective synthetic techniques, e.g., by using chiral starting materials.

[0217] The term “component A” refers to the compound of formula (I).

[0218] The following mixtures of components (A), wherein component (A) is a compound of formula (I) with component (B) as active ingredients are preferred (wherein the term “AX” means one component (A) selected from compounds (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.11), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), listed in table X according to the present invention): pydiflumetofen + AX, benzovindiflupyr + AX, bixafen + AX, fluxapyroxad + AX, isopyrazam + AX, penflufen + AX, penthiopyrad + AX, sedaxane + AX, boscalid + AX, fluopyram + AX, thifluzamide + AX, pyraziflumid + AX, isoflucypram + AX, inpyrfluxam + AX, isofetamid + AX, fluindapyr + AX, cyclo butriflu ram + AX, fluoxastrobin + AX, fenamidone + AX, mandestrobin + AX, picoxystrobin + AX, pyraclostrobin + AX, famoxadone + AX, kresoxim-methyl + AX, trifloxystrobin + AX, azoxystrobin + AX, metyltetraprole + AX, amisulbrom + AX, cyazofamid + AX, fenpicoxamid + AX, florylpicoxamid + AX, metharylpicoxamid + AX, ametoctradin + AX, fluazinam + AX, fentin hydroxide + AX, silthiofam + AX, fenpropimorph + AX, fenpropidin + AX, spiroxamine + AX, fenhexamid + AX, imazalil + AX, pyrisoxazole + AX, bromuconazole + AX, cyproconazole + AX, difenoconazole + AX, epoxiconazole, flutriafol + AX, hexaconazole + AX, ipconazole + AX, metconazole + AX, myclobutanil + AX, penconazole + AX, propiconazole + AX, tebuconazole + AX, tetraconazole + AX, triticonazole + AX, proth ioconazole + AX, fluoxytioconazole + AX, mefentrifluconazole + AX, flufenoxadiazam + AX, ipflufenoquin + AX, quinofumelin + AX, metalaxyl-M + AX, cyprodinil + AX, pyrimethanil + AX, kasugamycin + AX, mancozeb + AX, copper fungicides + AX, sulphur + AX, zinc thiazole + AX, captan + AX, folpet + AX, chlorothalonil + AX, dithianon + AX, quinoxyfen + AX, proquinazid + AX, fludioxonil + AX, iprodione + AX, procymidone + AX, thiabendazole + AX, zoxamide + AX, metrafenone + AX, fluopicolide + AX, propamocarb + AX, oxathiapiprolin + AX, fluoxapiprolin + AX, acibenzolar-S-methyl + AX, isotianil + AX, phosphorous acid + AX, cyflufenamid + AX, tebufloquin + AX, picarbutrazox + AX, tricyclazole + AX, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl]phenyl]methyl]cyclopropanecarboxamide + AX, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl]phenyl]methyl]propanamide + AX, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea + AX, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea + AX, N-[(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide + AX, N-[(1 S)-1-benzyl- 3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide + AX, N-[(1 R)-1-benzyl-3,3,3-trifluoro-1- methyl-propyl]-8-fluoro-quinoline-3-carboxamide + AX, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8- fluoro-quinoline-3-carboxamide + AX, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3- carboxamide + AX, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide + AX, 8-fluoro- N-[(1 R)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide + AX, 8-fluoro-N-[(1 S)-1 -[(3- fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide + AX, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide + AX, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide + AX, N-((1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide + AX, N-((1 S)-1-benzyl- 3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide + AX, methyl (Z)-3-methoxy-2-[2-methyl-5-[4- (trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate + AX, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-

[0219] 2-yl)phenoxy]prop-2-enoate + AX, methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy- prop-2-enoate + AX, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate + AX, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate + AX, methyl (Z)-2- (5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate + AX, methyl (Z)-2-(5-cyclopentyl-2-methyl- phenoxy)-3-methoxy-prop-2-enoate + AX, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-

[0220] 3-yl-thiazole-4-carboxamide + AX, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5- methyl-thiazole-4-carboxamide + AX, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5-methyl-thiazole-4- carboxamide + AX, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl- thiazole-4-carboxamide + AX, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide + AX, 2-[(2,6-difluoro-4-pyridyl)-(oxetane-3- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide + AX, 2-[(2,6-difluoro-4-pyridyl)- (tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide + AX, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide + AX, 2- [(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide + AX, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24) + AX, melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broadspectrum botanical biofungicide)) + AX, Reynoutria sachalinensis extract (commercially available as REGALIA®) + AX, a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®) + AX, and Aureobasidin A + AX.

[0221] In another embodiment of the invention the following mixtures of components (A), wherein component (A) is a compound of formula (I) with component (B) as active ingredients are preferred (wherein the term “AX” means one component (A) selected from compounds (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.11), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), listed in table X according to the present invention): pydiflumetofen + AX, benzovindiflupyr + AX, bixafen + AX, fluxapyroxad + AX, isopyrazam + AX, penflufen + AX, penthiopyrad + AX, sedaxane + AX, boscalid + AX, fluopyram + AX, thifluzamide + AX, pyraziflumid + AX, isoflucypram + AX, inpyrfluxam + AX, isofetamid + AX, fluindapyr + AX, cyclobutrifluram + AX, fluoxastrobin + AX, fenamidone + AX, mandestrobin + AX, picoxystrobin + AX, pyraclostrobin + AX, famoxadone + AX, kresoxim-methyl + AX, trifloxystrobin + AX, azoxystrobin + AX, metyltetraprole + AX, amisulbrom + AX, cyazofamid + AX, fenpicoxamid + AX, florylpicoxamid + AX, metharylpicoxamid + AX, ametoctradin + AX, fluazinam + AX, fentin hydroxide + AX, silthiofam + AX, fenpropimorph + AX, fenpropidin + AX, spiroxamine + AX, fenhexamid + AX, imazalil + AX, pyrisoxazole + AX, bromuconazole + AX, cyproconazole + AX, difenoconazole + AX, epoxiconazole, flutriafol + AX, hexaconazole + AX, ipconazole + AX, metconazole + AX, myclobutanil + AX, penconazole + AX, propiconazole + AX, tebuconazole + AX, tetraconazole + AX, triticonazole + AX, proth ioconazole + AX, fluoxytioconazole + AX, mefentrifluconazole + AX, flufenoxadiazam + AX, ipflufenoquin + AX, quinofumelin + AX, metalaxyl-M + AX, cyprodinil + AX, pyrimethanil + AX, kasugamycin + AX, mancozeb + AX, copper fungicides + AX, sulphur + AX, zinc thiazole + AX, captan + AX, folpet + AX, chlorothalonil + AX, dithianon + AX, quinoxyfen + AX, proquinazid + AX, fludioxonil + AX, iprodione + AX, procymidone + AX, thiabendazole + AX, zoxamide + AX, metrafenone + AX, fluopicolide + AX, propamocarb + AX, oxathiapiprolin + AX, fluoxapiprolin + AX, acibenzolar-S-methyl + AX, isotianil + AX, phosphorous acid + AX, cyflufenamid + AX, tebufloquin + AX, picarbutrazox + AX, tricyclazole + AX, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl]phenyl]methyl]cyclopropanecarboxamide + AX, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol- 3-yl]phenyl]methyl]propanamide + AX, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea + AX, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea + AX, N-[(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide + AX, N-[(1 S)-1-benzyl- 3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide + AX, N-[(1 R)-1-benzyl-3,3,3-trifluoro-1- methyl-propyl]-8-fluoro-quinoline-3-carboxamide + AX, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8- fluoro-quinoline-3-carboxamide + AX, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3- carboxamide + AX, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide + AX, 8-fluoro- N-[(1 R)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide + AX, 8-fluoro-N-[(1 S)-1 -[(3- fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide + AX, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide + AX, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide + AX, N-((1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide + AX, N-((1 S)-1-benzyl- 3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide + AX, methyl (Z)-3-methoxy-2-[2-methyl-5-[4- (trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate + AX, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-

[0222] 2-yl)phenoxy]prop-2-enoate + AX, methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy- prop-2-enoate + AX, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate + AX, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate + AX, methyl (Z)-2- (5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate + AX, methyl (Z)-2-(5-cyclopentyl-2-methyl- phenoxy)-3-methoxy-prop-2-enoate + AX, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-

[0223] 3-yl-thiazole-4-carboxamide + AX, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5- methyl-thiazole-4-carboxamide + AX, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5-methyl-thiazole-4- carboxamide + AX, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl- thiazole-4-carboxamide + AX, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide + AX, 2-[(2,6-difluoro-4-pyridyl)-(oxetane-3- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide + AX, 2-[(2,6-difluoro-4-pyridyl)- (tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide + AX, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide + AX, 2- [(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide + AX, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24) + AX, melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broadspectrum botanical biofungicide)) + AX, Reynoutria sachalinensis extract (commercially available as REGALIA®) + AX, a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®) + AX, and Aureobasidin A + AX, wherein the ratio of weight ratio of component (A) to component (B) is from 100:1 to 1 :40, preferably from 40:1 to 1 :40, even more preferably from 20:1 to 1 :20, still more preferably from 15:1 to 1 :30, still even more preferably from 10:1 to 1 :10, most preferably from 5:1 to 1 :5 and even most preferably from 2:1 to 1 :2.

[0224] In another embodiment of the invention the following mixtures of components (A), wherein component (A) is a compound of formula (I) with component (B) as active ingredients are preferred (wherein the term “AX” means one component (A) selected from compounds (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.11), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), listed in table X according to the present invention): TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24) + AX, melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)) + AX, Reynoutria sachalinensis extract (commercially available as REGALIA®) + AX, a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®) + AX, or Aureobasidin A + AX.

[0225] In another embodiment of the invention the following mixtures of components (A), wherein component (A) is a compound of formula (I) with component (B) as active ingredients are preferred (wherein the term “AX” means one component (A) selected from compounds (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.11), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), listed in table X according to the present invention): TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24) + AX, melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)) + AX, Reynoutria sachalinensis extract (commercially available as REGALIA®) + AX, a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®) + AX, or Aureobasidin A + AX, wherein the weight ratio of component (A) to component (B) is from 100:1 to 1 :40.

[0226] In another preferred embodiment of the invention the following mixtures of components (A), wherein component (A) is a compound of formula (I) with component (B) as active ingredients are preferred (wherein the term “AX” means one component (A) selected from compounds (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.1 1), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), listed in table X according to the present invention): TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24) + AX, melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)) + AX, Reynoutria sachalinensis extract (commercially available as REGALIA®) + AX, a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®) + AX, or Aureobasidin A + AX, wherein the weight ratio of component (A) to component (B) is from 40:1 to 1 :40.

[0227] In another more preferred embodiment of the invention the following mixtures of components (A), wherein component (A) is a compound of formula (I) with component (B) as active ingredients are preferred (wherein the term “AX” means one component (A) selected from compounds (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.1 1), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), listed in table X according to the present invention): TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24) + AX, melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)) + AX, Reynoutria sachalinensis extract (commercially available as REGALIA®) + AX, a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®) + AX, or Aureobasidin A + AX, wherein the weight ratio of component (A) to component (B) is from 40:1 to 1 :20.

[0228] In another even more preferred embodiment of the invention the following mixtures of components (A), wherein component (A) is a compound of formula (I) with component (B) as active ingredients are preferred (wherein the term “AX” means one component (A) selected from compounds (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.1 1), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), listed in table X according to the present invention): TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24) + AX, melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)) + AX, Reynoutria sachalinensis extract (commercially available as REGALIA®) + AX, a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®) + AX, or Aureobasidin A + AX, wherein the weight ratio of component (A) to component (B) is from 20:1 to 1 :20.

[0229] In a still more preferred embodiment of the invention the following mixtures of components (A), wherein component (A) is a compound of formula (I) with component (B) as active ingredients are preferred (wherein the term “AX” means one component (A) selected from compounds (X.02), (X.04), (X.05), (X.06), (X.07), (X.08), (X.09), (X.11), (X.12), (X.13), (X.14), (X.16), (X.19), (X.20), (X.21), or (X.22), listed in table X according to the present invention): TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24) + AX, melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broadspectrum botanical biofungicide)) + AX, Reynoutria sachalinensis extract (commercially available as REGALIA®) + AX, a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®) + AX, or Aureobasidin A + AX, wherein the weight ratio of component (A) to component (B) is from 20:1 to 1 :20.

[0230] In another still more preferred embodiment of the invention component (A) is compound no. X.05 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1 -methyl-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 40:1 to 1 :40, preferably from 20:1 to 1 :20. In a preferred embodiment this composition comprises the stereoisomers of X.05, wherein the methyl-group (R7) and the (1 -methylpyrazol-4-yl)-group have a syn- relationship to each other. Preferably this composition comprises the (1 S,4S)-enantiomer of compound X.05, or a salt or N-oxide thereof. Alternatively in another embodiment this composition comprises the (1 R,4R)- enantiomer of compound X.05, or a salt or N-oxide thereof.

[0231] In another still more preferred embodiment of the invention component (A) is compound no. X.09 methyl 2-[5- (2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinoline-1 -carboxylate, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 40:1 to 1 :40, preferably from 20:1 to 1 :20. In a preferred embodiment this composition comprises the stereoisomers of X.09, wherein the carboxylate-group (R7) and the (1-methylpyrazol-4-yl)-group have a syn-relationship to each other. Preferably this composition comprises the (1 S,4S)-enantiomer of compound X.09, or a salt or N-oxide thereof. Alternatively in another embodiment this composition comprises the (1 R,4R)-enantiomer of compound X.09, or a salt or N-oxide thereof.

[0232] In another still more preferred embodiment of the invention component (A) is compound no. X.16 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 40:1 to 1 :40, preferably from 20:1 to 1 :20. In another still more preferred embodiment of the invention component (A) is compound no. X.21 [5-(3,5- difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1 -methyl-3,4-dihydro-1 H-isoquinolin- 2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 40:1 to 1 :40, preferably from 20:1 to 1 :20. In a preferred embodiment this composition comprises the stereoisomers of X.21 , wherein the methyl group (R7) and the (1 ,5-dimethylpyrazol-4-yl)-group have a syn-relationship to each other. Preferably this composition comprises the (1 S,4S)-enantiomer of compound X.21 , or a salt or N-oxide thereof. Alternatively in another embodiment this composition comprises the (1 R,4R)-enantiomer of compound X.21 , or a salt or N-oxide thereof.

[0233] In another still more preferred embodiment of the invention component (A) is compound no. X.22 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-1 ,4-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 40:1 to 1 :40, preferably from 20:1 to 1 :20. ). In a preferred embodiment this composition comprises the stereoisomers of X.22, wherein the methyl group (R7) and the (1-methylpyrazol-4-yl)-group have a syn- relationship to each other. Preferably this composition comprises the (1 S,4S)-enantiomer of compound X.22, or a salt or N-oxide thereof. Alternatively in another embodiment this composition comprises the (1 R,4R)- enantiomer of compound X.22, or a salt or N-oxide thereof.

[0234] In a preferred composition according to the invention component (A) is compound no. X.02 [3-(2,4- difluorophenyl)-1 ,2,4-oxadiazol-5-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0235] In another preferred composition according to the invention component (A) is compound no. X.04 (5-cyclohexyl- 1 ,3, 4-th iadiazol-2-yl)-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0236] In another preferred composition according to the invention component (A) is compound no. X.05 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1 -methyl-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S- methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3- yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl- thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0237] In another preferred composition according to the invention component (A) is compound no. X.06 [5-(2,4- difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[(4R)-4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0238] In another preferred composition according to the invention component (A) is compound no. X.07 [5-(2,4- difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[4-methyl-4-(1 -methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0239] In another preferred composition according to the invention component (A) is compound no. X.08 1-[4-[2-[5- (2,4-difluorophenyl)isoxazole-3-carbonyl]-3,4-dihydro-1 H-isoquinolin-4-yl]-2-methyl-pyrazol-3-yl]ethenone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0240] In another preferred composition according to the invention component (A) is compound no. X.09 methyl 2-[5- (2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinoline-1 -carboxylate, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0241] In another preferred composition according to the invention component (A) is compound no. X.11 [4-(5-chloro- 1 -methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2,4-difluorophenyl)isoxazol-3-yl]methanon3, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0242] In another preferred composition according to the invention component (A) is compound no. X.12 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[4-(5-fluoro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0243] In another preferred composition according to the invention component (A) is compound no. X.13 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[3,3-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,4-dihydroisoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0244] In another preferred composition according to the invention component (A) is compound no. X.14 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[4-methyl-4-(1 -methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0245] In another preferred composition according to the invention component (A) is compound no. X.16 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0246] In another preferred composition according to the invention component (A) is compound no. X.19 [4-(1- methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 ,3,4-oxadiazol-2-yl)methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0247] In another preferred composition according to the invention component (A) is compound no. X.20 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0248] In another preferred composition according to the invention component (A) is compound no. X.21 [5-(3,5- difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1 -methyl-3,4-dihydro-1 H-isoquinolin- 2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0249] In another preferred composition according to the invention component (A) is compound no. X.22 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-1 ,4-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 15:1 to 1 :30.

[0250] In a still more preferred composition according to the invention component (A) is compound no. X.02 [3-(2,4- difluorophenyl)-1 ,2,4-oxadiazol-5-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0251] In another still more preferred composition according to the invention component (A) is compound no. X.04 (5- cyclohexyl-1 ,3,4-th iadiazol-2-yl)-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0252] In another still more preferred composition according to the invention component (A) is compound no. X.05 [5- (2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1-methyl-4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S- methyl, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3- yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl- thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0253] In another still more preferred composition according to the invention component (A) is compound no. X.06 [5- (2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[(4R)-4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0254] In another still more preferred composition according to the invention component (A) is compound no. X.07 [5- (2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0255] In another still more preferred composition according to the invention component (A) is compound no. X.08 1- [4-[2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-3,4-dihydro-1 H-isoquinolin-4-yl]-2-methyl-pyrazol-3- yl]ethenone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0256] In another still more preferred composition according to the invention component (A) is compound no. X.09 methyl 2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinoline-1 - carboxylate, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0257] In another still more preferred composition according to the invention component (A) is compound no. X.11 [4- (5-chloro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2,4-difluorophenyl)isoxazol-3- yl]methanon3, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1 -benzyl- 1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0258] In another still more preferred composition according to the invention component (A) is compound no. X.12 [5- (2,4-difluorophenyl)isoxazol-3-yl]-[4-(5-fluoro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0259] In another still more preferred composition according to the invention component (A) is compound no. X.13 [5- (2,4-difluorophenyl)isoxazol-3-yl]-[3,3-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,4-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1 -benzyl- 1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0260] In another still more preferred composition according to the invention component (A) is compound no. X.14 [5- (2,4-difluorophenyl)isoxazol-3-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2-yl] methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0261] In another still more preferred composition according to the invention component (A) is compound no. X.16 [5- (2,4-difluorophenyl)isoxazol-3-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0262] In another still more preferred composition according to the invention component (A) is compound no. X.19 [4- (1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 ,3,4-oxadiazol-2-yl)methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0263] In another still more preferred composition according to the invention component (A) is compound no. X.20 [5- (2,4-difluorophenyl)isoxazol-3-yl]-[4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2- [cyano- (2,6- difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0264] In another still more preferred composition according to the invention component (A) is compound no. X.21 [5- (3,5-difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1 -methyl-3,4-dihydro-1 H- isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S- methyl, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3- yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl- thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0265] In another still more preferred composition according to the invention component (A) is compound no. X.22 [5- (2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-1 ,4-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), or Aureobasidin A, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0266] In a most preferred composition according to the invention component (A) is compound no. X.02 [3-(2,4- difluorophenyl)-1 ,2,4-oxadiazol-5-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5). In another most preferred composition according to the invention component (A) is compound no. X.04 (5- cyclohexyl-1 ,3, 4-th iadiazol-2-yl)-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0267] In another most preferred composition according to the invention component (A) is compound no. X.05 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1 -methyl-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S- methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0268] In another most preferred composition according to the invention component (A) is compound no. X.06 [5-(2,4- difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[(4R)-4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0269] In another most preferred composition according to the invention component (A) is compound no. X.07 [5-(2,4- difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[4-methyl-4-(1 -methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0270] In another most preferred composition according to the invention component (A) is compound no. X.08 1-[4- [2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-3,4-dihydro-1 H-isoquinolin-4-yl]-2-methyl-pyrazol-3- yl]ethenone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0271] In another most preferred composition according to the invention component (A) is compound no. X.09 methyl 2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinoline-1- carboxylate, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5). In another most preferred composition according to the invention component (A) is compound no. X.11 [4-(5- chloro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2,4-difluorophenyl)isoxazol-3-yl]methanon3, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0272] In another most preferred composition according to the invention component (A) is compound no. X.12 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[4-(5-fluoro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0273] In another most preferred composition according to the invention component (A) is compound no. X.13 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[3,3-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,4-dihydroisoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0274] In another most preferred composition according to the invention component (A) is compound no. X.14 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[4-methyl-4-(1 -methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0275] In another most preferred composition according to the invention component (A) is compound no. X.16 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0276] In another most preferred composition according to the invention component (A) is compound no. X.19 [4-(1- methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 ,3,4-oxadiazol-2-yl)methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5). In another most preferred composition according to the invention component (A) is compound no. X.20 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0277] In another most preferred composition according to the invention component (A) is compound no. X.21 [5-(3,5- difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1 -methyl-3,4-dihydro-1 H-isoquinolin- 2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0278] In another most preferred composition according to the invention component (A) is compound no. X.22 [5-(2,4- difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-1 ,4-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5).

[0279] In still another most preferred composition according to the invention component (A) is compound no. X.05 [5- (2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1-methyl-4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S- methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5). ). In a preferred embodiment this composition comprises the stereoisomers of X.05, wherein the methyl-group (R7) and the (1-methylpyrazol-4-yl)-group have a syn-relationship to each other. Preferably this composition comprises the (1 S,4S)-enantiomer of compound X.05, or a salt or N-oxide thereof. Alternatively in another embodiment this composition comprises the (1 R,4R)-enantiomer of compound X.05, or a salt or N-oxide thereof.

[0280] In another most preferred composition according to the invention component (A) is compound no. X.09 methyl 2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1 -methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinoline-1- carboxylate, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5). In a preferred embodiment this composition comprises the stereoisomers of X.09, wherein the carboxylate-group (R7) and the (1-methylpyrazol-4-yl)-group have a syn-relationship to each other. Preferably this composition comprises the (1 S,4S)-enantiomer of compound X.09, or a salt or N-oxide thereof. Alternatively in another embodiment this composition comprises the (1 R,4R)-enantiomer of compound X.09, or a salt or N-oxide thereof.

[0281] In still another most preferred composition according to the invention component (A) is compound no. X.21 [5- (3,5-difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1 -methyl-3,4-dihydro-1 H- isoquinolin-2-yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S- methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5). In a preferred embodiment this composition comprises the stereoisomers of X.21 , wherein the methyl group (R7) and the (1 ,5-dimethylpyrazol-4-yl)-group have a syn-relationship to each other. Preferably this composition comprises the (1 S,4S)-enantiomer of compound X.21 , or a salt or N-oxide thereof. Alternatively in another embodiment this composition comprises the (1 R,4R)-enantiomer of compound X.21 , or a salt or N-oxide thereof.

[0282] In still another most preferred composition according to the invention component (A) is compound no. X.22 [5- (2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-1 ,4-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone, or a salt enantiomer, tautomer or N-oxide thereof, and component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, or acibenzolar-S-methyl, wherein the weight ratio of component (A) to component (B) is from 10:1 to 1 :10 (or even more preferably, 5:1 to 1 :5). In a preferred embodiment this composition comprises the stereoisomers of X.22, wherein the methyl group (R7) and the (1- methylpyrazol-4-yl)-group have a syn-relationship to each other. Preferably this composition comprises the (1 S,4S)-enantiomer of compound X.22, or a salt or N-oxide thereof. Alternatively in another embodiment this composition comprises the (1 R,4R)-enantiomer of compound X.22, or a salt or N-oxide thereof.

[0283] The term “compounds of formula (I)” refers to component A.

[0284] In any of the compositions according to the invention, the composition may comprise an additional active ingredient component (C), which is different to component (B), and is selected from the group consisting of pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penflufen, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, isofetamid, fluindapyr, cyclobutrifluram, fluoxastrobin, fenamidone, mandestrobin, picoxystrobin, pyraclostrobin, famoxadone, kresoxim-methyl, trifloxystrobin, azoxystrobin, metyltetraprole, amisulbrom, cyazofamid, fenpicoxamid, florylpicoxamid, metharylpicoxamid, ametoctradin, fluazinam, fentin hydroxide, silthiofam, fenpropimorph, fenpropidine, spiroxamine, fenhexamid, imazalil, pyrisoxazole, bromuconazole, cyproconazole, difenoconazole, epoxiconazole, flutriafol, hexaconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole, triticonazole, prothioconazole, fluoxytioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, kasugamycin, mancozeb, copper fungicides, sulphur, zinc thiazole, captan, folpet, chlorothalonil, dithianon, quinoxyfen, proquinazid, fludioxonil, iprodione, procymidone, thiabendazole, zoxamide, metrafenone, fluopicolide, propamocarb, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, isotianil, phosphorous acid, cyflufenamid, tebufloquin, picarbutrazox, tricyclazole, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N- [(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3-chloro-1- methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1 -[(3-fluorophenyl)methyl]-1 ,3- dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl- butyl]quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N- [(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-((1 R)-1 -benzyl-3-chloro-1 -methyl-but- 3-enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline- 3-carboxamide, methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3- isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3- propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1 - yl]phenoxy]prop-2-enoate, methyl (Z)-2-(5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5- methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5- methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)- (oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A.

[0285] Preferably, component (C), which is different to component (B), is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, fluindapyr, cyclobutrifluram, pyraclostrobin, trifloxystrobin, azoxystrobin, metyltetraprole, fenpicoxamid, florylpicoxamid, metarylpicoxamid, fluazinam, fenpropidin, fenhexamid, cyproconazole, difenoconazole, metconazole, penconazole, propiconazole, tebuconazole, tetraconazole, prothioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, mancozeb, copper-compounds (different salts), sulphur, folpet, chlorothalonil, dithianon, proquinazid, fludioxonil, metrafenone, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, phosphorous acid, cyflufenamid, tricyclazole, N-methoxy-N-[[4-[5- (trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5- (trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1 -[[4-[5-

[0286] (trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl]phenyl]methyl]urea, N-[(1 R)-1 -benzyl-3-chloro-1 -methyl-but-3-enyl]-8-fluoro-quinoline-3- carboxamide, N-[(1 S)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1- benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1 - methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-

[0287] 3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1-

[0288] [(3-fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1-[(3- fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N- ((1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1-benzyl-3-chloro-1- methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, methyl (Z)-3-methoxy-2-[2-methyl-5-[4- (trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2- yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2- enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl (Z)-3- methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl (Z)-2-(5-cyclohexyl-2- methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3-methoxy-prop- 2-enoate (these compounds may be prepared from the methods described in W02020 / 193387), 2-[cyano- (2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-

[0289] 4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4- pyridyl)amino]-N-hexyl-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]- N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)- (oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A.

[0290] Even more preferably, component (C), which is different to component (B), is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1-benzyl-1 ,3- dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A.

[0291] In another embodiment of the present invention, there is provided a fungicidal composition comprising a mixture of component (A) and a component (B) and a component (C) as active ingredients, wherein component (A) is a compound of formula (I) selected from compounds (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.11), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), listed in table X according to the present invention, and wherein component (C), and component (B), are a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penflufen, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, isofetamid, fluindapyr, cyclobutrifluram, fluoxastrobin, fenamidone, mandestrobin, picoxystrobin, pyraclostrobin, famoxadone, kresoxim-methyl, trifloxystrobin, azoxystrobin, metyltetraprole, amisulbrom, cyazofamid, fenpicoxamid, florylpicoxamid, metharylpicoxamid, ametoctradin, fluazinam, fentin hydroxide, silthiofam, fenpropimorph, fenpropidine, spiroxamine, fenhexamid, imazalil, pyrisoxazole, bromuconazole, cyproconazole, difenoconazole, epoxiconazole, flutriafol, hexaconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole, triticonazole, prothioconazole, fluoxytioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, kasugamycin, mancozeb, copper fungicides, sulphur, zinc thiazole, captan, folpet, chlorothalonil, dithianon, quinoxyfen, proquinazid, fludioxonil, iprodione, procymidone, thiabendazole, zoxamide, metrafenone, fluopicolide, propamocarb, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, isotianil, phosphorous acid, cyflufenamid, tebufloquin, picarbutrazox, tricyclazole, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N- [(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3-chloro-1- methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1 -[(3-fluorophenyl)methyl]-1 ,3- dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl- butyl]quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N- [(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-((1 R)-1 -benzyl-3-chloro-1 -methyl-but- 3-enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1 -benzyl-3-chloro-1 -methyl-but-3-enyl)-8-fluoro-quinoline- 3-carboxamide, methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3- isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3- propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1 - yl]phenoxy]prop-2-enoate, methyl (Z)-2-(5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5- methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5- methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)- (oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A, and wherein component (B) and (C) are not the same compound.

[0292] Preferably, there is provided a fungicidal composition comprising a mixture of component (A) and a component (B) and a component (C) as active ingredients, wherein component (A) is a compound of formula (I) selected from compounds (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.11), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), listed in table X according to the present invention, and wherein component (C), and component (B), are a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, fluindapyr, cyclobutrifluram, pyraclostrobin, trifloxystrobin, azoxystrobin, metyltetraprole, fenpicoxamid, florylpicoxamid, metarylpicoxamid, fluazinam, fenpropidin, fenhexamid, cyproconazole, difenoconazole, metconazole, penconazole, propiconazole, tebuconazole, tetraconazole, prothioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, mancozeb, copper-compounds (different salts), sulphur, folpet, chlorothalonil, dithianon, proquinazid, fludioxonil, metrafenone, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, phosphorous acid, cyflufenamid, tricyclazole, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N- [(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3-chloro-1- methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8- fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1 -[(3-fluorophenyl)methyl]-1 ,3- dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl- butyl]quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N- [(1 S)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-((1 R)-1 -benzyl-3-chloro-1 -methyl-but- 3-enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1 -benzyl-3-chloro-1 -methyl-but-3-enyl)-8-fluoro-quinoline- 3-carboxamide, methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3- isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3- propylpyrazol-1 -yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1 - yl]phenoxy]prop-2-enoate, methyl (Z)-2-(5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate (these compounds may be prepared from the methods described in W02020 / 193387), 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N- spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5- methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)- (oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A, and wherein component (B) and (C) are not the same compound.

[0293] More preferably, there is provided a fungicidal composition comprising a mixture of component (A) and a component (B) and a component (C) as active ingredients, wherein component (A) is a compound of formula (I) selected from compounds (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.1 1), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), listed in table X according to the present invention, and wherein component (C), and component (B), are a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 - benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl- N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4- pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A, and wherein component (B) and (C) are not the same compound.

[0294] The component (C) compounds are referred to herein and above by a so-called "ISO common name" or another "common name" being used in individual cases or a trademark name. The component (C) compounds are known and are commercially available and / or can be prepared using procedures known in the art and / or procedures reported in the literature such as indicated above.

[0295] Components (B) and (C) in combination with component (A) may enhance the effectiveness of the latter against fungi, and vice versa. Additionally, the fungicidal compositions may be effective against a wider spectrum of fungal pathogens that can be combated with the individual active ingredients when used solely. Generally, the weight ratio of component (A) to the mixture of components (B) and (C) may be from 100:1 to 1 :100, or 50:1 to 1 :50, or 20:1 to 1 :20, or 10:1 to 1 :10, or 5:1 and 1 :5. Otherwise, the weight ratio of component (A) to the mixture of components (B) and (C) may be from 2:1 to 1 :2, or 4:1 to 2:1 , or 1 :1 , or 5:1 , or 5:2, or 5:3, or 5:4, or 4:1 , or 4:2, or 4:3, or 3:1 , or 3:2, or 2:1 , or 1 :5, or 2:5, or 3:5, or 4:5, or 1 :4, or 2:4, or 3:4, or 1 :3, or 2:3, or 1 :2, or 1 :600, or 1 :300, or 1 :150, or 1 :35, or 2:35, or 4:35, or 1 :75, or 2:75, or 4:75, or 1 :6000, or 1 :3000, or 1 :1500, or 1 :350, or 2:350, or 4:350, or 1 :750, or 2:750, or 4:750. Those mixing ratios are understood to include, on the one hand, ratios by weight and also, on other hand, molar ratios.

[0296] In embodiments of the invention where the composition comprise a component (A), a component (B) and a component (C), the weight ratio of component (A) to the sum of component (B) and component (C) may be from 100:1 to 1 :100, preferably from 50:1 to 1 :50, more preferably from 20:1 to 1 :40, even more preferably from 15:1 to 1 :30, still more preferably from 12:1 to 1 :25, or from 10:1 to 1 :20, or from 10:1 to 1 :10, or from 5:1 to 1 :15, or from 5:1 to 1 :5, or from 4:1 to 1 :4, or from 3:1 to 1 :10, or from 3:1 to 1 :3, or from 2:1 to 1 :5, or 1 :1 .

[0297] The compounds of formula (I) according to the present invention can be made as shown in the following Schemes below, in which, unless otherwise stated, the definition of each variable is as defined above for a compound of formula (I). The compounds of formula (I) according to the present invention can be made as shown in the following Schemes 1 to 20, in which, unless otherwise stated, the definition of each variable is as defined above for a compound of formula (I).

[0298] In particular, compounds of formula (I), wherein R4and R6are hydrogen and R5is hydrogen or methyl, can be made as shown in the following Schemes 1 to 7, in which, unless otherwise stated, the definition of each variable is as defined above for a compound of formula (I).

[0299] In any of the Schemes below, the presence of one or more possible asymmetric carbon atoms in a compound of formula (I) according to the invention means that the compounds may occur in chiral isomeric forms, i.e., enantiomeric or diastereomeric forms.

[0300] Compounds of formula (I) may be prepared by a person skilled in the art following known methods. More specifically, ccompounds of formula (I) may be prepared from compounds of formula (III) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, B1and B2are as defined for the compounds of formula (I) by reaction with a compound of formula (II), wherein A1, A2, A3and are as defined for the compounds of formula (I). This reaction is shown in Scheme 1 .

[0301] Scheme 1

[0302] In Scheme 1 , compounds of formula (II), wherein A1, A2, A3and Z1are as defined forthe compounds of formula (I), are activated to compounds of formula (Ila) by methods known to a person skilled in the art and described, for example, in Tetrahedron 2005, 61 (46), 10827-10852. For example, compounds of formula (Ila), where X° is halogen, are formed by treatment of compounds of formula (II) with, for example, oxalyl chloride or thionyl chloride in the presence of catalytic quantities of N,N-dimethylformamide (DMF) in inert solvents such as methylene dichloride or tetra hydrofuran (THF) at temperatures between 20°C to 100°C, preferably 25°C. Treatment of compounds of formula (Ila) with compounds of formula (III), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, B1and B2are as defined for the compounds of formula (I), optionally in the presence of a base, e.g. triethylamine or pyridine, leads to compounds of formula (I). Alternatively, compounds of formula (I) may be prepared by treatment of compounds of formula (II) with dicyclohexyl carbodiimide (DCC), 1 -ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC) or 1-[bis(dimethylamino)methylene]-1 H-1 ,2,3-triazolo[4,5- b]pyridinium 3-oxide hexafluorophosphate (HATU) to give the activated compound of formula (Ila), wherein X° is G1, G2or G3as set forth in Scheme 1 a, in an inert solvent, e.g. pyridine, DMF, acetonitrile, CH2CI2 or THF, optionally in the presence of a base, e.g. triethylamine, at temperatures between 30°C and 180°C. Finally, a compound of formula (II) can also be activated by reaction with a coupling reagent such as propanephosphonic acid anhydride (T3P) to provide compounds of formula (Ila), wherein X° is G4as set forth in Scheme 1 a, as described for example in Synthesis 2013, 45, 1569. Further reaction with an amine (or a salt thereof) of the compound of formula (III) leads to compounds of formula (I). Scheme 1 a

[0303] Compounds of formula (II) can be prepared from compounds of formula (lib), wherein A1, A2, A3are N and Z1are as described in formula (I), and R° is Ci-C4alkyl, by ester hydrolysis. A variety of conditions can be used, as for example aqueous sodium hydroxide or lithium hydroxide and an organic water miscible solvent like THF or dimethoxyethane or methanol or ethanol. Such ester hydrolyses are well known to those skilled in the art. Compounds of formula (lib) can also be directly converted to compounds of formula (I) by reacting compounds of formula (lib) with compounds of formula (III) in the presence of trimethyl aluminium, or trimethyl aluminium- DABCO complex in an inert solvent such as toluene or methylene chloride. Such reactions have been reported in the literature (see Tetrahedron Lett. 1977, 4171-4174, Tetrahedron Lett. 2006, 5767-5769, and references cited therein). Compounds of formula (II) and (lib) are commercially available or can be synthesized as described vide infra.

[0304] For example, compounds of formula (Illa), wherein R4and R6are hydrogen, R5is hydrogen or methyl and R1, R2, R3, R7, R8, R9, B1and B2are as defined forthe compounds of formula (I), may be prepared from compounds of formula (IVa), wherein R4and R6are hydrogen, R5is hydrogen or methyl and R1, R2, R3, R7, R8, R9, B1and B2are as defined for the compounds of formula (I), by treatment with a reducing agent such as NaBHsCN and an acid, for example hydrochloric acid, or acetic acid in a protic solvent such as methanol or ethanol and the like. Such reactions are well known in the literature and analogous reactions have been described for example in Deng, Zeping et al, CN103772278, and Synthesis 1979, 4, 281 -283. Alternatively, compounds of formula (Illa) may be prepared from compounds of formula (IVa) by reduction with hydrogen in the presence of a suitable metal catalyst, such as Pd, Ir, Rh with a suitable ligand, e.g., diphosphine [1 ,2- bis(diphenylphosphino)ethane (dppe), 1 ,3-bis(diphenylphosphino)propane (dppp) or 1 ,4- bis(diphenylphosphino)butane (dppb)]. Similar reactions have been reported for example in React. Kinet. Cat. Lett. 2007, 92, 99-104. This reaction is shown in Scheme 2.

[0305] Scheme 2

[0306] As shown in Scheme 3, compounds of formula (lllb), wherein R4, R6and R7are hydrogen, R5is hydrogen or methyl and R1, R2, R3, R8, R9, B1and B2are as defined for the compounds of formula (I), can be converted to compounds of formula (V), wherein R4, R6and R7are hydrogen, R5is hydrogen or methyl and R1, R2, R3, R8, R9, B1and B2are as defined for the compounds of formula (I), by treatment of compounds of formula (lllb) with a compound of formula (VI), wherein X° is a leaving group, such as halogen, and R° is Ci-Cealkyl, by methods known to a person skilled in the art and by those described in Scheme 1 . Alternatively, compounds of formula (V) may be prepared by treatment with an anhydride of formula (R°CO)2O, wherein R° is Ci-Cealkyl, in an inert solvent such as methylene chloride, THF or 2-methyl-THF, optionally in the presence of a base, such as triethylamine or dimethylaminopyridine at temperatures between 0°C and 60°C. Compounds of formula (V) are then metalated with a base, for example an alkyl metal base, such as tert-butyl lithium, and an additive such as / V, / V, / V, / V-tetramethylethylendiamine (TMEDA) at low temperature, for example -78°C to room temperature, in an inert polar solvent such as THF or 2-methyl-THF. Subsequent treatment of the anion of formula (V) formed under such conditions with an electrophile of formula R7-X°, wherein X° is as previously defined and R7is C1-C4 alkyl, C1-C4 alkylcarbonyl, C1-C4 alkoxycarbonyl, N-methoxy-N-methyl-carbonyl, C1-C4 alkylaminocarbonyl, di(Ci-C4 alkylamino)carbonyl or C3-C6 cycloalkyl, wherein the Cs-Ce-cycloalkyl is optionally substituted by 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl and C1-C4 alkoxy, yields compounds of formula (Va), wherein R4and R6are hydrogen, R5is hydrogen or methyl, R° is Ci-Ce alkyl and R1, R2, R3, R7, R8, R9, B1and B2are as defined for the compounds of formula (I). This reaction is shown in Scheme 3.

[0307]

[0308] Scheme 3

[0309] Compounds of formula (Va) may be converted to compounds of formula (Illa), wherein R4and R6are hydrogen, R5is hydrogen or methyl and R1, R2, R3, R7, R8, R9, B1and B2are as defined for the compounds of formula (I), by methods known to a person skilled in the art. For example, compounds of formula (Va), wherein R° is tertbutyl, may be treated with an organic or inorganic acid such as trifluoroacetic acid or HCI to give compounds of formula (Illa). This reaction is shown in Scheme 4. Scheme 4

[0310] Compounds of formula (IVa), wherein R4and R6are hydrogen, R5is hydrogen or methyl and R1, R2, R3, R7, R8, R9, B1and B2are as defined for the compounds of formula (I), may be prepared by reacting compounds of formula (VIII), wherein R1, R2and R3are as defined for the compounds of formula (I) and X° is halogen, preferably chlorine, bromine or iodine, with compounds of formula (VII), wherein R5is hydrogen or methyl and R7, R8, R9, B1and B2are as defined for the compounds of formula (I), by means of a C-C bond formation reaction typically under palladium-catalyzed (alternatively nickel-catalyzed) cross-coupling conditions. This reaction is shown in Scheme 5.

[0311] Scheme 5

[0312] Suzuki-Miyaura cross-coupling reactions between compounds of formula (VIII) and compound of formula (VII) are well known to a person skilled in the art and are usually carried out in the presence of a palladium catalyst, such as tetrakis(triphenylphosphine)-palladium(0) or [1 ,1 '-bis(diphenylphosphino)ferrocene]palladium(ll) dichloride dichloromethane complex, and a base, such as sodium or potassium carbonate, in a solvent, such as N,N-dimethylformamide, dioxane or dioxane-water mixtures, at temperatures between room temperature and 160°C, optionally under microwave heating conditions, and preferably under inert atmosphere. Such reactions have been reviewed for example in J. Organomet. Chem. 1999, 576, 147-168. A person skilled in the art will also recognize that the reaction can be reversed, i.e. by reacting a compound of formula (X), wherein R1, R2and R3are as defined for the compounds of formula (I), with a compound of formula (IX), wherein R5is hydrogen or methyl, R7, R8, R9, B1and B2are as defined for the compounds of formula (I) and X° is halogen, preferably chlorine, bromine or iodine, to provide a compound of formula (IVa), wherein R4and R6are hydrogen, R5is hydrogen or methyl and R1, R2, R3, R7, R8, R9, B1and B2are as defined for the compounds of formula (I). This reaction is shown in Scheme 6.

[0313] Scheme 6

[0314] A further cross-coupling chemistry, namely C-H activation, can also be used to prepare compounds of formula (IVa), wherein R4and R6are hydrogen, R5is hydrogen or methyl and R1, R2, R3, R7, R8, R9, B1and B2are as defined for the compounds of formula (I) (Scheme 7).

[0315] Scheme 7

[0316] As shown in Scheme 7, compounds of formula (IX), wherein R5is hydrogen or methyl, R7, R8, R9, B1and B2are as defined for the compounds of formula (I) and X° is halogen, preferably chlorine, bromine or iodine, are reacted with compounds of formula (XI), wherein R1, R2and R3are as defined for the compounds of formula (I), in the presence of a palladium catalyst, typically palladium acetate Pd(OAc)2, a suitable ligand, for example 1 ,10-phenanthroline, in the presence of a base such as cesium carbonate or potassium carbonate, in inert solvents such as chlorobenzene, toluene or xylene at temperatures between room temperature and 180°C, optionally under microwave heating conditions, preferably under inert atmosphere. Similar reactions have been reported in the literature for example in Chem. Sci. 2013, 4, 2374-2379.

[0317] Also, compounds of formula (III) may be prepared from compounds of formula (XVI) (Scheme 8).

[0318] Scheme 8

[0319] As shown in Scheme 8, compounds of formula (III) may be prepared by a person skilled in the art by a carbamate deprotection reaction of compounds of formula (XVI), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, B1and B2are as defined for the compounds of formula (I) and R01may be a member of a common carbamate protecting group substituent, for example methyl, te / Y-butyl, allyl, 2,2,2-trichloroethyl or benzyl. For example, when R01is methyl, a suitable solvent such as dichloromethane and a suitable reagent such as iodotrimethylsilane may be employed to afford the product upon heating at temperatures between room temperature and 200°C, preferably between 20°C and the boiling point of the reaction mixture as described, for example, in J. Am. Chem. Soc. 1992, 114, 5959. The compounds of formula (III) thus obtained are converted to compounds of formula (I) (Scheme 1).

[0320] Compounds of formula (XVI), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, B1and B2are as defined for the compounds of formula (I) and wherein R01is as described above, may be formed by a Pictet-Spengler reaction between an aldehyde (including formaldehyde in its various forms) of formula (XV), wherein R7is as defined for the compounds of formula (I), and a compound of formula (XIV), wherein R1, R2, R3, R4, R5, R6, R8, R9, B1and B2are as defined for the compounds of formula (I) and wherein R01is as described above, by combination with an acid in a suitable solvent, for example as described in Tetrahedron 1987, 43, 439 (Scheme 9).

[0321] Scheme 9

[0322] Compounds of formula (XIV), wherein R1, R2, R3, R4, R5, R6, R8, R9, B1and B2are as defined forthe compounds of formula (I) and wherein R01is as described above, may be prepared by a reaction between amines of formula (XIII), wherein R1, R2, R3, R4, R5, R6, R8, R9, B1and B2are as defined for the compounds of formula (I), and a suitable protecting reagent such as methyl chloroformate, optionally in the presence of a base such as triethylamine or pyridine, in a suitable solvent such as dichloromethane at temperatures between -20°C and the boiling point of the mixture, as for example described in Org. Biomol. Chem. 2016, 14, 6853. This reaction is shown in Scheme 10.

[0323] Scheme 10

[0324] Compounds of formula (XIII), or salts thereof, wherein R1, R2, R3, R4, R5, R6, R8, R9, B1and B2are as defined for the compounds of formula (I), may be prepared by a person skilled in the art by a reaction between nitriles of formula (XII), wherein R1, R2, R3, R4, R8, R9, B1and B2are as defined for the compounds of formula (I), and a suitable nucleophile such as (dimethyl sulfide)dihydroboron (BMS) in a suitable aprotic solvent such as tetrahydrofuran, for example as described in J. Org Chem. 1981 , 47, 3153. Alternatively, Grignard reagents R5MgBr or R6MgBr, wherein R5and R6are as defined for the compounds of formula (I), may be added as nucleophiles to compounds of formula (XII), sequentially or simultaneously, to allow more highly substituted amines of formula (XIII) to be prepared. Such Grignard additions to nitriles are carried out in an inert solvent such as diethyl ether, tert-butylmethyl ether, and cyclopentyl methyl ether in the presence of a Lewis acid such as Ti(O-'Pr)4 (see Synlett 2007, (4), 652-654). This reaction is shown in Scheme 11.

[0325] Scheme 11

[0326] Alternatively compounds of formula (XIII), wherein R1, R2, R3, R4, R5, R6, R8, R9, B1and B2are as defined for the compounds of formula (I), and wherein R5, R6are hydrogen, namely compounds of formula (Xllla) may be prepared by a person skilled in the art by a reaction between unsaturated nitro compounds of formula (Xlllb), wherein R1, R2, R3, R4, R8, R9, B1and B2are as defined for the compounds of formula (I), and compounds of formula (VIII), wherein R1, R2and R3are as defined for the compounds of formula (I) and X° is halogen, preferably iodine, followed by subsequent reduction of compounds of formula (Xlllb), wherein R1, R2, R3, R4, R8, R9, B1and B2are as defined for the compounds of formula (I), to compounds formula (Xllla). Such a reaction is described in the preparatory section under Example P1 , Step 8 (Option B - Step A and Step B). This reaction is shown in Scheme 12.

[0327] Scheme 12 Compounds of formula (XII), wherein R1, R2, R3, R4, R8, R9, B1and B2are as defined for the compounds of formula (I), may be prepared by a person skilled in the art following known methods. More specifically, compounds of formula (XII), and intermediates thereof, may be prepared from compounds of formula (XVII) as shown in Scheme 13.

[0328] (XVII) (Xlla) (XII)

[0329] Scheme 13

[0330] For example, compounds of formula (XII), wherein R1, R2, R3, R8, R9, B1and B2are as defined for the compounds of formula (I) and R4is different from hydrogen, may be prepared by a person skilled in the art by deprotonation of compound of formula (Xlla) wherein R1, R2, R3, R8, R9, B1and B2are as defined for the compounds of formula (I), using a strong base such as n-butyl lithium or sodium hydride at cryogenic temperatures in an inert solvent such as tetrahydrofuran, followed by addition of a suitable alkylating agent R4- X, wherein R4is Ci-C4alkyl and X is halogen, for example iodomethane.

[0331] Compounds of formula (Xlla), wherein R1, R2, R3, R8, R9, B1and B2are as defined for the compounds of formula (I), may be prepared from alcohols of formula (XVII) by treatment with cyanotrimethylsilane (TMSCN) in the presence of a base such as lithium carbonate in a nonpolar solvent such as dichloromethane at temperatures between 0°C and the boiling point of the reaction mixture. Such transformations are well known in the literature under a variety of conditions, for example as described in Org. Lett. 2008, 10, 4570 and references therein. This reaction is shown in Scheme 13.

[0332] A further synthesis of compounds of formula (III) wherein B1is CR10, B2is CR11, R1ais Ci-C4alkyl, R2ais hydrogen, halogen, or Ci-C4alkyl, R3is hydrogen, R4a, R5a, R6aR7aare hydrogen or C1-C4 alkyl, and R8, R9, R10, and R11are as defined for the compounds of formula (I), namely compounds of formula (lllc) is described below.

[0333] Compounds of formula (lllc) also be prepared by treating compounds of formula (XVIII)

[0334]

[0335] (XVIII) wherein R1is Ci-C4alkyl, R2is hydrogen, halogen, or Ci-C4alkyl, R3is hydrogen, R4is hydrogen or Ci-C4alkyl, R5, R6, R7are hydrogen or Ci-C4alkyl, and R8, R9, R10, and R11are as previously defined, with strong acids, for example sulphuric, hydrochloric, hydrobromic, trifluoroacetic, trifllic, or methane sulphonic acids and the like, or Lewis acids, such as aluminium trichloride, or bismuth (I I l)triflate , in an inert solvent such as chlorobenzene, nitrobenzene at temperature between 0°C to 180°C to yield compounds of formula (lllc). These are converted to compounds of formula (I) as previously described vide supra. Those skilled in the art will realize that such cyclisation’s can proceed through intermediates such as compounds of formula (XIX), and (when R4is methyl), compound of formula (XX) and wherein the substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11in these compounds are as defined for the compounds of formula (I). Depending on the conditions of the reaction these intermediates can be isolated and / or converted further directly to compounds of formula (lllc). Those skilled in the art will also realize that when R7is Ci-C4alkyl, mixtures of diastereoisomers racemic-(syn-\ lie) and racemic-(anti-\\\c) can be obtained in ratios that can be controlled to direct preferential formation of one isomer over the other (Scheme 14).

[0336]

[0337] Scheme 14

[0338] The intermediates (XVIII), (XIX), and (XX) are novel and as such form part of the current invention.

[0339] Compounds (XVIII), (XIX), and (XX) can be prepared as shown in the following Scheme 15.

[0340]

[0341] Scheme 15

[0342] As shown in Scheme 15, a benzyl amine of formula (XXI) is used to alkylate a compound of formula (XXII), in the presence of a base, such as EtsN in an inert solvent, such as DMF. The compound (XXIII) so obtained, may be isolated, or treated directly with BOC-anhydride in situ, to give a compound of formula (XXIV).

[0343] Compound of formula (XXIV) can be reduced with a hydride source (e.g. NaBH4 in MeOH / THF) to give the target molecule (XVIIIb), which can then be cyclized with, for example with camphor sulphonic acid in EtOAc, to give compounds of formula (XlXb). Alternatively, compounds of formula (XXIV) can be reacted with a Grignard reagent R4MgBr in an inert ethereal solvent (e.g. THF) to give compounds of formula (XVI Ila), which can the cyclized with camphorsulphonic acid in, e.g. EtOAc, to give compounds of formula (XIXa). In compounds (XIX) and (XVIII) R1ais Ci-C4alkyl, R2ais hydrogen, halogen, or Ci-C4alkyl, R4ais hydrogen or Ci- C4alkyl, R5a, R6a, and R7aare hydrogen or C1-C4 alkyl, and R8, R9, R10, and R11are as defined for the compounds of formula (I). A further aspect of this Friedel-Crafts chemistry should be noted. If the chemistry is carried out starting with a chiral amine (XXIa), i.e. R7is Ci-C4alkyl, the stereochemistry is retained in the final compounds of formula (I). This is illustrated below in Scheme 16, for when R7is methyl:

[0344] Scheme 16

[0345] Compounds of formula (XVII) may be prepared by methods known to a person skilled in the art. Compounds of formula (XXI) and (XXII) are easily prepared by those skilled in the art or can be purchased.

[0346] Compounds of formula II, wherein A1is N, A2is O, A3is CH, and Z1is as defined for the compounds of formula (I), namely compounds of formula (He) can be prepared as shown in Scheme 17.

[0347] Scheme 17

[0348] As shown in Scheme 17, compounds of formula (lie) wherein Z1is as defined for the compounds of formula (I), and X05is C1-C4 alkyl may be prepared by hydrolysis of compounds of formula (lib) by treatment with, for example, an alkaline earth metal hydroxide in water, or with a water miscible organic solvent, such as THF, methanol, ethanol and the like. Such ester hydrolyses are well known to those skilled in the art. Compounds of formula (lib) can be obtained by the treatment of compounds of formula (XXVII) wherein Z1is as defined for the compounds of formula (I) and X05is C1-C4 alkyl with hydroxylamine hydrochloride in a polar solvent, for example ethanol and optionally in the presence of a base, e.g. triethyl amine, K2CO3 and the like.

[0349] Compounds of formula (XXVII) are prepared by reaction of compounds of formula (XXV), wherein Z1is as defined for the compounds of formula (I), with compounds of formula (XXVI) or compounds of formula (XXVIa), wherein X05is C1-C4 alkyl in presence of base such potassium terbutoxide, sodium hydride or Lithium bis(trimethylsilyl)amid in a solvent such tetrahydrofuran or toluene. Similar reaction sequences to those described in Scheme 17 to prepare compounds of formula (lib) and (lie) have been described in for example CN111072582 and WO2019 / 195810, and WO2018 / 019929. Further reaction conditions for preparation of compounds of formula (XXVII) are described in for example Bioorg. Med. Chem. 2016, 109, 350-359.

[0350] Compounds of formula (II) wherein A1is O, A2and A3are N, and Z1is as defined for the compounds of formula (I), namely compounds of formula (He) can be prepared as shown in Scheme 18. (XXVIII)

[0351] Scheme 18

[0352] As shown in Scheme 18, compounds of formula (He) are obtained by ester hydrolysis of compounds of formula (lid) as described previously in Scheme 17. Compounds of formula (lid), wherein Z1is as defined for the compounds of formula (I) and X05is C1-C4 alkyl are prepared by reaction of compounds of formula (XXVIa) with compounds of formula (XXVIII), optionally in the presence of base, for example pyridine or triethylamine, in a solvent such as acetonitrile, chloroform or tetrahydrofuran. Similar reactions have been reported in for example Bioorg. Med. Chem. 2016, 24(22), 5693-5701 and CN114933573. Compounds of formula (XXVIII) wherein Z1is as defined for the compounds of formula (I), can be obtained by treatment of compounds of formula (XXIX) with hydroxylamine hydrochloride in presence of base such K2CO3 or Na2COs in a polar solvent for example ethanol. The reaction can also be performed without base using a solution of hydroxylamine. Such reactions have been described in, for example, Bioorg. Med. Chem. Lett. 2020, 30(21), 127508 and Bioorg. Med. Chem. Lett. 2016, 26(23), 5679-5684. Compounds of formula (XXVIII) wherein Z1is as defined for the compounds of formula (I), may be also prepared by “one-pot” synthesis via Pd-catalyzed cyanation and amidoximation of compound of formula (XXX) wherein Z1is as defined for the compounds of formula (I), using potassium ferrocyanide trihydrate and hydroxylamine hydrochloride as described in for example Org. Biomol. Chem. 2015, 13(9), 2541-2545. Compounds of formula (II) wherein A1and A2are N, and A3is O, and Z1is as previously described, (namely compounds of formula (llg)), and A1and A2are N, and A3is S, and Z1is as defined for the compounds of formula (I), (namely compounds of formula (Hi)) can be prepared as shown in Scheme 19.

[0353] Scheme 19 As shown in Scheme 19, compounds of formula (llg) and (Hi) are obtained by ester hydrolysis of (Ilf) and (llg), respectively. In the latter compounds, X05and Z1are as previously described. Compounds of formula (Ilf) are obtained from compounds of formula (Ilf) are obtained by dehydration of compounds of formula (XXXI). Compounds of formula (XXXI) are obtained by acylation of hydrazides of formula (XXXII) with compounds of formula (XXVIa). Such sequences of reactions to produce oxadiazoles is well known to those skilled in the art. Similar reactions are described in Bioorg. Med. Chem. Lett. 2005, 15, 1423-1428 and W02006 / 044617. Compounds of formula (XXXI) can also be prepared by reaction of activated carboxylic acids of formula (XXXIIIa), wherein Z1is as defined for the compounds of formula (I), and X° are as described in Scheme 1 / Scheme 1a respectively, with compounds of formula (XXXIV). Compounds of formula (XXXIIIa) can be prepared from the corresponding acids of formula (XXXIII) as described in scheme 1. Such reactions are described for example in, for example, J. Prakt. Chem. 1985, 327, 109-116. Compounds of formula (llh) can also be prepared from the common intermediate of formula (XXXI), wherein Z1is as defined for the compounds of formula (I), and X05is as previously described, by treatment with Lawesson’s reagent or phosphorous pentasulfide neat, or in inert solvents such as toluene or xylene. Similar reactions are known in the literature (see for example WO2010 / 006713, W02009 / 149858 and J. Org Chem. 1961 , 26, 4410-12).

[0354] Compounds of formula (II) wherein A1is O, A2is N, A3is methine, and Z1is as defined for the compounds of formula (I), namely compounds of formula (Ilk), can be prepared, for example, as shown in Scheme 20.

[0355] (XXXVII) (XXXV) (llj) (||k)

[0356] Scheme 20

[0357] As shown in Scheme 20, compounds of formula (Ilk) are readily obtained by hydrolysis of esters of formula (llj) by methods known to those skilled in the art and described vide supra. Compounds of formula (llj) can be obtained by reaction of compounds of formula (XXXV) with compounds of formula (XXXVI) in the presence of an oxidizing agent, for example (diacetoxyiodo)benzene or N-chlorosuccinimide, in an inert solvent such as methanol or DMF respectively. Such reaction sequences have been described, for example, in J. Het. Chem. 2013, 50(4), 774-780 and J. Chin. Chem. Soc. 2007, 54(3), 643-652. Compounds of formula (XXXV) are readily prepared from compounds of formula (XXXVII), wherein Z1is as defined for the compounds of formula (I), by treatment with hydroxylamine under conditions well known to those skilled in the art.

[0358] Salts of compounds of formula (I) may be prepared in a manner known perse. Thus, for example, acid addition salts of compounds of formula (I) are obtained by treatment with a suitable acid or a suitable ion exchanger reagent and salts with bases are obtained by treatment with a suitable base or with a suitable ion exchanger reagent.

[0359] Salts of compounds of formula (I) can be converted in the customary manner into the free compounds (I), acid addition salts, for example, by treatment with a suitable basic compound or with a suitable ion exchanger reagent and salts with bases, for example, by treatment with a suitable acid or with a suitable ion exchanger reagent.

[0360] Salts of compounds of formula (I) can be converted in a manner known per se into other salts of compounds of formula (I), acid addition salts, for example, into other acid addition salts, for example by treatment of a salt of inorganic acid such as hydrochloride with a suitable metal salt such as a sodium, barium or silver salt, of an acid, for example with silver acetate, in a suitable solvent in which an inorganic salt which forms, for example silver chloride, is insoluble and thus precipitates from the reaction mixture.

[0361] Depending on the procedure or the reaction conditions, the compounds of formula (I), which have salt-forming properties, can be obtained in free form or in the form of salts.

[0362] The compounds of formula (I) and, where appropriate, the tautomer’s thereof, in each case in free form or in salt form, can be present in the form of one of the isomers which are possible or as a mixture of these, for example in the form of pure isomers, such as antipodes and / or diastereomers, or as isomer mixtures, such as enantiomer mixtures, for example racemates, or diastereomer mixtures, depending on the number, absolute and relative configuration of asymmetric carbon atoms which occur in the molecule and / or depending on the configuration of non-aromatic double bonds which occur in the molecule, the invention relates to the pure isomers and also to all isomer mixtures which are possible and is to be understood in each case in this sense hereinabove and herein below, even when stereochemical details are not mentioned specifically in each case.

[0363] Diastereomeric mixtures or racemic mixtures of compounds of formula (I), in free form or in salt form, which can be obtained depending on which starting materials and procedures have been chosen can be separated in a known manner into the pure diastereomers or racemates on the basis of the physicochemical differences of the components, for example by fractional crystallization, distillation and / or chromatography.

[0364] Enantiomeric mixtures, such as racemates, which can be obtained in a similar manner can be resolved into the optical antipodes by known methods, for example by recrystallization from an optically active solvent, by chromatography on chiral adsorbents, for example high-performance liquid chromatography (HPLC) on acetyl cellulose, with the aid of suitable microorganisms, by cleavage with specific, immobilized enzymes, via the formation of inclusion compounds, for example using chiral crown ethers, where only one enantiomer is complexed, or by conversion into diastereomeric salts, for example by reacting a basic end-product racemate with an optically active acid, such as a carboxylic acid, for example camphor, tartaric or malic acid, or sulfonic acid, for example camphorsulfonic acid, and separating the diastereomer mixture which can be obtained in this manner, for example by fractional crystallization based on their differing solubilities, to give the diastereomers, from which the desired enantiomer can be set free by the action of suitable agents, for example basic agents.

[0365] Pure diastereomers or enantiomers can be obtained according to the invention not only by separating suitable isomer mixtures, but also by generally known methods of diastereoselective or enantioselective synthesis, for example by carrying out the process according to the invention with starting materials of a suitable stereochemistry.

[0366] It is advantageous to isolate or synthesize in each case the biologically more effective isomer, for example enantiomer or diastereomer, or isomer mixture, for example enantiomer mixture or diastereomer mixture, if the individual components have a different biological activity.

[0367] As an example, compounds with more than one asymmetric carbon atoms may exist in diastereomeric forms which can be optionally separated using for example supercritical fluid chromatography (SFC) chromatography with chiral columns. Such diastereomers can show a different fungicidal activity profile, but all isomers and diastereomers form part of this invention.

[0368] The compounds of formula (I) have three chiral carbon atoms, (three stereocenters, wherein the star (*) indicates the chiral carbon atom), such there are eight stereoisomers available. These eight stereoisomers consist of four sets of enantiomers.

[0369] For compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, B1, B2, A (A1, A2, A3) and Z1are as defined forthe compounds of formula (I) and wherein R7is not hydrogen, the relationship between enantiomers and diastereomers is illustrated in Scheme 21.

[0370]

[0371] Scheme 21

[0372] A person skilled in the art is well aware that these diastereomeres and enantiomers of formula (I) (as shown in Scheme 21) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, B1, B2, A (A1, A2, A3) and Z1are as defined for formula (I) and wherein R7is not hydrogen, are within the scope if the invention.

[0373] For compounds of formula (I), wherein R1is methyl, R3, R4, R5, R6are hydrogen and R2, R7, R8, R9, B1, B2, and Z1are as defined for the compounds of formula (I), and wherein A is as defined as for compounds of formula (l-A), and wherein R7is not hydrogen, the relationship between enantiomers and diastereomers is illustrated in Scheme 22.

[0374]

[0375] Scheme 22

[0376] In one embodiment the compounds of formula (I), wherein R1is methyl, R3, R4, R5, R6are hydrogen and R2, R7, R8, R9, B1, B2, and Z1are as defined for the compounds of formula (I), and wherein A is as defined as for compounds of formula (l-A), and wherein R7is not hydrogen the pyrazole-moiety and R7have a syn- relationship to each other.

[0377] The syn-lsomers of the compounds of formula (I), wherein R1is methyl, R3, R4, R5, R6are hydrogen and R2, R7, R8, R9, B1, B2, and Z1are as defined for the compounds of formula (I), and wherein A is as defined as for compounds of formula (l-A), and wherein R7is not hydrogen are shown in Scheme 23.

[0378] Scheme 23

[0379] Preferably the compounds of formula (I), wherein R1is methyl, R3, R4, R5, R6are hydrogen and R2, R7, R8, R9, B1, B2, and Z1are as defined for the compounds of formula (I), and wherein A is as defined as for compounds of formula (l-A), and wherein R7is not hydrogen the pyrazole-moiety and R7have a syn-relationship to each other, as shown in Scheme 23.

[0380] The term “compounds of formula (I)” refers to component A.

[0381] The term “fungicide” as used herein means a compound that controls, modifies, or prevents the growth of fungi.

[0382] The term “fungicidally effective amount” means the quantity of such a compound or combination of such compounds that is capable of producing an effect on the growth of fungi. Controlling or modifying effects include all deviation from natural development, such as killing, retardation and the like, and prevention includes barrier or other defensive formation in or on a plant to prevent fungal infection.

[0383] The term “plants” refers to all physical parts of a plant, including seeds, seedlings, saplings, roots, tubers, stems, stalks, foliage, and fruits.

[0384] The term "plant propagation material” denotes all generative parts of a plant, for example seeds or vegetative parts of plants such as cuttings and tubers. It includes seeds in the strict sense, as well as roots, fruits, tubers, bulbs, rhizomes, and parts of plants.

[0385] The term “locus” as used herein means fields in or on which plants are growing, or where seeds of cultivated plants are sown, or where seed will be placed into the soil. It includes soil, seeds, and seedlings, as well as established vegetation.

[0386] The term “g a.i. / ha” as used herein refer to the application rate given in gramm [g ] of active ingredient [a.i.] per unit of surface [ha]. The unit hectare (symbol ha) is the metric unit of area that equals a square with 100 m side (1 hm2) or 10,000 square meters. Hectare is a commonly used unit of area in the metric system.

[0387] As used herein, the term "controlling" refers to reducing the number of pests, eliminating pests and / or preventing further pest damage such that damage to a plant or to a plant derived product is reduced.

[0388] As used herein, the term "pest" refers to insects, and molluscs that are found in agriculture, horticulture, forestry, the storage of products of vegetable origin (such as fruit, grain and timber); and those pests associated with the damage of man-made structures. The term pest encompasses all stages in the life cycle of the pest.

[0389] As used herein, the term "effective amount" refers to the amount of the compound, or a salt thereof, which, upon single or multiple applications provides the desired effect.

[0390] An effective amount is readily determined by the skilled person in the art, by the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount a number of factors are considered including, but not limited to: the type of plant or derived product to be applied; the pest to be controlled and its lifecycle; the particular compound applied; the type of application; and other relevant circumstances.

[0391] As used herein, the term “room temperature” or “RT” or “rt” refer to a temperature of about 15° C to about 35° C. For example, rt can refer to a temperature of about 20° C to about 30° C. Throughout this document the expression “composition” stands for the various mixtures or combinations of components (A) and (B) (including the above-defined embodiments), for example in a single “ready-mix” form, in a combined spray mixture composed from separate formulations of the single active ingredient components, such as a “tank-mix”, and in a combined use of the single active ingredients when applied in a sequential manner, i.e. one after the other with a reasonably short period, such as a few hours or days. The order of applying the components (A) and (B) is not essential for working the present invention.

[0392] The composition according to the invention is effective against harmful microorganisms, such as microorganisms, that cause phytopathogenic diseases, in particular against phytopathogenic fungi and bacteria.

[0393] The composition of the invention may be used to control plant diseases caused by a broad spectrum of fungal plant pathogens in the Basidiomycete, Ascomycete, Oomycete and / or Deuteromycete, Blastocladiomycete, Chrytidiomycete, Glomeromycete and / or Mucoromycete classes.

[0394] The composition is effective in controlling a broad spectrum of plant diseases, such as foliar pathogens of ornamental, turf, vegetable, field, cereal, and fruit crops.

[0395] These pathogens may include:

[0396] Oomycetes, including Phytophthora diseases such as those caused by Phytophthora capsici, Phytophthora infestans, Phytophthora sojae, Phytophthora fragariae, Phytophthora nicotianae, Phytophthora cinnamomi, Phytophthora citricola, Phytophthora citrophthora and Phytophthora erythrose ptica; Pythium diseases such as those caused by Pythium aphanidermatum, Pythium arrhenomanes, Pythium graminicola, Pythium irregulare and Pythium ultimurrr, diseases caused by Peronosporales such as Peronospora destructor, Peronospora parasitica, Plasmopara viticola, Plasmopara halstedii, Pseudoperonospora cubensis, Albugo Candida, Sclerophthora macrospora and Bremia lactucae; and others such as Aphanomyces cochlioides, Labyrinthula zosterae, Peronosclerospora sorghi and Sclerospora graminicola;

[0397] Ascomycetes, including blotch, spot, blast or blight diseases and / or rots for example those caused by Pleosporales such as Stemphylium solani, Stagonospora tainanensis, Spilocaea oleaginea, Setosphaeria turcica, Pyrenochaeta lycoperisici, Pleospora herbarum, Phoma destructiva, Phaeosphaeria herpotrichoides, Phaeocryptocus gaeumannii, Ophiosphaerella graminicola, Ophiobolus graminis, Leptosphaeria maculans, Hendersonia creberrima, Helminthosporium triticirepentis, Setosphaeria turcica, Drechslera glycines, Didymella bryoniae, Cycloconium oleagineum, Corynespora cassiicola, Cochliobolus sativus, Bipolaris cactivora, Venturia inaequalis, Pyrenophora teres, Pyrenophora tritici-repentis, Alternaria alternata, Altemaria brassicicola, Altemaria solani and Alternaria tomatophila, Capnodiales such as Septoria tritici, Septoria nodorum, Septoria glycines, Cercospora arachidicola, Cercospora sojina, Cercospora zeae-maydis, Cercosporella capsellae and Cercosporella herpotrichoides, Cladosporium carpophilum, Cladosporium effusum, Passalora fulva, Cladosporium oxysporum, Dothistroma septosporum, Isariopsis clavispora, Mycosphaerella fijiensis, Mycosphaerella graminicola, Mycovellosiella koepkeii, Phaeoisariopsis bataticola, Pseudocercospora vitis, Pseudocercosporella herpotrichoides, Ramularia beticola, Ramularia collo-cygni, Magnaporthales such as Gaeumannomyces graminis, Magnaporthe grisea, Pyricularia oryzae, Diaporthales such as Anisogramma anomala, Apiognomonia errabunda, Cytospora platani, Diaporthe phaseolorum, Discula destructiva, Gnomonia fructicola, Greeneria uvicola, Melanconium juglandinum, Phomopsis viticola, Sirococcus clavigignenti-juglandacearum, Tubakia dryina, Dicarpella spp., Valsa ceratosperma, and others such as Actinothyrium graminis, Ascochyta pisi, Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Asperisporium caricae, Blumeriella jaapii, Candida spp., Capnodium ramosum, Cephaloascus spp., Cephalosporium gramineum, Ceratocystis paradoxa, Chaetomium spp., Hymenoscyphus pseudoalbidus, Coccidioides spp., Cylindrosporium padi, Diplocarpon malae, Drepanopeziza campestris, Elsinoe ampelina, Epicoccum nigrum, Epidermophyton spp., Eutypa lata, Geotrichum candidum, Gibellina cerealis, Gloeocercospora sorghi, Gloeodes pomigena, Gloeosporium perennans; Gloeotinia temulenta, Griphospaeria corticola, Kabatiella lini, Leptographium microsporum, Leptosphaerulinia crassiasca, Lophodermium seditiosum, Marssonina graminicola, Microdochium nivale, Monilinia fructicola, Monographella albescens, Monosporascus cannonballus, Naemacyclus spp., Ophiostoma novo-ulmi, Paracoccidioides brasiliensis, Penicillium expansum, Pestalotia rhododendri, Petriellidium spp., Pezicula spp., Phialophora gregata, Phyllachora pomigena, Phymatotrichum omnivora, Physalospora abdita, Plectosporium tabacinum, Polyscytalum pustulans, Pseudopeziza medicaginis, Pyrenopeziza brassicae, Ramulispora sorghi, Rhabdocline pseudotsugae, Rhynchosporium secalis, Sacrocladium oryzae, Scedosporium spp., Schizothyrium pomi, Sclerotinia sclerotiorum, Sclerotinia minor, Sclerotium spp., Typhula ishikariensis, Seimatosporium mariae, Lepteutypa cupressi, Septocyta ruborum, Sphaceloma perseae, Sporonema phacidioides, Stigmina palmivora, Tapesia yallundae, Taphrina bullata, Thielviopsis basicola, Trichoseptoria fructigena, Zygophiala jamaicensis; powdery mildew diseases for example those caused by Erysiphales such as Blumeria graminis, Erysiphe polygon!, Uncinula necator, Sphaerotheca fuligena, Podosphaera leucotricha, Podospaera macularis Golovinomyces cichoracearum, Leveillula taurica, Microsphaera diffusa, Oidiopsis gossypii, Phyllactinia guttata and Oidium arachidis; molds for example those caused by Botryosphaeriales such as Dothiorella aromatica, Diplodia seriata, Guignardia bidwellii, Botrytis cinerea, Botryotinia aim, Botryotinia fabae, Fusicoccum amygdali, Lasiodiplodia theobromae, Macrophoma theicola, Macrophomina phaseolina, Phyllosticta cucurbitacearum; anthracnoses for example those caused by Glommerelales such as Colletotrichum gloeosporioides, Colletotrichum lagenarium, Colletotrichum gossypii, Glomerella cingulata, and Colletotrichum graminicola; and wilts or blights for example those caused by Hypocreales such as Acremonium strictum, Claviceps purpurea, Fusarium culmorum, Fusarium graminearum, Fusarium virguliforme, Fusarium oxysporum, Fusarium subglutinans, Fusarium oxysporum f.sp. cubense, Gerlachia nivale, Gibberella fujikuroi, Gibberella zeae, Gliocladium spp., Myrothecium verrucaria, Nectria ramulariae, Trichoderma viride, Trichothecium roseum, and Verticillium theobromae;

[0398] Basidiomycetes, including smuts for example those caused by Ustilaginales such as Ustilaginoidea virens, Ustilago nuda, Ustilago tritici, Ustilago zeae, rusts for example those caused by Pucciniales such as Cerotelium fici, Chrysomyxa arctostaphyli, Coleosporium ipomoeae, Hemileia vastatrix, Puccinia arachidis, Puccinia cacabata, Puccinia graminis, Puccinia recondita, Puccinia sorghi, Puccinia horde!, Puccinia striiformis f.sp. Hordei, Puccinia striiformis f.sp. Secalis, Pucciniastrum coryli, or Uredinales such as Cronartium ribicola, Gymnosporangium juniperi-virginianae, Melampsora medusae, Phakopsora pachyrhizi, Phragmidium mucronatum, Physopella ampelosidis, Tranzschelia discolor and Uromyces viciae-fabae; and other rots and diseases such as those caused by Cryptococcus spp., Exobasidium vexans, Marasmiellus inoderma, Mycena spp., Sphacelotheca reiliana, Typhula ishikariensis, Urocystis agropyri, Itersonilia perplexans, Corticium invisum, Laetisaria fuciformis, Waitea circinata, Rhizoctonia solani, Thanetephorus cucurmeris, Entyloma dahliae, Entylomella microspora, Neovossia moliniae and Tilletia caries;

[0399] Blastocladiomycetes, such as Physoderma maydis;

[0400] Mucoromycetes, such as Choanephora cucurbitarum.; Mucor spp.; Rhizopus arrhizus; as well as diseases caused by other species and genera closely related to those listed above.

[0401] In addition to their fungicidal activity, the compositions may also have activity against bacteria such as Erwinia amylovora, Erwinia caratovora, Xanthomonas campestris, Pseudomonas syringae, Strptomyces scabies and other related species as well as certain protozoa.

[0402] The composition according to the invention is particularly effective against phytopathogenic fungi belonging to the following classes: Ascomycetes (e.g. Venturia, Podosphaera, Erysiphe, Monilinia, Mycosphaerella, Uncinula); Basidiomycetes (e.g. the genus Hemileia, Rhizoctonia, Phakopsora, Puccinia, Ustilago, Tilletia); Fungi imperfecti (also known as Deuteromycetes; e.g. Botrytis, Helminthosporium, Rhynchosporium, Fusarium, Septoria, Cercospora, Alternaria, Pyricularia and Pseudocercosporella); Oomycetes (e.g. Phytophthora, Peronospora, Pseudoperonospora, Albugo, Bremia, Pythium, Pseudosclerospora, Plasmopara).

[0403] Crops of useful plants in which the composition according to the invention can be used include perennial and annual crops, such as berry plants for example blackberries, blueberries, cranberries, raspberries and strawberries; cereals for example barley, maize (corn), millet, oats, rice, rye, sorghum triticale and wheat; fibre plants for example cotton, flax, hemp, jute and sisal; field crops for example sugar and fodder beet, coffee, hops, mustard, oilseed rape (canola), poppy, sugar cane, sunflower, tea and tobacco; fruit trees for example apple, apricot, avocado, banana, cherry, citrus, nectarine, peach, pear and plum; grasses for example Bermuda grass, bluegrass, bentgrass, centipede grass, fescue, ryegrass, St. Augustine grass and Zoysia grass; herbs such as basil, borage, chives, coriander, lavender, lovage, mint, oregano, parsley, rosemary, sage and thyme; legumes for example beans, lentils, peas and soya beans; nuts for example almond, cashew, ground nut, hazelnut, peanut, pecan, pistachio and walnut; palms for example oil palm; ornamentals for example flowers, shrubs and trees; othertrees, for example cacao, coconut, olive and rubber; vegetables for example asparagus, aubergine, broccoli, cabbage, carrot, cucumber, garlic, lettuce, marrow, melon, okra, onion, pepper, potato, pumpkin, rhubarb, spinach and tomato; and vines for example grapes.

[0404] Crops are to be understood as being those which are naturally occurring, obtained by conventional methods of breeding, or obtained by genetic engineering. They include crops which contain so-called output traits (e.g. improved storage stability, higher nutritional value and improved flavour).

[0405] Crops are to be understood as also including those crops which have been rendered tolerant to herbicides like bromoxynil or classes of herbicides such as ALS-, EPSPS-, GS-, HPPD- and PPO-inhibitors. An example of a crop that has been rendered tolerant to imidazolinones, e.g., imazamox, by conventional methods of breeding is Clearfield® summer canola. Examples of crops that have been rendered tolerant to herbicides by genetic engineering methods include e.g., glyphosate- and glufosinate-resistant maize varieties commercially available under the trade names RoundupReady®, Herculex I® and LibertyLink®.

[0406] Crops are also to be understood as being those which naturally are or have been rendered resistant to harmful insects. This includes plants transformed by the use of recombinant DNA techniques, for example, to be capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxinproducing bacteria. Examples of toxins which can be expressed include 8-endotoxins, vegetative insecticidal proteins (Vip), insecticidal proteins of bacteria colonising nematodes, and toxins produced by scorpions, arachnids, wasps and fungi.

[0407] An example of a crop that has been modified to express the Bacillus thuringiensis toxin is the Bt maize KnockOut® (Syngenta Seeds). An example of a crop comprising more than one gene that codes for insecticidal resistance and thus expresses more than one toxin is VipCot® (Syngenta Seeds). Crops or seed material thereof can also be resistant to multiple types of pests (so-called stacked transgenic events when created by genetic modification). For example, a plant can have the ability to express an insecticidal protein while at the same time being herbicide tolerant, for example Herculex I® (Dow AgroSciences, Pioneer Hi-Bred International).

[0408] The term "useful plants" is to be understood as including also useful plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.

[0409] Examples of such plants are: YieldGard® (maize variety that expresses a CrylA(b) toxin); YieldGard Rootworm ® (maize variety that expresses a Cryl I IB(b1 ) toxin); YieldGard Plus® (maize variety that expresses a CrylA(b) and a Cry 111 B(b1 ) toxin); Starlink® (maize variety that expresses a Cry9(c) toxin); Herculex I® (maize variety that expresses a CrylF(a2) toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a CrylA(c) toxin); Bollgard I® (cotton variety that expresses a CrylA(c) toxin); Bollgard II® (cotton variety that expresses a CrylA(c) and a CryllA(b) toxin); VIPCOT® (cotton variety that expresses a VIP toxin); NewLeaf® (potato variety that expresses a Cryl HA toxin); NatureGard® Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt1 1 corn borer (CB) trait), Agrisure® RW (corn rootworm trait) and Protecta®.

[0410] The term "crops" is to be understood as including also crop plants which have been so transformed by the use of recombinant DNA techniques that they are capable of synthesising one or more selectively acting toxins, such as are known, for example, from toxin-producing bacteria, especially those of the genus Bacillus.

[0411] Toxins that can be expressed by such transgenic plants include, for example, insecticidal proteins from Bacillus cereus or Bacillus popilliae; or insecticidal proteins from Bacillus thuringiensis, such as 8-endotoxins, e.g. CrylAb, CrylAc, Cry1 F, Cry1 Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), e.g. Vip1 , Vip2, Vip3 or Vip3A; or insecticidal proteins of bacteria colonising nematodes, for example Photorhabdus spp. or Xenorhabdus spp., such as Photorhabdus luminescens, Xenorhabdus nematophilus; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins and other insect-specific neurotoxins; toxins produced by fungi, such as Streptomycetes toxins, plant lectins, such as pea lectins, barley lectins or snowdrop lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin, papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxysteroidoxidase, ecdysteroid- UDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors, HMG-COA-reductase, ion channel blockers, such as blockers of sodium or calcium channels, juvenile hormone esterase, diuretic hormone receptors, stilbene synthase, bibenzyl synthase, chitinases and glucanases.

[0412] In the context of the present invention there are to be understood by 8-endotoxins, for example CrylAb, CrylAc, Cry1 F, Cry1 Fa2, Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), for example Vip1 , Vip2, Vip3 or Vip3A, expressly also hybrid toxins, truncated toxins and modified toxins. Hybrid toxins are produced recombinantly by a new combination of different domains of those proteins (see, for example, W002 / 15701). Truncated toxins, for example a truncated CrylAb, are known. In the case of modified toxins, one or more amino acids of the naturally occurring toxin are replaced. In such amino acid replacements, preferably non-naturally present protease recognition sequences are inserted into the toxin, such as, for example, in the case of Cry3A055, a cathepsin-G-recognition sequence is inserted into a Cry3A toxin (see WG03 / 018810).

[0413] Examples of such toxins or transgenic plants capable of synthesising such toxins are disclosed, for example, in EP-A-0 374 753, WO 93 / 07278, WO 95 / 34656, EP-A-0 427 529, EP-A-451 878 and WO 03 / 052073.

[0414] The processes for the preparation of such transgenic plants are generally known to the person skilled in the art and are described, for example, in the publications mentioned above. Cryl-type deoxyribonucleic acids and their preparation are known, for example, from WO 95 / 34656, EP-A-0 367 474, EP-A-0 401 979 and WO 90 / 13651.

[0415] The toxin contained in the transgenic plants imparts to the plants tolerance to harmful insects. Such insects can occur in any taxonomic group of insects but are especially commonly found in the beetles (Coleoptera), two-winged insects (Diptera) and butterflies (Lepidoptera).

[0416] Transgenic plants containing one or more genes that code for an insecticidal resistance and express one or more toxins are known and some of them are commercially available. Examples of such plants are: YieldGard ® (maize variety that expresses a CrylAb toxin); YieldGard Rootworm® (maize variety that expresses a Cry3Bb1 toxin); YieldGard Plus® (maize variety that expresses a CrylAb and a Cry3Bb1 toxin); Starlink® (maize variety that expresses a Cry9C toxin); Herculex I® (maize variety that expresses a Cry1 Fa2 toxin and the enzyme phosphinothricine N-acetyltransferase (PAT) to achieve tolerance to the herbicide glufosinate ammonium); NuCOTN 33B® (cotton variety that expresses a CrylAc toxin); Bollgard I® (cotton variety that expresses a Cry1 Ac toxin); Bollgard II® (cotton variety that expresses a Cry1 Ac and a Cry2Ab toxin); VipCot ® (cotton variety that expresses a Vip3A and a CrylAb toxin); NewLeaf® (potato variety that expresses a Cry3A toxin); NatureGard®, Agrisure® GT Advantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt11 corn borer (CB) trait) and Protecta®.

[0417] Further examples of such transgenic crops are:

[0418] 1. Bt11 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C / FR / 96 / 05 / 10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a truncated CrylAb toxin. Bt11 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.

[0419] 2. Bt176 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C / FR / 96 / 05 / 10. Genetically modified Zea mays which has been rendered resistant to attack by the European corn borer (Ostrinia nubilalis and Sesamia nonagrioides) by transgenic expression of a CrylAb toxin. Bt176 maize also transgenically expresses the enzyme PAT to achieve tolerance to the herbicide glufosinate ammonium.

[0420] 3. MIR604 Maize from Syngenta Seeds SAS, Chemin de I'Hobit 27, F-31 790 St. Sauveur, France, registration number C / FR / 96 / 05 / 10. Maize which has been rendered insect-resistant by transgenic expression of a modified Cry3A toxin. This toxin is Cry3A055 modified by insertion of a cathepsin-G-protease recognition sequence. The preparation of such transgenic maize plants is described in WO 03 / 018810.

[0421] 4. MON 863 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C / DE / 02 / 9. MON 863 expresses a Cry3Bb1 toxin and has resistance to certain Coleoptera insects.

[0422] 5. IPC 531 Cotton from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C / ES / 96 / 02.

[0423] 6. 1507 Maize from Pioneer Overseas Corporation, Avenue Tedesco, 7 B-1160 Brussels, Belgium, registration number C / NL / 00 / 10. Genetically modified maize forthe expression of the protein Cry1 F for achieving resistance to certain Lepidoptera insects and of the PAT protein for achieving tolerance to the herbicide glufosinate ammonium.

[0424] 7. NK603 x MON 810 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren, B-1150 Brussels, Belgium, registration number C / GB / 02 / M3 / 03. Consists of conventionally bred hybrid maize varieties by crossing the genetically modified varieties NK603 and MON 810. NK603 x MON 810 Maize transgenically expresses the protein CP4 EPSPS, obtained from Agrobacterium sp. strain CP4, which imparts tolerance to the herbicide Roundup® (contains glyphosate), and also a CrylAb toxin obtained from Bacillus thuringiensis subsp. kurstaki which brings about tolerance to certain Lepidoptera, include the European corn borer. Additionally, to date, no cross- resista nee has been observed between the composition comprising a mixture of components (A) and (B) and any fungicidal solutions used to control phytopathogenic fungi such as Absidia corymbifera, Alternaria spp, Aphanomyces spp, Ascochyta spp, Aspergillus spp. including A. flavus, A. fumigatus, A. nidulans, A. niger, A. terras, Aureobasidium spp. including A. pullulans, Blastomyces dermatitidis, Blumeria graminis, Bremia lactucae, Botryosphaeria spp. including B. dothidea, B. obtusa, Botrytis spp. inclusing B. cinerea, Candida spp. including C. albicans, C. glabrata, C. krusei, C. lusitaniae, C. parapsilosis, C. tropicalis, Cephaloascus fragrans, Ceratocystis spp, Cercospora spp. including C. arachidicola, Cercosporidium personatum, Cladosporium spp, Claviceps purpurea, Coccidioides immitis, Cochliobolus spp, Colletotrichum spp. including C. musae, Cryptococcus neoformans, Diaporthe spp, Didymella spp, Drechslera spp, Elsinoe spp, Epidermophyton spp, Erwinia amylovora, Erysiphe spp. including E. cichoracearum, Eutypa lata, Fusarium spp. including F. culmorum, F. graminearum, F. langsethiae, F. moniliforme, F. oxysporum, F. proliferatum, F. subglutinans, F. solani, Gaeumannomyces graminis, Gibberella fujikuroi, Gloeodes pomigena, Gloeosporium musarum, Glomerella cingulate, Guignardia bidwellii, Gymnosporangium juniperi-virginianae, Helminthosporium spp, Hemileia spp, Histoplasma spp. including H. capsulatum, Laetisaria fuciformis, Leptographium lindbergi, Leveillula taurica, Lophodermium seditiosum, Microdochium nivale, Microsporum spp, Monilinia spp, Mucor spp, Mycosphaerella spp. including M. graminicola, M. pomi, Oncobasidium theobromaeon, Ophiostoma piceae, Paracoccidioides spp, Penicillium spp. including P. digitatum, P. italicum, Petriellidium spp, Peronosclerospora spp. Including P. maydis, P. philippinensis and P. sorghi, Peronospora spp, Phaeosphaeria nodorum, Phakopsora pachyrhizi, Phellinus igniarus, Phialophora spp, Phoma spp, Phomopsis viticola, Phytophthora spp. including P. infestans, Plasmopara spp. including P. halstedii, P. viticola, Pleospora spp., Podosphaera spp. including P. leucotricha, Polymyxa graminis, Polymyxa betae, Pseudocercosporella herpotrichoides, Pseudomonas spp, Pseudoperonospora spp. including P. cubensis, P. humuli, Pseudopeziza tracheiphila, Puccinia Spp. including P. hordei, P. recondita, P. striiformis, P. triticina, Pyrenopeziza spp, Pyrenophora spp, Pyricularia spp. including P. oryzae, Pythium spp. including P. ultimum, Ramularia spp, Rhizoctonia spp, Rhizomucor pusillus, Rhizopus arrhizus, Rhynchosporium spp, Scedosporium spp. including S. apiospermum and S. prolificans, Schizothyrium pomi, Sclerotinia spp, Sclerotium spp, Septoria spp, including S. nodorum, S. tritici, Sphaerotheca macularis, Sphaerotheca fusca (Sphaerotheca fuliginea), Sporothorix spp, Stagonospora nodorum, Stemphylium spp., Stereum hirsutum, Thanatephorus cucumeris, Thielaviopsis basicola, Tilletia spp, Trichoderma spp., including T. harzianum, T. pseudokoningii, T. viride, Trichophyton spp, Typhula spp, Uncinula necator, Urocystis spp, Ustilago spp, Venturia spp. including V. inaequalis, Vertici Ilium spp, and Xanthomonas spp., in particular, Zymoseptoria tritici, Puccinia recondita, Puccinia striiformis, Erysiphe graminis, Uncinula necator, Sphaerotheca fuliginea, Leveillula taurica, Phakopsora pachyrhizi, Pyricularia oryzae, Alternaria solani, Alternaria alternata, Mycosphaerella fijiensis, Colletotrichum lagenarium, Didymella bryoniae, Ascochyta pisii, Verticillium dahliae, Pyrenophora teres, Cercospora beticola, Ramularia collo-cygni, Botrytis cinerea, Sclerotinia sclerotiorum, Monilinia laxa, Monographella nivalis and Venturia inaequalis.

[0425] Indeed, fungicidal-resistant strains in any of the species as outlined above have been reported in the scientific literature, with strains resistant to one or more fungicides from at least one of the following fungicidal mode of action classes: quinone-outside-inhibitors (Qol), quinone-inside-inhibitors (Qil), succinate dehydrogenase inhibitors (SDHI) and sterol demethylation-inhibitors (DMI). Such fungicidal-resistant strains may contain:

[0426] 1. A mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, wherein the mutation is G143A, F129L or G137R. See for example: Gisi et al., Pest Manag Sci. 2000, 56, 833-841 , Lucas, Pestic Outlook2003, 14(6), 268-70, Fraaije et al., Phytopathol 2005 , 95(8), 933-41 , Sierotzki et al., Pest Manag. Sci. 2007, 63(3), 225-233 (2007), Semar et al., J. Plant Dis. Prot. 2007, (3), 117-119; and Pasche et al., J. Crop Prot. 2008, 27(3-5), 427-435 (2008).

[0427] 2. A mutation in the mitochondrial cytochrome b gene conferring resistance to Qi inhibitors, wherein the mutation is G37A / C / D / S / V or N31 K. See for example: Meunier et al., Pest Manag Sci. 2019; 75: 2107-2114, Young et al., Pest Manag Sci. 2018; 74(2): 489-498, Walker et al., Environ. Microbiol. 2021

[0428] 3. A mutation in the genes encoding the SdhB,C,D subunits conferring resistance to SDHI inhibitors wherein the mutation is in the following major pathogens:

[0429] . Botrytis cinerea: B-P225H / L / T / Y / F, B-N230I, B-H272L / Y / R, C-P80H / L, C-N87S;

[0430] • Alternaria solani: B-H278R / Y, C-H134R / Q, D-D123E, D-H133R and C-H134R;

[0431] • Zymoseptoria tritici: sdhB: N225T, N225I, R265P, T268I, T268A. In sdhC: T79N, T79I, W80S, W80A, A84F, N86S, N86A, P127A, R151 M / S / T / G, R151S, R151T, H152R / Y, V166M, T168R. In sdhD: I50F, M114V, D129G, T20P+K186R;

[0432] . Pyrenophora teres: In sdhB: S66P, N235I, H277Y. In sdhC: K49E, R64K, N75S, G79R, H134R, S135R. In sdhD: D124E, H134R, G138V, D145G;

[0433] • Ramularia collo-cygni: In sdhB: N224T, T267I. In sdhC: N87S, G91 R, H146R / L, G171 D, H153R;

[0434] • Phakopsora pachyrhizi: C- 186 F ;

[0435] • Sclerotinia sclerotiorum: In sdhB: H273Y. In sdhC: G91 R, H146R. In sdhD: T108K, H132R, G150R.

[0436] Major source of information is www.frac.info, Sierotzki and Scalliet, Phytopathology (2013) 103(9): 880-887 and Simoes et al., J. Plant Dis. Prot. 2018, 125: 21-2.

[0437] A mutation or combination of mutations in the CYP51 gene conferring resistance to DMI inhibitors wherein the mutations are: L50S, D134G, V136A / C, Y137F, S188N, A379G, 1381V, deletion 459-460, Y461 H / S, N513K, S524T. Major source of information is www.frac.info, Cools et al., Plant Pathol. 2013, 62: 36-42 and Schmitz HK et al., Pest Manag. Sci. 2014, 70: 378-388.

[0438] Thus, in a preferred embodiment, the compositions according to the present invention comprising a mixture of components (A) and (B), are used to control fungal strains which are resistant to one or more fungicides from any of the following fungicidal MoA classes: quinone-outside-inhibitors (Qol), quinone-inside-inhibitors (Qil), succinate dehydrogenase inhibitors (SDHI) and sterol demethylation-inhibitors (DMI). Compositions of this invention, including all of the above disclosed embodiments and preferred examples thereof, can be mixed with one or more further pesticides including further fungicides, insecticides, nematocides, bactericides, acaricides, growth regulators, chemosterilants, semiochemicals, repellents, attractants, pheromones, feeding stimulants or other biologically active compounds to form a multi-component pesticide giving an even broader spectrum of agricultural protection.

[0439] Examples of such agricultural protectants with which the composition of this invention can be formulated are:

[0440] Fungicides such as etridiazole, fluazinam, benalaxyl, benalaxyl-M (kiralaxyl), furalaxyl, metalaxyl, metalaxyl-M (mefenoxam), dodicin, N'-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine, N'-[4-(4,5-dichloro- thiazol-2-yloxy)-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine, N'-[4-[[3-[(4-chlorophenyl)methyl]-1 ,2,4- thiadiazol-5-yl]oxy]-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine, ethirimol, 3'-chloro-2-methoxy-N- [(3RS)-tetrahydro-2-oxofuran-3-yl]acet-2',6'-xylidide (clozylacon), cyprodinil, mepanipyrim, pyrimethanil, dithianon, aureofungin, blasticidin-S, biphenyl, chloroneb, dicloran, benzovindiflupyr, pydiflumetofen, hexachlorobenzene, quintozene, tecnazene (TCNB), tolclofos-methyl, metrafenone, 2,6-dichloro-N-(4- trifluoromethylbenzyl)-benzamide, fluopicolide (flupicolide), tioxymid, flusulfamide, benomyl, carbendazim, carbendazim chlorhydrate, chlorfenazole, fuberidazole, thiabendazole, thiophanate-methyl, benthiavalicarb, chlobenthiazone, probenazole, acibenzolar, bethoxazin, pyriofenone (IKF-309), acibenzolar-S-methyl, pyribencarb (KIF-7767), butylamine, 3-iodo-2-propinyl n-butylcarbamate (IPBC), picarbutrazox, polycarbamate, propamocarb, tolprocarb, 3-(difluoromethyl)-N-(7-fluoro-1 ,1 ,3,3-tetramethyl-indan-4-yl)-1- methyl-pyrazole-4-carboxamide, diclocymet, N-[(5-chloro-2-isopropyl-phenyl)methyl]-N-cyclopropyl-3- (difluoromethyl)-5-fluoro-1-methyl-pyrazole-4-carboxamide, N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-[(2- isopropylphenyl)methyl]-1-methyl-pyrazole-4-carboxamide, carpropamid, chlorothalonil, flumorph, oxinecopper, cymoxanil, phenamacril, cyazofamid, flutianil, thicyofen, chlozolinate, iprodione, procymidone, vinclozolin, bupirimate, dinocton, dinopenton, dinobuton, dinocap, meptyldinocap, diphenylamine, phosdiphen, 2,6-dimethyl-[1 ,4]dithiino[2,3-c:5,6-c']dipyrrole-1 ,3,5,7(2H,6H)-tetraone, azithiram, etem, ferbam, mancozeb, maneb, metam, metiram (polyram), metiram-zinc, nabam, propineb, thiram, vapam (metam sodium), zineb, ziram, dithioether, isoprothiolane, ethaboxam, fosetyl, phosetyl-AI (fosetyl-al), methyl bromide, methyl iodide, methyl isothiocyanate, cyclafuramid, fenfuram, validamycin, streptomycin, (2RS)-2-bromo-2- (bromomethyl)glutaronitrile (bromothalonil), dodine, doguadine, guazatine, iminoctadine, iminoctadine triacetate, 2,4-D, 2,4-DB, kasugamycin, dimethirimol, fenhexamid, hymexazole, hydroxyisoxazole imazalil, imazalil sulphate, oxpoconazole, pefurazoate, prochloraz, triflumizole, fenamidone, Bordeaux mixture, calcium polysulfide, copper acetate, copper carbonate, copper hydroxide, copper naphthenate, copper oleate, copper oxychloride, copper oxyquinolate, copper silicate, copper sulphate, copper tallate, cuprous oxide, sulphur, carbaryl, phthalide (fthalide), dingjunezuo (Jun Si Qi), oxathiapiprolin, fluoroimide, mandipropamid, KSF-1002, benzamorf, dimethomorph, fenpropimorph, tridemorph, dodemorph, diethofencarb, fentin acetate, fentin hydroxide, carboxin, oxycarboxin, drazoxolon, famoxadone, m-phenylphenol, p-phenylphenol, tribromophenol (TBP), 2-[2-[(7,8-difluoro-2-methyl-3-quinolyl)oxy]-6-fluoro-phenyl]propan-2-ol 2-[2-fluoro-6-[(8-fluoro-2- methyl-3-quinolyl)oxy]phenyl]propan-2-ol, cyflufenamid, ofurace, oxadixyl, flutolanil, mepronil, isofetamid, fenpiclonil, fludioxonil, pencycuron, edifenphos, iprobenfos, pyrazophos, phosphorus acids, tecloftalam, captafol, captan, ditalimfos, triforine, fenpropidin, piperalin, osthol, 1 -methylcyclopropene, 4-CPA, chlormequat, clofencet, dichlorprop, dimethipin, endothal, ethephon, flumetralin, forchlorfenuron, gibberellic acid, gibberellins, hymexazol, maleic hydrazide, mepiquat, naphthalene acetamide, paclobutrazol, prohexadione, prohexadione-calcium, thidiazuron, tribufos (tributyl phosphorotrithioate), trinexapac, uniconazole, a- naphthalene acetic acid, polyoxin D (polyoxrim), BLAD, chitosan, fenoxanil, folpet, 3-(difluoromethyl)-N- methoxy-1-methyl-N-[1-methyl-2-(2,4,6-trichlorophenyl)ethyl]pyrazole-4-carboxamide, bixafen, fluxapyroxad, furametpyr, isopyrazam, penflufen, penthiopyrad, sedaxane, fenpyrazamine, diclomezine, pyrifenox, boscalid, fluopyram, diflumetorim, fenarimol, 5-fluoro-2-(p-tolylmethoxy)pyrimidin-4-amine, ferimzone, dimetachlone (dimethaclone), pyroquilon, proquinazid, ethoxyquin, quinoxyfen, 4,4,5-trifluoro-3,3-dimethyl-1-(3- quinolyl)isoquinoline, 4,4-difluoro-3,3-dimethyl-1-(3-quinolyl)isoquinoline, 5-fluoro-3,3,4,4-tetramethyl-1-(3- quinolyl)isoquinoline, 9-fluoro-2,2-dimethyl-5-(3-quinolyl)-3H-1 ,4-benzoxazepine, tebufloquin, oxolinic acid, chinomethionate (oxythioquinox, quinoxymethionate), spiroxamine, (E)-N-methyl-2- [2-(2,5- dimethylphenoxymethyl)phenyl]-2-methoxy-iminoacetamide, azoxystrobin, coumoxystrobin, dimoxystrobin, enestroburin, enoxastrobin, fenamistrobin, flufenoxystrobin, fluoxastrobin, kresoxim-methyl, mandestrobin, metaminostrobin, metominostrobin, orysastrobin, picoxystrobin, pyraclostrobin, pyrametostrobin, pyraoxystrobin, triclopyricarb, trifloxystrobin, amisulbrom, dichlofluanid, tolylfluanid, but-3-ynyl N-[6-[[(Z)-[(1- methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate, dazomet, isotianil, tiadinil, thifluzamide, benthiazole (TCMTB), silthiofam, zoxamide, anilazine, tricyclazole, ( / 'ac)-cis-1-(4-chlorophenyl)-

[0441] 2-(1 H-1 ,2,4-triazol-1-yl)-cycloheptanol (huanjunzuo), 1-(5-bromo-2-pyridyl)-2-(2,4-difluorophenyl)-1 , 1 -difluoro-

[0442] 3-(1 ,2,4-triazol-1-yl)propan-2-ol 2-(1-tert-butyl)-1-(2-chlorophenyl)-3-(1 ,2,4-triazol-1-yl)-propan-2-ol (TCDP), azaconazole, bitertanol (biloxazol), bromuconazole, climbazole, cyproconazole, difenoconazole, dimetconazole, diniconazole, diniconazole-M, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, hexaconazole, imibenconazole, ipconazole, ipfentrifluconazole, metconazole, myclobutanil, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, triazoxide, triticonazole, mefentrifluconazole, 2-[[(1 R,5S)-5-[(4-fluorophenyl)methyl]-

[0443] 1 -hydroxy-2, 2-dimethyl-cyclopentyl]methyl]-4H-1 ,2,4-triazole-3-thione, 2-[[3-(2-chlorophenyl)-2-(2,4- difluorophenyl)oxiran-2-yl]methyl]-4H-1 ,2,4-triazole-3-thione, ametoctradin (imidium), iprovalicarb, valifenalate,

[0444] 2-benzyl-4-chlorophenol (Chlorophene), allyl alcohol, azafenidin, benzalkonium chloride, chloropicrin, cresol, daracide, dichlorophen (dichlorophene), difenzoquat, dipyrithione, N-(2-p-chlorobenzoylethyl)-hexaminium chloride, NNF-0721 , octhilinone, oxasulfuron, propamidine and propionic acid.

[0445] Insecticides such as abamectin, acephate, acetamiprid, amidoflumet (S-1955), avermectin, azadirachtin, azinphos-methyl, bifenthrin, bifenazate, buprofezin, carbofuran, cartap, chlorantraniliprole (DPX-E2Y45), chlorfenapyr, chlorfluazuron, chlorpyrifos, chlorpyrifos-methyl, chromafenozide, clothianidin, cyflumetofen, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, cypermethrin, cyromazine, deltamethrin, diafenthiuron, diazinon, dieldrin, diflubenzuron, dimefluthrin, dimethoate, dinotefuran, diofenolan, emamectin, endosulfan, esfenvalerate, ethiprole, fenothiocarb, fenoxycarb, fenpropathrin, fenvalerate, fipronil, flonicamid, flubendiamide, flucythrinate, tau-fluvalinate, flufenerim (UR-50701), flufenoxuron, fonophos, halofenozide, hexaflumuron, hydramethylnon, imidacloprid, indoxacarb, isofenphos, lufenuron, malathion, metaflumizone, metaldehyde, methamidophos, methidathion, methomyl, methoprene, methoxychlor, metofluthrin, monocrotophos, methoxyfenozide, nitenpyram, nithiazine, novaluron, noviflumuron (XDE-007), oxamyl, parathion, parathion-methyl, permethrin, phorate, phosalone, phosmet, phosphamidon, pirimicarb, profenofos, profluthrin, pymetrozine, pyrafluprole, pyrethrin, pyridalyl, pyrifluquinazon, pyriprole, pyriproxyfen, rotenone, ryanodine, spinetoram, spinosad, spirodiclofen, spiromesifen (BSN 2060), spirotetramat, sulprofos, tebufenozide, teflubenzuron, tefluthrin, terbufos, tetrachlorvinphos, thiacloprid, thiamethoxam, thiodicarb, thiosultap-sodium, tralomethrin, triazamate, trichlorfon and triflumuron;

[0446] Bactericides such as streptomycin;

[0447] Acaricides such as amitraz, chinomethionat, chlorobenzilate, cyenopyrafen, cyhexatin, dicofol, dienochlor, etoxazole, fenazaquin, fenbutatin oxide, fenpropathrin, fenpyroximate, hexythiazox, propargite, pyridaben and tebufenpyrad; and

[0448] Biological agents such as Bacillus thuringiensis, Bacillus thuringiensis delta endotoxin, baculovirus, and entomopathogenic bacteria, virus and fungi.

[0449] Other examples of “reference” mixture compositions are as follows (wherein the term “TX” represents a compound (according to the definition of component (A) of the compositions of the present invention) selected from compound no. (X.01), (X.02), (X.03), (X.04), (X.05), (X.06), (X.07), (X.08), (X.9), (X.10), (X.11), (X.12), (X.13), (X.14), (X.15), (X.16), (X.17), (X.18), (X.19), (X.20), (X.21), (X.22), (X.23), (X.24), (X.25), (X.26), (X.27), (X.28), or (X.29), as defined in the Table X above): a compound selected from the group of substances consisting of petroleum oils + TX, 1 ,1-bis(4-chloro-phenyl)-2-ethoxyethanol + TX, 2,4-dichlorophenyl benzenesulfonate + TX, 2-fluoro-N-methyl-N-1 -naphthylacetamide + TX, 4-chlorophenyl phenyl sulfone + TX, acetoprole + TX, aldoxycarb + TX, amidithion + TX, amidothioate + TX, amiton + TX, amiton hydrogen oxalate + TX, amitraz + TX, aramite + TX, arsenous oxide + TX, azobenzene + TX, azothoate + TX, benomyl + TX, benoxa-fos + TX, benzyl benzoate + TX, bixafen + TX, brofenvalerate + TX, bromo-cyclen + TX, bromophos + TX, bromopropylate + TX, buprofezin + TX, butocarboxim + TX, butoxycarboxim + TX, butylpyridaben + TX, calcium polysulfide + TX, camphechlor + TX, carbanolate + TX, carbophenothion + TX, cymiazole + TX, chino-methionat + TX, chlorbenside + TX, chlordimeform + TX, chlordimeform hydrochloride + TX, chlorfenethol + TX, chlorfenson + TX, chlorfensulfide + TX, chlorobenzilate + TX, chloromebuform + TX, chloromethiuron + TX, chloropropylate + TX, chlorthiophos + TX, cinerin I + TX, cinerin II + TX, cinerins + TX, closantel + TX, coumaphos + TX, crotamiton + TX, crotoxyphos + TX, cufraneb + TX, cyanthoate + TX, DCPM + TX, DDT + TX, demephion + TX, demephion-O + TX, demephion-S + TX, demeton-methyl + TX, demeton- O + TX, demeton-O-methyl + TX, demeton-S + TX, demeton-S-methyl + TX, demeton-S-methylsulfon + TX, dichlofluanid + TX, dichlorvos + TX, dicliphos + TX, dienochlor + TX, dimefox + TX, dinex + TX, dinex-diclexine + TX, dinocap-4 + TX, dinocap-6 + TX, dinocton + TX, dino-penton + TX, dinosulfon + TX, dinoterbon + TX, dioxathion + TX, diphenyl sulfone + TX, disulfiram + TX, DNOC + TX, dofenapyn + TX, doramectin + TX, endothion + TX, eprinomectin + TX, ethoate-methyl + TX, etrimfos + TX, fenazaflor + TX, fenbutatin oxide + TX, fenothiocarb + TX, fenpyrad + TX, fen-pyroximate + TX, fenpyrazamine + TX, fenson + TX, fentrifanil + TX, flubenzimine + TX, flucycloxuron + TX, fluenetil + TX, fluorbenside + TX, FMC 1 137 + TX, formetanate + TX, formetanate hydrochloride + TX, formparanate + TX, gamma-HCH + TX, glyodin + TX, halfenprox + TX, hexadecyl cyclopropanecarboxylate + TX, isocarbophos + TX, jasmolin I + TX, jasmolin II + TX, jodfenphos + TX, lindane + TX, malonoben + TX, mecarbam + TX, mephosfolan + TX, mesulfen + TX, methacrifos + TX, methyl bromide + TX, metolcarb + TX, mexacarbate + TX, milbemycin oxime + TX, mipafox + TX, monocrotophos + TX, morphothion + TX, moxidectin + TX, naled + TX, 4-chloro-2-(2-chloro-2-methyl-propyl)- 5-[(6-iodo-3-pyridyl)methoxy]pyridazin-3-one + TX, nifluridide + TX, nikkomycins + TX, nitrilacarb + TX, nitrilacarb 1 :1 zinc chloride complex + TX, omethoate + TX, oxydeprofos + TX, oxydisulfoton + TX, pp'-DDT + TX, parathion + TX, permethrin + TX, phenkapton + TX, phosalone + TX, phosfolan + TX, phosphamidon + TX, polychloroterpenes + TX, polynactins + TX, proclonol + TX, promacyl + TX, propoxur + TX, prothidathion + TX, prothoate + TX, pyrethrin I + TX, pyrethrin II + TX, pyrethrins + TX, pyridaphenthion + TX, pyrimitate + TX, quinalphos + TX, quintiofos + TX, R-1492 + TX, phosglycin + TX, rotenone + TX, schradan + TX, sebufos + TX, selamectin + TX, sophamide + TX, SSI-121 + TX, sulfiram + TX, sulfluramid + TX, sulfotep + TX, sulfur + TX, diflovidazin + TX, tau-fluvalinate + TX, TEPP + TX, terbam + TX, tetradifon + TX, tetrasul + TX, thiafenox + TX, thiocarboxime + TX, thiofanox + TX, thiometon + TX, thioquinox + TX, thuringiensin + TX, triamiphos + TX, triarathene + TX, triazophos + TX, triazuron + TX, trifenofos + TX, trinactin + TX, vamidothion + TX, vaniliprole + TX, bethoxazin + TX, copper dioctanoate + TX, copper sulfate + TX, cybutryne + TX, dichlone + TX, dichlorophen + TX, endothal + TX, fentin + TX, hydrated lime + TX, nabam + TX, quinoclamine + TX, quinonamid + TX, simazine + TX, triphenyltin acetate + TX, triphenyltin hydroxide + TX, crufomate + TX, piperazine + TX, thiophanate + TX, chloralose + TX, fenthion + TX, pyridin-4-amine + TX, strychnine + TX, 1 - hydroxy-1 H-pyridine-2-thione + TX, 4-(quinoxalin-2-ylamino)benzenesulfonamide + TX, 8-hydroxyquinoline sulfate + TX, bronopol + TX, copper hydroxide + TX, cresol + TX, dipyrithione + TX, dodicin + TX, fenaminosulf + TX, formaldehyde + TX, hydrargaphen + TX, kasugamycin + TX, kasugamycin hydrochloride hydrate + TX, nickel bis(dimethyldithiocarbamate) + TX, nitrapyrin + TX, octhilinone + TX, oxolinic acid + TX, oxytetracycline + TX, potassium hydroxyquinoline sulfate + TX, probenazole + TX, streptomycin + TX, streptomycin sesquisulfate + TX, tecloftalam + TX, thiomersal + TX, Adoxophyes orana GV + TX, Agrobacterium radiobacter + TX, Amblyseius spp. + TX, Anagrapha falcifera NPV + TX, Anagrus atomus + TX, Aphelinus abdominalis + TX, Aphidius colemani + TX, Aphidoletes aphidimyza + TX, Autographa californica NPV + TX, Bacillus sphaericus Neide + TX, Beauveria brongniartii + TX, Chrysoperla carnea + TX, Cryptolaemus montrouzieri + TX, Cydia pomonella GV + TX, Dacnusa sibirica + TX, Diglyphus isaea + TX, Encarsia formosa + TX, Eretmocerus eremicus + TX, Heterorhabditis bacteriophora and H. megidis + TX, Hippodamia convergens + TX, Leptomastix dactylopii + TX, Macrolophus caliginosus + TX, Mamestra brassicae NPV + TX, Metaphycus helvolus + TX, Metarhizium anisopliae var. acridum + TX, Metarhizium anisopliae var. anisopliae + TX, Neodiprion sertifer NPV and N. lecontei NPV + TX, Orius spp. + TX, Paecilomyces fumosoroseus + TX, Phytoseiulus persimilis + TX, Steinernema bibionis + TX, Steinernema carpocapsae + TX, Steinernema feltiae + TX, Steinernema glaseri + TX, Steinernema riobrave + TX, Steinernema riobravis + TX, Steinernema scapterisci + TX, Steinernema spp. + TX, Trichogramma spp. + TX, Typhlodromus occidentalis + TX, Verticillium lecanii + TX, apholate + TX, bisazir + TX, busulfan + TX, dimatif + TX, hemel + TX, hempa + TX, metepa + TX, methiotepa + TX, methyl apholate + TX, morzid + TX, penfluron + TX, tepa + TX, thiohempa + TX, thiotepa + TX, tretamine + TX, uredepa + TX, (E)-dec-5-en-1-yl acetate with (E)-dec-5-en-1-ol + TX, (E)- tridec-4-en-1-yl acetate + TX, (E)-6-methylhept-2-en-4-ol + TX, (E,Z)-tetradeca-4,10-dien-1-yl acetate + TX, (Z)-dodec-7-en-1-yl acetate + TX, (Z)-hexadec-11 -enal + TX, (Z)-hexadec-11-en-1-yl acetate + TX, (Z)- hexadec-13-en-11-yn-1-yl acetate + TX, (Z)-icos-13-en-10-one + TX, (Z)-tetradec-7-en-1-al + TX, (Z)-tetradec- 9-en-1-ol + TX, (Z)-tetradec-9-en-1-yl acetate + TX, (7E,9Z)-dodeca-7,9-dien-1-yl acetate + TX, (9Z,11 E)- tetradeca-9,11-dien-1-yl acetate + TX, (9Z,12E)-tetradeca-9,12-dien-1-yl acetate + TX, 14-methyloctadec-1- ene + TX, 4-methylnonan-5-ol with 4-methylnonan-5-one + TX, alpha-multistriatin + TX, brevicomin + TX, codlelure + TX, codlemone + TX, cuelure + TX, disparlure + TX, dodec-8-en-1-yl acetate + TX, dodec-9-en-1- yl acetate + TX, dodeca-8,10-dien-1-yl acetate + TX, dominicalure + TX, ethyl 4-methyloctanoate + TX, eugenol + TX, frontalin + TX, grandlure + TX, grandlure I + TX, grandlure II + TX, grandlure III + TX, grandlure IV + TX, hexalure + TX, ipsdienol + TX, ipsenol + TX, japonilure + TX, lineatin + TX, litlure + TX, looplure + TX, medlure + TX, megatomoic acid + TX, methyl eugenol + TX, muscalure + TX, octadeca-2,13-dien-1-yl acetate + TX, octadeca-3,13-dien-1-yl acetate + TX, orfralure + TX, oryctalure + TX, ostramone + TX, siglure + TX, sordidin + TX, sulcatol + TX, tetradec-11 -en-1 -yl acetate + TX, trimedlure + TX, trimedlure A + TX, trimedlure Bi + TX, trimedlure B2 + TX, trimedlure C + TX, trunc-call + TX, 2-(octylthio)-ethanol + TX, butopyronoxyl + TX, butoxy(polypropylene glycol) + TX, dibutyl adipate + TX, dibutyl phthalate + TX, dibutyl succinate + TX, diethyltoluamide + TX, dimethyl carbate + TX, dimethyl phthalate + TX, ethyl hexanediol + TX, hexamide + TX, methoquin-butyl + TX, methylneodecanamide + TX, oxamate + TX, picaridin + TX, 1 -dichloro-1 -nitroethane + TX, 1 ,1-dichloro-2,2-bis(4-ethylphenyl)-ethane + TX, 1 ,2-dichloropropane with 1 ,3-dichloropropene + TX, 1- bromo-2-chloroethane + TX, 2,2,2-trichloro-1-(3,4-dichloro-phenyl)ethyl acetate + TX, 2,2-dichlorovinyl 2- ethylsulfinylethyl methyl phosphate + TX, 2-(1 ,3-dithiolan-2-yl)phenyl dimethylcarbamate + TX, 2-(2- butoxyethoxy)ethyl thiocyanate + TX, 2-(4,5-dimethyl-1 ,3-dioxolan-2-yl)phenyl methylcarbamate + TX, 2-(4- chloro-3,5-xylyloxy)ethanol + TX, 2-chlorovinyl diethyl phosphate + TX, 2-imidazolidone + TX, 2- isovalerylindan-1 ,3-dione + TX, 2-methyl(prop-2-ynyl)aminophenyl methylcarbamate + TX, 2-thiocyanatoethyl laurate + TX, 3-bromo-1 -chloroprop-1 -ene + TX, 3-methyl-1-phenylpyrazol-5-yl dimethyl-carbamate + TX, 4- methyl(prop-2-ynyl)amino-3,5-xylyl methylcarbamate + TX, 5,5-dimethyl-3-oxocycloheX.1-enyl dimethylcarbamate + TX, acethion + TX, acrylonitrile + TX, aldrin + TX, allosamidin + TX, allyxycarb + TX, alpha-ecdysone + TX, aluminium phosphide + TX, aminocarb + TX, anabasine + TX, athidathion + TX, azamethiphos + TX, Bacillus thuringiensis delta endotoxins + TX, barium hexafluorosilicate + TX, barium polysulfide + TX, barthrin + TX, Bayer 22 / 190 + TX, Bayer 22408 + TX, beta-cyfluthrin + TX, beta-cypermethrin + TX, bioethanomethrin + TX, biopermethrin + TX, bis(2-chloroethyl) ether + TX, borax + TX, bromfenvinfos + TX, bromo-DDT + TX, bufencarb + TX, butacarb + TX, butathiofos + TX, butonate + TX, calcium arsenate + TX, calcium cyanide + TX, carbon disulfide + TX, carbon tetrachloride + TX, cartap hydrochloride + TX, cevadine + TX, chlorbicyclen + TX, chlordane + TX, chlordecone + TX, chloroform + TX, chloropicrin + TX, chlorphoxim + TX, chlorprazophos + TX, cis-resmethrin + TX, cismethrin + TX, clocythrin + TX, copper acetoarsenite + TX, copper arsenate + TX, copper oleate + TX, coumithoate + TX, cryolite + TX, CS 708 + TX, cyanofenphos + TX, cyanophos + TX, cyclethrin + TX, cythioate + TX, d-tetramethrin + TX, DAEP + TX, dazomet + TX, decarbofuran + TX, diamidafos + TX, dicapthon + TX, dichlofenthion + TX, dicresyl + TX, dicyclanil + TX, dieldrin + TX, diethyl 5-methylpyrazol-3-yl phosphate + TX, dilor + TX, dimefluthrin + TX, dimetan + TX, dimethrin + TX, dimethylvinphos + TX, dimetilan + TX, dinoprop + TX, dinosam + TX, dinoseb + TX, diofenolan + TX, dioxabenzofos + TX, dithicrofos + TX, DSP + TX, ecdysterone + TX, El 1642 + TX, EMPC + TX, EPBP + TX, etaphos + TX, ethiofencarb + TX, ethyl formate + TX, ethylene dibromide + TX, ethylene dichloride + TX, ethylene oxide + TX, EXD + TX, fenchlorphos + TX, fenethacarb + TX, fenitrothion + TX, fenoxacrim + TX, fenpirithrin + TX, fensulfothion + TX, fenthion-ethyl + TX, flucofuron + TX, fosmethilan + TX, fospirate + TX, fosthietan + TX, furathiocarb + TX, furethrin + TX, guazatine + TX, guazatine acetates + TX, sodium tetrathiocarbonate + TX, halfenprox + TX, HCH + TX, HEOD + TX, heptachlor + TX, heterophos + TX, HHDN + TX, hydrogen cyanide + TX, hyquincarb + TX, IPSP + TX, isazofos + TX, isobenzan + TX, isodrin + TX, isofenphos + TX, isolane + TX, isoprothiolane + TX, isoxathion + TX, juvenile hormone I + TX, juvenile hormone II + TX, juvenile hormone III + TX, kelevan + TX, kinoprene + TX, lead arsenate + TX, leptophos + TX, lirimfos + TX, lythidathion + TX, m-cumenyl methylcarbamate + TX, magnesium phosphide + TX, mazidox + TX, mecarphon + TX, menazon + TX, mercurous chloride + TX, mesulfenfos + TX, metam + TX, metam- potassium + TX, metam-sodium + TX, methanesulfonyl fluoride + TX, methocrotophos + TX, methoprene + TX, methothrin + TX, methoxychlor + TX, methyl isothiocyanate + TX, methylchloroform + TX, methylene chloride + TX, metoxadiazone + TX, mirex + TX, naftalofos + TX, naphthalene + TX, NC-170 + TX, nicotine + TX, nicotine sulfate + TX, nithiazine + TX, nornicotine + TX, 0-5-dichloro-4-iodophenyl O-ethyl ethylphosphonothioate + TX, O,O-diethyl 0-4-methyl-2-oxo-2H-chromen-7-yl phosphorothioate + TX, 0,0- diethyl 0-6-methyl-2-propylpyrimidin-4-yl phosphorothioate + TX, 0,0,0',0'-tetrapropyl dithiopyrophosphate + TX, oleic acid + TX, para-dichlorobenzene + TX, parathion-methyl + TX, pentachlorophenol + TX, pentachlorophenyl laurate + TX, PH 60-38 + TX, phenkapton + TX, phosnichlor + TX, phosphine + TX, phoximmethyl + TX, pirimetaphos + TX, polychlorodicyclopentadiene isomers + TX, potassium arsenite + TX, potassium thiocyanate + TX, precocene I + TX, precocene II + TX, precocene III + TX, primidophos + TX, profluthrin + TX, promecarb + TX, prothiofos + TX, pyrazophos + TX, pyresmethrin + TX, quassia + TX, quinalphos-methyl + TX, quinothion + TX, rafoxanide + TX, resmethrin + TX, rotenone + TX, kadethrin + TX, ryania + TX, ryanodine + TX, sabadilla + TX, schradan + TX, sebufos + TX, SI-0009 + TX, thiapronil + TX, sodium arsenite + TX, sodium cyanide + TX, sodium fluoride + TX, sodium hexafluorosilicate + TX, sodium pentachlorophenoxide + TX, sodium selenate + TX, sodium thiocyanate + TX, sulcofuron + TX, sulcofuron- sodium + TX, sulfuryl fluoride + TX, sulprofos + TX, tar oils + TX, tazimcarb + TX, TDE + TX, tebupirimfos + TX, temephos + TX, terallethrin + TX, tetrachloroethane + TX, thicrofos + TX, thiocyclam + TX, thiocyclam hydrogen oxalate + TX, thionazin + TX, thiosultap + TX, thiosultap-sodium + TX, tralomethrin + TX, transpermethrin + TX, triazamate + TX, trichlormetaphos-3 + TX, trichloronat + TX, trimethacarb + TX, tolprocarb + TX, triclopyricarb + TX, triprene + TX, veratridine + TX, veratrine + TX, XMC + TX, zetamethrin + TX, zinc phosphide + TX, zolaprofos + TX, meperfluthrin + TX, tetramethylfluthrin + TX, bis(tributyltin) oxide + TX, bromoacetamide + TX, ferric phosphate + TX, niclosamide-olamine + TX, tributyltin oxide + TX, pyrimorph + TX, trifenmorph + TX, 1 ,2-dibromo-3-chloropropane + TX, 1 ,3-dichloropropene + TX, 3,4- dichlorotetrahydrothio-phene 1 ,1 -dioxide + TX, 3-(4-chlorophenyl)-5-methylrhodanine + TX, 5-methyl-6-thioxo- 1 ,3,5-thiadiazinan-3-ylacetic acid + TX, 6-isopentenylaminopurine + TX, anisiflupurin + TX, benclothiaz + TX, cytokinins + TX, DCIP + TX, furfural + TX, isamidofos + TX, kinetin + TX, Myrothecium verrucaria composition + TX, tetrachlorothiophene + TX, xylenols + TX, zeatin + TX, potassium ethylxanthate + TX, acibenzolar + TX, acibenzolar-S-methyl + TX, Reynoutria sachalinensis extract + TX, alpha-chlorohydrin + TX, antu + TX, barium carbonate + TX, bisthiosemi + TX, brodifacoum + TX, bromadiolone + TX, bromethalin + TX, chlorophacinone + TX, cholecalciferol + TX, coumachlor + TX, coumafuryl + TX, coumatetralyl + TX, crimidine + TX, difenacoum + TX, difethialone + TX, diphacinone + TX, ergocalciferol + TX, flocoumafen + TX, fluoroacetamide + TX, flupropadine + TX, flupropadine hydrochloride + TX, norbormide + TX, phosacetim + TX, phosphorus + TX, pindone + TX, pyrinuron + TX, scilliroside + TX, -sodium fluoroacetate + TX, thallium sulfate + TX, warfarin + TX, -2-(2-butoxyethoxy)ethyl piperonylate + TX, 5-(1 ,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone + TX, farnesol with nerolidol + TX, verbutin + TX, MGK 264 + TX, piperonyl butoxide + TX, piprotal + TX, propyl isomer + TX, S421 + TX, sesamex + TX, sesasmolin + TX, sulfoxide + TX, anthraquinone + TX, copper naphthenate + TX, copper oxychloride + TX, dicyclopentadiene + TX, thiram + TX, zinc naphthenate + TX, ziram + TX, imanin + TX, ribavirin + TX, chloroinconazide + TX, mercuric oxide + TX, thiophanate-methyl + TX, azaconazole + TX, bitertanol + TX, bromuconazole + TX, cyproconazole + TX, difenoconazole + TX, diniconazole -+ TX, epoxiconazole + TX, fenbuconazole + TX, fluquinconazole + TX, flusilazole + TX, flutriafol + TX, furametpyr + TX, hexaconazole + TX, imazalil- + TX, imiben-conazole + TX, ipconazole + TX, metconazole + TX, myclobutanil + TX, paclobutrazole + TX, pefurazoate + TX, penconazole + TX, prothioconazole + TX, pyrifenox + TX, prochloraz + TX, propiconazole + TX, pyrisoxazole + TX, -simeconazole + TX, tebucon-azole + TX, tetraconazole + TX, triadimefon + TX, triadimenol + TX, triflumizole + TX, triticonazole + TX, ancymidol + TX, fenarimol + TX, nuarimol + TX, bupirimate + TX, dimethirimol + TX, ethirimol + TX, dodemorph + TX, fenpropidin + TX, fenpropimorph + TX, spiroxamine + TX, tridemorph + TX, cyprodinil + TX, mepanipyrim + TX, pyrimethanil + TX, fenpiclonil + TX, fludioxonil + TX, benalaxyl + TX, furalaxyl + TX, -metalaxyl -+ TX, metalaxyl-M + TX, ofurace + TX, oxadixyl + TX, carbendazim + TX, debacarb + TX, fuberidazole -+ TX, thiabendazole + TX, chlozolinate + TX, dichlozoline + TX, myclozoline- + TX, procymidone + TX, vinclozoline + TX, boscalid + TX, carboxin + TX, fenfuram + TX, flutolanil + TX, mepronil + TX, oxycarboxin + TX, penthiopyrad + TX, thifluzamide + TX, dodine + TX, iminoctadine + TX, azoxystrobin + TX, dimoxystrobin + TX, enestroburin + TX, fenaminstrobin + TX, flufenoxystrobin + TX, fluoxastrobin + TX, kresoxim-methyl + TX, metominostrobin + TX, trifloxystrobin + TX, orysastrobin + TX, picoxystrobin + TX, pyraclostrobin + TX, pyrametostrobin + TX, pyraoxystrobin + TX, ferbam + TX, mancozeb + TX, maneb + TX, metiram + TX, propineb + TX, zineb + TX, captafol + TX, captan + TX, fluoroimide + TX, folpet + TX, tolylfluanid + TX, bordeaux mixture + TX, copper oxide + TX, mancopper + TX, oxine-copper + TX, nitrothal-isopropyl + TX, edifenphos + TX, iprobenphos + TX, phosdiphen + TX, tolclofos-methyl + TX, anilazine + TX, benthiavalicarb + TX, blasticidin-S + TX, chloroneb -+ TX, chloro-tha-lonil + TX, cyflufenamid + TX, cymoxanil + TX, cyclobutrifluram + TX, diclocymet + TX, diclomezine -+ TX, dicloran + TX, diethofencarb + TX, dimethomorph -+ TX, flumorph + TX, dithianon + TX, ethaboxam + TX, etridiazole + TX, famoxadone + TX, fenamidone + TX, fenoxanil + TX, ferimzone + TX, fluazinam + TX, flumetylsulforim + TX, fluopicolide + TX, fluoxytioconazole + TX, flusulfamide + TX, fluxapyroxad + TX, -fenhexamid + TX, fosetyl-aluminium -+ TX, hymexazol + TX, iprovalicarb + TX, cyazofamid + TX, methasulfocarb + TX, metrafenone + TX, pencycuron + TX, phthalide + TX, polyoxins + TX, propamocarb + TX, pyribencarb + TX, proquinazid + TX, pyroquilon + TX, pyriofenone + TX, quinoxyfen + TX, quintozene + TX, tiadinil + TX, triazoxide + TX, tricyclazole + TX, triforine + TX, validamycin + TX, valifenalate + TX, zoxamide + TX, mandipropamid + TX, flubeneteram + TX, isopyrazam + TX, sedaxane + TX, benzovindiflupyr + TX, pydiflumetofen + TX, 3-difluoromethyl-1-methyl-1 H- pyrazole-4-carboxylic acid (3',4',5'-trifluoro-biphenyl-2-yl)-amide + TX, isoflucypram + TX, isotianil + TX, dipymetitrone + TX, 6-ethyl-5,7-dioxo-pyrrolo[4,5][1 ,4]dithiino[1 ,2-c]isothiazole-3-carbonitrile + TX, 2- (difluoromethyl)-N-[3-ethyl-1 ,1-dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, 4-(2,6-difluorophenyl)-6- methyl-5-phenyl-pyridazine-3-carbonitrile + TX, (R)-3-(difluoromethyl)-1-methyl-N-[1 ,1 ,3-trimethylindan-4- yl]pyrazole-4-carboxamide + TX, 4-(2-bromo-4-fluoro-phenyl)-N-(2-chloro-6-fluoro-phenyl)-2,5-dimethyl- pyrazol-3-amine + TX, 4- (2- bromo- 4- fluorophenyl) - N- (2- chloro- 6- fluorophenyl) - 1 , 3- dimethyl- 1 H- pyrazol- 5- amine + TX, fluindapyr + TX, coumethoxystrobin (jiaxiangjunzhi) + TX, Ivbenmixianan + TX, dichlobentiazox + TX, mandestrobin + TX, 3-(4,4-difluoro-3,4-dihydro-3,3-dimethylisoquinolin-1-yl)quinolone + TX, 2-[2-fluoro-6-[(8-fluoro-2-methyl-3-quinolyl)oxy]phenyl]propan-2-ol + TX, oxathiapiprolin + TX, tert-butyl N- [6-[[[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate + TX, pyraziflumid + TX, inpyrfluxam + TX, trolprocarb + TX, mefentrifluconazole + TX, ipfentrifluconazole + TX, 2-(difluoromethyl)-N- [(3R)-3-ethyl-1 ,1-dimethyl-indan-4-yl]pyridine-3-carboxamide + TX, N'-(2,5-dimethyl-4-phenoxy-phenyl)-N- ethyl-N-methyl-formamidine + TX, N'-[4-(4,5-dichlorothiazol-2-yl)oxy-2,5-dimethyl-phenyl]-N-ethyl-N-methyl- formamidine + TX, [2-[3-[2-[1-[2-[3,5-bis(difluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]thiazol-4-yl]-4,5- dihydroisoxazol-5-yl]-3-chloro-phenyl] methanesulfonate + TX, but-3-ynyl N-[6-[[(Z)-[(1-methyltetrazol-5-yl)- phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate + TX, methyl N-[[5-[4-(2,4-dimethylphenyl)triazol-2- yl]-2-methyl-phenyl]methyl]carbamate + TX, 3-chloro-6-methyl-5-phenyl-4-(2,4,6-trifluorophenyl)pyridazine + TX, pyridachlometyl + TX, 3-(difluoromethyl)-1-methyl-N-[1 ,1 ,3-trimethylindan-4-yl]pyrazole-4-carboxamide + TX, 1-[2-[[1-(4-chlorophenyl)pyrazol-3-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one + TX, 1-methyl- 4-[3-methyl-2-[[2-methyl-4-(3,4,5-trimethylpyrazol-1-yl)phenoxy]methyl]phenyl]tetrazol-5-one + TX, aminopyrifen + TX, ametoctradin + TX, amisulbrom + TX, penflufen + TX, (Z,2E)-5-[1-(4-chlorophenyl)pyrazol- 3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide + TX, florylpicoxamid + TX, fenpicoxamid + TX, metarylpicoxamid + TX, tebufloquin + TX, ipflufenoquin + TX, quinofumelin + TX, isofetamid + TX, N-[2-[2,4- dichloro-phenoxy]phenyl]-3-(difluoromethyl)-1 -methyl-pyrazole-4-carboxamide + TX, N-[2-[2-chloro-4- (trifluoromethyl)phenoxy]phenyl]-3-(difluoromethyl)-1 -methyl-pyrazole-4-carboxamide + TX, benzothiostrobin + TX, phenamacril + TX, 5-amino-1 ,3,4-thiadiazole-2-thiol zinc salt (2:1) + TX, fluopyram + TX, flufenoxadiazam + TX, flutianil + TX, fluopimomide + TX, pyrapropoyne + TX, picarbutrazox + TX, 2-(difluoromethyl)-N-(3-ethyl- 1 ,1-dimethyl-indan-4-yl)pyridine-3-carboxamide + TX, 2- (difluoromethyl) - N- ((3R) - 1 , 1 , 3- trimethylindan- 4- yl) pyridine- 3- carboxamide + TX, 4-[[6-[2-(2,4-difluorophenyl)-1 ,1-difluoro-2-hydroxy-3-(1 ,2,4-triazol-1 - yl)propyl]-3-pyridyl]oxy]benzonitrile + TX, metyltetraprole + TX, 2- (difluoromethyl) - N- ((3R) - 1 , 1 , 3- trimethylindan- 4- yl) pyridine- 3- carboxamide + TX, a- (1 , 1- dimethylethyl) - a- [4'- (trifluoromethoxy) [1 , T- biphenyl] - 4- yl] -5- pyrimidinemethanol + TX, fluoxapiprolin + TX, enoxastrobin + TX, 4-[[6-[2-(2,4- difluorophenyl)-1 ,1-difluoro-2-hydroxy-3-(1 ,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy] benzonitrile + TX, 4-[[6-[2- (2,4-difluorophenyl)-1 ,1-difluoro-2-hydroxy-3-(5-sulfanyl-1 ,2,4-triazol-1-yl)propyl]-3-pyridyl]oxy] benzonitrile + TX, 4-[[6-[2-(2,4-difluorophenyl)-1 ,1-difluoro-2-hydroxy-3-(5-thioxo-4H-1 ,2,4-triazol-1-yl)propyl]-3- pyridyl]oxy]benzonitrile + TX, trinexapac + TX, coumoxystrobin + TX, zhongshengmycin + TX, thiodiazole copper + TX, zinc thiazole + TX, amectotractin + TX, iprodione + TX, seboctylamine + TX; N'-[5-bromo-2- methyl-6-[(1 S)-1 -methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5-bromo-2- methyl-6-[(1 R)-1-methyl-2-propoxy-ethoxy]-3-pyridyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5-bromo-2- methyl-6-(1-methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5-chloro-2-methyl-6- (1 -methyl-2-propoxy-ethoxy)-3-pyridyl]-N-ethyl-N-methyl-formamidine + TX, N'-[5-bromo-2-methyl-6-(1 - methyl-2-propoxy-ethoxy)-3-pyridyl]-N-isopropyl-N-methyl-formamidine + TX (these compounds may be prepared from the methods described in WO2015 / 155075); N'-[5-bromo-2-methyl-6-(2-propoxypropoxy)-3- pyridyl]-N-ethyl-N-methyl-formamidine + TX (this compound may be prepared from the methods described in IPCOM000249876D); N-isopropyl-N’-[5-methoxy-2-methyl-4-(2, 2, 2 -trifluoro- 1 -hydroxy-1 -phenyl-ethyl)phenyl]- N-methyl-formamidine + TX, N’-[4-(1-cyclopropyl-2,2,2-trifluoro-1-hydroxy-ethyl)-5-methoxy-2-methyl-phenyl]- N-isopropyl-N-methyl-formamidine + TX (these compounds may be prepared from the methods described in WO2018 / 228896); N-ethyl-N’-[5-methoxy-2-methyl-4-[(2-trifluoromethyl)oxetan-2-yl]phenyl]-N-methyl- formamidine + TX, N-ethyl-N’-[5-methoxy-2-methyl-4-[(2-trifuoromethyl)tetrahydrofuran-2-yl]phenyl]-N-methyl- formamidine + TX (these compounds may be prepared from the methods described in WO2019 / 110427); N- [(1 R)-1 -benzyl-3-chloro-1 -methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1 S)-1 -benzyl-3- chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1 R)-1-benzyl-3,3,3-trifluoro-1-methyl- propyl]-8-fluoro-quinoline-3-carboxamide + TX, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8-fluoro- quinoline-3-carboxamide + TX, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide + TX, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide + TX, 8-fluoro-N-[(1 R)-1-[(3- fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide + TX, 8-fluoro-N-[(1 S)-1-[(3- fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide + TX, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8- fluoro-quinoline-3-carboxamide + TX, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide + TX, N-((1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide + TX, N-((1 S)-1-benzyl- 3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide + TX (these compounds may be prepared from the methods described in WO2017 / 153380); 1 -(6,7-dimethylpyrazolo[1 ,5-a]pyridin-3-yl)-4,4,5-trifluoro-3,3- dimethyl-isoquinoline + TX, 1-(6,7-dimethylpyrazolo[1 ,5-a]pyridin-3-yl)-4,4,6-trifluoro-3,3-dimethyl-isoquinoline + TX, 4,4-difluoro-3,3-dimethyl-1-(6-methylpyrazolo[1 ,5-a]pyridin-3-yl)isoquinoline + TX, 4,4-difluoro-3,3- dimethyl-1-(7-methylpyrazolo[1 ,5-a]pyridin-3-yl)isoquinoline + TX, 1 -(6-chloro-7-methyl-pyrazolo[1 ,5-a]pyridin- 3-yl)-4,4-difluoro-3,3-dimethyl-isoquinoline + TX (these compounds may be prepared from the methods described in WO2017 / 025510); 1-(4,5-dimethylbenzimidazol-1-yl)-4,4,5-trifluoro-3,3-dimethyl-isoquinoline + TX, 1-(4,5-dimethylbenzimidazol-1-yl)-4,4-difluoro-3,3-dimethyl-isoquinoline + TX, 6-chloro-4,4-difluoro-3,3- dimethyl-1 -(4-methylbenzimidazol-1 -y I) isoq u in o li ne + TX, 4,4-difluoro-1 -(5-fluoro-4-methyl-benzimidazol-1 -yl)- 3,3-dimethyl-isoquinoline + TX, 3-(4,4-difluoro-3,3-dimethyl-1-isoquinolyl)-7,8-dihydro-6H- cyclopenta[e]benzimidazole + TX (these compounds may be prepared from the methods described in WO2016 / 156085); N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]cyclopropanecarboxamide + TX, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide + TX, N-ethyl-2-methyl-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide + TX, 1-methoxy-3-methyl-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea + TX, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea + TX, 3-ethyl-1-methoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea + TX, N-[[4-[5- (trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide + TX, 4,4-dimethyl-2-[[4-[5-(trifluoromethyl)-

[0450] 1 .2.4-oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one + TX, 5,5-dimethyl-2-[[4-[5-(trifluoromethyl)-1 ,2,4- oxadiazol-3-yl]phenyl]methyl]isoxazolidin-3-one + TX, ethyl 1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]pyrazole-4-carboxylate + TX, N,N-dimethyl-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]-1 ,2,4-triazol-3-amine + TX. The compounds in this paragraph may be prepared from the methods described in WO 2017 / 055473, WO 2017 / 055469, WO 2017 / 093348 and WO 2017 / 118689; 2-[6-(4- chlorophenoxy)-2-(trifluoromethyl)-3-pyridyl]-1-(1 ,2,4-triazol-1-yl)propan-2-ol + TX (this compound may be prepared from the methods described in WO 2017 / 029179); 2-[6-(4-bromophenoxy)-2-(trifluoromethyl)-3- pyridyl]-1-(1 ,2,4-triazol-1-yl)propan-2-ol + TX (this compound may be prepared from the methods described in WO 2017 / 029179); 3-[2-(1-chlorocyclopropyl)-3-(2-fluorophenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile + TX (this compound may be prepared from the methods described in WO 2016 / 156290); 3-[2-(1- chlorocyclopropyl)-3-(3-chloro-2-fluoro-phenyl)-2-hydroxy-propyl]imidazole-4-carbonitrile + TX (this compound may be prepared from the methods described in WO 2016 / 156290); (4-phenoxyphenyl...

Claims

CLAIMS1 . A fungicidal composition comprising a mixture of components (A) and (B) as active ingredients, wherein component (A) is a compound of formula (I):whereinR1is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl and C3-C6 cycloalkyl;R2is selected from hydrogen, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, C1-C4 alkylcarbonyl, N-C1-C4 alkoxy-C-Ci-C4 alkyl-carbonimidoyl, N-hydroxy-C-Ci-C4 alkylcarbonimidoyl and C1-C4 alkoxycarbonyl;R3and R4are independently selected from hydrogen, halogen and C1-C4 alkyl;R5and R6are independently selected from hydrogen and C1-C4 alkyl;R7is selected from hydrogen, C1-C4 alkyl, C1-C4 alkylcarbonyl, N-C1-C4 alkoxy-C-Ci-C4 alkylcarbonimidoyl, N-hydroxy-C-Ci-C4 alkyl-carbonimidoyl, C1-C4 alkoxycarbonyl, N-methoxy-N-methyl- carbonyl, C1-C4 alkylaminocarbonyl, di(Ci-C4 alkylamino)carbonyl, phenyl, 5- or 6-membered heteroaryl and C3-C6 cycloalkyl; wherein said 5- or 6-membered heteroaryl contains 1 , 2, 3 or 4 heteroatoms individually selected from N, O and S, with the proviso that no more than one is O or S; and wherein any of said phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl are unsubstituted or substituted by 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl or C1-C4 alkoxy;B1is CR10or N;B2is CR11or N;R8, R9, R10and R11are independently selected from hydrogen, halogen, C1-C4 alkyl, C1-C4 haloalkyl, Ci- 04 alkoxy, C1-C4 haloalkoxy, C2-C4 alkenyloxy, C2-C4 alkynyloxy, C1-C4 alkylsulfanyl, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, Ci-C4 alkoxy-Ci-C4 alkyl, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, N-Ci-C4 alkoxy- C-C1-C4 alkyl-carbonimidoyl, N-hydroxy-C-Ci-C4 alkyl-carbonimidoyl, hydroxy, trifluoromethylsulfonyloxy, cyano, carboxy, phenyl, 5- or 6-membered heteroaryl and C3-C6 cycloalkyl; wherein said 5- or 6-membered heteroaryl contains 1 , 2, 3 or 4 heteroatoms individually selected from N, O and S, with the proviso that no more than one is O or S; and wherein any of said phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl are unsubstituted or substituted by 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl or C1-C4 alkoxy;A1, A2and A3are independently selected from CR12, N, NR13, O and S, with the proviso that at least one of A1, A2and A3is selected from N, O and S, and that no more than one of A1, A2and A3is O or S;R12is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl and C2-C4 alkynyl;R13is selected from hydrogen, C1-C4 alkyl, C2-C4 alkenyl and C2-C4 alkynyl; andZ1is selected from C3-C4 alkyl, phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl; wherein said 5- or 6-membered heteroaryl contains 1 , 2, 3 or 4 heteroatoms individually selected from N, O and S, with the proviso that no more than one is O or S; and wherein any of said phenyl, 5- or 6-membered heteroaryl and Cs-Ce-cycloalkyl are unsubstituted or substituted by 1 , 2 or 3 substituents independently selected from halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylsulfanyl, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, or C2-C4 alkynyl; and component (B) is a compound selected from the group consisting of: pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penflufen, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, isofetamid, fluindapyr, cyclobutrifluram, fluoxastrobin, fenamidone, mandestrobin, picoxystrobin, pyraclostrobin, famoxadone, kresoxim-methyl, trifloxystrobin, azoxystrobin, metyltetraprole, amisulbrom, cyazofamid, fenpicoxamid, florylpicoxamid, metharylpicoxamid, ametoctradin, fluazinam, fentin hydroxide, silthiofam, fenpropimorph, fenpropidin, spiroxamine, fenhexamid, imazalil, pyrisoxazole, bromuconazole, cyproconazole, difenoconazole, epoxiconazole, flutriafol, hexaconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole, triticonazole, prothioconazole, fluoxytioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, kasugamycin, mancozeb, copper fungicides, sulphur, zinc thiazole, captan, folpet, chlorothalonil, dithianon, quinoxyfen, proquinazid, fludioxonil, iprodione, procymidone, thiabendazole, zoxamide, metrafenone, fluopicolide, propamocarb, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, isotianil, phosphorous acid, cyflufenamid, tebufloquin, picarbutrazox, tricyclazole, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]propanamide, 1-methoxy-3- methyl-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5- (trifluoromethyl)-l ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[(1 R)-1-benzyl-3-chloro-1-methyl-but-3- enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro- quinoline-3-carboxamide, N-[(1 R)-1 -benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro-quinoline-3- carboxamide, N-[(1 S)-1-benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N- [(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl- butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1-[(3-fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3-fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline- 3-carboxamide, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1- benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-((1 R)-1 -benzyl-3-chloro-1 -methyl-but-3- enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1 -benzyl-3-chloro-1 -methyl-but-3-enyl)-8-fluoro- quinoline-3-carboxamide, methyl (Z)-3-methoxy-2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]- prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy-prop-2-enoate, methyl (Z)-3-methoxy- 2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3- (trifluoromethyl)pyrazol-1-yl]phenoxy]prop-2-enoate, methyl (Z)-2-(5-cyclohexyl-2-methyl-phenoxy)-3- methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, 2- [cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano- (2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[cyano- (2,6-difluoro-4-pyridyl)amino]-N-hexyl-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2- methoxyacetyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4- pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5- methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)- amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A, with the proviso that the compound of formula (I) is notThe fungicidal composition according to claim 1 , wherein component (A) is a compound of formula (l-A),whereinR1is methyl;R2is hydrogen, chlorine, or methyl;R3is hydrogen;R4is hydrogen, or methyl;R5and R6are hydrogen;R7is hydrogen, C1-C4 alkyl, or Cs-Ce-cycloalkyl;R8is hydrogen;R9is hydrogen, bromine, chlorine, cyano, methyl, or methoxy;B1is CH;B2is N or CR11, wherein R11is hydrogen;A is selected from A1 , A4, A7, A9, or A10;A1 A4 , A7 , A9, or A10 wherein denotes the bond to the C(=O) group and the arrow denotes the bond to the Z1group, andZ1is selected from phenyl or a 6-membered heteroaryl; wherein said heteroaryl contains 1 heteroatom selected from N; and wherein said phenyl and said 6-membered heteroaryl are unsubstituted or substituted with 1 to 2 substituents selected from fluorine. The fungicidal composition according to claim 1 or claim 2, wherein component (A) is a compound selected from: [5-(2,4-difluorophenyl)-1 ,3,4-oxadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.01), [3-(2,4-difluorophenyl)-1 ,2,4-oxadiazol-5-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.02),[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-propyl-1 ,3, 4-thiadiazol-2-yl) methanone (X.03),(5-cyclohexyl-1 ,3,4-thiadiazol-2-yl)-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.04), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1-methyl-4-(1-methylpyrazol-4-yl)-3,4-dihydro- 1 H-isoquinolin-2-yl]methanone (X.05),[5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[(4R)-4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3- dihydroisoquinolin-2-yl]methanone (X.06),[5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2-yl]methanone (X.07),1-[4-[2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-3,4-dihydro-1 H-isoquinolin-4-yl]-2-methyl-pyrazol-3-yl]ethenone (X.08), methyl 2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinoline-1 -carboxylate (X.09),[5-(4-fluorophenyl)-1 ,3,4-oxadiazol-2-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.10), [4-(5-chloro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2,4-difluorophenyl)isoxazol-3- yl]methanone (X.11),[5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(5-fluoro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.12), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[3,3-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,4-dihydroisoquinolin-2- yl]methanone (X.13),[5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.14),[5-(2,4-difluorophenyl)isoxazol-3-yl]-[5-(1 ,3,5-trimethylpyrazol-4-yl)-6,8-dihydro-5H-1 ,7-naphthyridin-7- yl]methanone (X.15),[5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.16),[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 , 2, 4-oxadiazol-3-yl) methanone (X.17),(3-cyclohexylisoxazol-5-yl)-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.18), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 , 3, 4-oxadiazol-2-yl) methanone (X.19),[5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.20), [5-(3,5-difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1-methyl-3,4-dihydro- 1 H-isoquinolin-2-yl]methanone (X.21 ),[5- (2 ,4-d ifluoro pheny I) isoxazol-3-y l]-[(1 S,4S)-1 ,4-dimethyl-4-(1 -methylpyrazol-4-yl)-1 ,3- dihydroisoquinolin-2-yl]methanone (X.22), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(4-pyridyl)isoxazol-3-yl]methanone (X.23), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(3-pyridyl)isoxazol-3-yl]methanone (X.24), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2-pyridyl)isoxazol-3-yl]methanone (X.25), [5-(6-methoxy-3-pyridyl)isoxazol-3-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.26), [5-(2-methoxy-3-pyridyl)isoxazol-3-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.27), [5-(3,5-difluoro-2-pyridyl)-1 ,3,4-thiadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin- 2-yl]methanone (X.28), or[5-(2,6-difluoro-3-pyridyl)-1 ,3,4-thiadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin- 2-yl]methanone (X.29).

4. The fungicidal composition according to any of claims 1 to 3, wherein component (A) is: [5-(2,4-difluorophenyl)-1 ,3,4-oxadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.01),[3-(2,4-difluorophenyl)-1 ,2,4-oxadiazol-5-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.02),[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-propyl-1 ,3, 4-thiadiazol-2-yl) methanone (X.03),(5-cyclohexyl-1 ,3,4-thiadiazol-2-yl)-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.04), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1-methyl-4-(1-methylpyrazol-4-yl)-3,4-dihydro- 1 H-isoquinolin-2-yl]methanone (X.05),[5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[(4R)-4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3- dihydroisoquinolin-2-yl]methanone (X.06), [5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2-yl]methanone (X.07), 1-[4-[2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-3,4-dihydro-1 H-isoquinolin-4-yl]-2-methyl-pyrazol-3-yl]ethenone (X.08), methyl 2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinoline-1 -carboxylate (X.09),[5-(4-fluorophenyl)-1 ,3,4-oxadiazol-2-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.10), [4-(5-chloro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2,4-difluorophenyl)isoxazol-3- yl]methanone (X.11),[5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(5-fluoro-1 -methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.12), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[3,3-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,4-dihydroisoquinolin-2- yl]methanone (X.13), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.14), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[5-(1 ,3,5-trimethylpyrazol-4-yl)-6,8-dihydro-5H-1 ,7-naphthyridin-7- yl]methanone (X.15), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.16), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 , 2, 4-oxadiazol-3-yl) methanone (X.17), (3-cyclohexylisoxazol-5-yl)-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]methanone (X.18), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 , 3, 4-oxadiazol-2-yl) methanone (X.19), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.20), [5-(3,5-difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1-methyl-3,4-dihydro- 1 H-isoquinolin-2-yl]methanone (X.21 ), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-1 ,4-dimethyl-4-(1 -methylpyrazol-4-yl)-1 ,3- dihydroisoquinolin-2-yl]methanone (X.22), [5-(3,5-difluoro-2-pyridyl)-1 ,3,4-thiadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin- 2-yl]methanone (X.28), or [5-(2,6-difluoro-3-pyridyl)-1 ,3,4-thiadiazol-2-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin- 2-yl]methanone (X.29). The fungicidal composition according to any one of claims 1 to 4, wherein component (A) is: [3-(2,4-difluorophenyl)-1 ,2,4-oxadiazol-5-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.02), (5-cyclohexyl-1 ,3,4-thiadiazol-2-yl)-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.04), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-6-methoxy-1-methyl-4-(1-methylpyrazol-4-yl)-3,4-dihydro- 1 H-isoquinolin-2-yl]methanone (X.05), [5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[(4R)-4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3- dihydroisoquinolin-2-yl]methanone (X.06), [5-(2,4-difluorophenyl)-1 ,3,4-thiadiazol-2-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin- 2-yl]methanone (X.07),1-[4-[2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-3,4-dihydro-1 H-isoquinolin-4-yl]-2-methyl-pyrazol- 3-yl]ethenone (X.08), methyl 2-[5-(2,4-difluorophenyl)isoxazole-3-carbonyl]-4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H- isoquinoline-1 -carboxylate (X.09), [4-(5-chloro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-[5-(2,4-difluorophenyl)isoxazol-3- yl]methanone (X.11), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(5-fluoro-1-methyl-pyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.12), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[3,3-dimethyl-4-(1-methylpyrazol-4-yl)-1 ,4-dihydroisoquinolin-2- yl]methanone (X.13), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-methyl-4-(1-methylpyrazol-4-yl)-1 ,3-dihydroisoquinolin-2- yl]methanone (X.14), [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1 ,5-dimethylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.16), [4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2-yl]-(5-phenyl-1 , 3, 4-oxadiazol-2-yl) methanone (X.19) [5-(2,4-difluorophenyl)isoxazol-3-yl]-[4-(1-methylpyrazol-4-yl)-3,4-dihydro-1 H-isoquinolin-2- yl]methanone (X.20), [5-(3,5-difluoro-2-pyridyl)isoxazol-3-yl]-[rac-(1 S,4S)-4-(1 ,5-dimethylpyrazol-4-yl)-1-methyl-3,4-dihydro- 1 H-isoquinolin-2-yl]methanone (X.21), or [5-(2,4-difluorophenyl)isoxazol-3-yl]-[(1 S,4S)-1 ,4-dimethyl-4-(1 -methylpyrazol-4-yl)-1 ,3- dihydroisoquinolin-2-yl]methanone (X.22). The fungicidal composition according to any one of claims 1 to 5, wherein component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, fluindapyr, cyclobutrifluram, pyraclostrobin, trifloxystrobin, azoxystrobin, metyltetraprole, fenpicoxamid, florylpicoxamid, metarylpicoxamid, fluazinam, fenpropidin, fenhexamid, cyproconazole, difenoconazole, metconazole, penconazole, propiconazole, tebuconazole, tetraconazole, prothioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, mancozeb, copper-compounds (different salts), sulphur, folpet, chlorothalonil, dithianon, proquinazid, fludioxonil, metrafenone, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, phosphorous acid, cyflufenamid, tricyclazole, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3- chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1 -benzyl-3, 3, 3-trifluoro-1 -methyl-propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3,3,3-trifluoro-1-methyl-propyl]-8-fluoro- quinoline-3-carboxamide, N-[(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N- [(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1-[(3- fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3-fluorophenyl)- methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro- quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N- ((1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, N-((1 S)-1-benzyl-3- chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, methyl (Z)-3-methoxy-2-[2-methyl-5-[4- (trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(4-propyltriazol- 2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl-phenoxy]-3-methoxy- prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1-yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1 -yl]phenoxy]prop-2-enoate, methyl (Z)- 2-(5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl- phenoxy)-3-methoxy-prop-2-enoate (these compounds may be prepared from the methods described in W02020 / 193387), 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-hexyl-5-methyl-thiazole-4-carboxamide, 2-[(2,6- difluoro-4-pyridyl)-(2-methoxyacetyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)- 5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(oxetane-3-carbonyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydrofuran-3- carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4- pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)- (2-methylpropanoyl)amino]-N-(2,2-dimethyl-cyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A. The fungicidal composition according to any one of claims 1 to 6, wherein component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, acibenzolar-S-methyl, N- [(1 R)-1 -benzyl- 1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl- 1 ,3-dimethyl- butyl]-8-fluoro-quinoline-3-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-5-methyl-N-spiro[3.4] octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)- 5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydropyran-4-carbonyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A. The fungicidal composition according to any one of claims 1 to 7, wherein component (B) is a compound selected from the group consisting of pydiflumetofen, benzovindiflupyr, azoxystrobin, florylpicoxamid, difenoconazole, prothioconazole, mefentrifluconazole, cyprodinil, fludioxonil, and acibenzolar-S-methyl. The fungicidal composition according to any one of claims 1 to 8, wherein the weight ratio of component (A) to component (B) is from 12:1 to 1 :

25. The fungicidal composition according to any one of claims 1 to 9, wherein the weight ratio of component (A) to component (B) is from 5:1 to 1 :

15. The fungicidal composition according to any one of claims 1 to 10, wherein the weight ratio of component (A) to component (B) is from 2:1 to 1 :

5. The fungicidal composition according to any of claims 1 to 11 , wherein the composition may comprise an additional active ingredient component (C), which is different to component (B), and is selected from the group consisting of pydiflumetofen, benzovindiflupyr, bixafen, fluxapyroxad, isopyrazam, penflufen, penthiopyrad, sedaxane, boscalid, fluopyram, thifluzamide, pyraziflumid, isoflucypram, inpyrfluxam, isofetamid, fluindapyr, cyclobutrifluram, fluoxastrobin, fenamidone, mandestrobin, picoxystrobin, pyraclostrobin, famoxadone, kresoxim-methyl, trifloxystrobin, azoxystrobin, metyltetraprole, amisulbrom, cyazofamid, fenpicoxamid, florylpicoxamid, metharylpicoxamid, ametoctradin, fluazinam, fentin hydroxide, silthiofam, fenpropimorph, fenpropidine, spiroxamine, fenhexamid, imazalil, pyrisoxazole, bromuconazole, cyproconazole, difenoconazole, epoxiconazole, flutriafol, hexaconazole, ipconazole, metconazole, myclobutanil, penconazole, propiconazole, tebuconazole, tetraconazole, triticonazole, prothioconazole, fluoxytioconazole, mefentrifluconazole, flufenoxadiazam, ipflufenoquin, quinofumelin, metalaxyl-M, cyprodinil, pyrimethanil, kasugamycin, mancozeb, copper fungicides, sulphur, zinc thiazole, captan, folpet, chlorothalonil, dithianon, quinoxyfen, proquinazid, fludioxonil, iprodione, procymidone, thiabendazole, zoxamide, metrafenone, fluopicolide, propamocarb, oxathiapiprolin, fluoxapiprolin, acibenzolar-S-methyl, isotianil, phosphorous acid, cyflufenamid, tebufloquin, picarbutrazox, tricyclazole, N-methoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]cyclopropanecarboxamide, N,2-dimethoxy-N-[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]propanamide, 1 -methoxy-3-methyl-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3- yl]phenyl]methyl]urea, 1 ,3-dimethoxy-1 -[[4-[5-(trifluoromethyl)-1 ,2,4-oxadiazol-3-yl]phenyl]methyl]urea, N-[(1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-3- chloro-1-methyl-but-3-enyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 R)-1-benzyl-3,3,3-trifluoro-1-methyl- propyl]-8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1 -benzyl-3,3,3-trifluoro-1 -methyl-propyl]-8-fluoro- quinoline-3-carboxamide, N-[(1 R)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, N- [(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-7,8-difluoro-quinoline-3-carboxamide, 8-fluoro-N-[(1 R)-1-[(3- fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide, 8-fluoro-N-[(1 S)-1 -[(3- fluorophenyl)methyl]-1 ,3-dimethyl-butyl]quinoline-3-carboxamide, N-[(1 R)-1 -benzyl- 1 , 3-d imethy I- buty I]- 8-fluoro-quinoline-3-carboxamide, N-[(1 S)-1-benzyl-1 ,3-dimethyl-butyl]-8-fluoro-quinoline-3- carboxamide, N-((1 R)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, N- ((1 S)-1-benzyl-3-chloro-1-methyl-but-3-enyl)-8-fluoro-quinoline-3-carboxamide, methyl (Z)-3-methoxy- 2-[2-methyl-5-[4-(trifluoromethyl)triazol-2-yl]phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl- 5-(4-propyltriazol-2-yl)phenoxy]prop-2-enoate, methyl (Z)-2-[5-(3-isopropylpyrazol-1-yl)-2-methyl- phenoxy]-3-methoxy-prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-(3-propylpyrazol-1 - yl)phenoxy]prop-2-enoate, methyl (Z)-3-methoxy-2-[2-methyl-5-[3-(trifluoromethyl)pyrazol-1 - yl]phenoxy]prop-2-enoate, methyl (Z)-2-(5-cyclohexyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, methyl (Z)-2-(5-cyclopentyl-2-methyl-phenoxy)-3-methoxy-prop-2-enoate, 2-[cyano-(2,6-difluoro-4- pyridyl)amino]-5-methyl-N-spiro[3.4]octan-3-yl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4- pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[cyano-(2,6-difluoro-4- pyridyl)amino]-N-hexyl-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methoxyacetyl)- amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)- (tetrahydropyran-4-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, 2- [(2,6-difluoro-4-pyridyl)-(oxetane-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)-5-methyl-thiazole-4- carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(tetrahydrofuran-3-carbonyl)amino]-N-(2,2-dimethylcyclobutyl)- 5-methyl-thiazole-4-carboxamide, 2-[acetyl-(2,6-difluoro-4-pyridyl)amino]-N-(2,2-dimethylcyclobutyl)-5- methyl-thiazole-4-carboxamide, 2-[(2,6-difluoro-4-pyridyl)-(2-methylpropanoyl)amino]-N-(2,2- dimethylcyclobutyl)-5-methyl-thiazole-4-carboxamide, TAEGRO® (i.e, Bacillus amyloliquefaciens strain FZB24), melaluca alternifolia oil (an extract of the tea tree plant Melaluca alternifolia (commercially available as Timorex Gold®, which is a broad-spectrum botanical biofungicide)), Reynoutria sachalinensis extract (commercially available as REGALIA®), a plant extract based on the extract of Quillaja saponaria Molina (commercially available as BOTRISTOP®), and Aureobasidin A.

13. The fungicidal composition according to any one of claims 1 to 12, wherein the composition further comprises an agriculturally acceptable carrier and, optionally, a surfactant and / or formulation adjuvants.

14. A method of controlling or preventing phytopathogenic diseases, especially phytopathogenic fungi, on useful plants or on propagation material thereof, which comprises applying to the useful plants, the locus thereof or propagation material thereof a fungicidal composition as defined in any one of claims 1 to 12.

15. The method according to claim 14, wherein the composition components (A) and (B) are applied in a sequential manner.